UREIAS BICÍCLICAS COMO INIBIDORES DE QUINASE

Abstract

The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.

Description

[001] This application contains a Sequence Listing that was sent electronically as an XML file named 204430806WO1_SL_ST26.XML. The XML file, created on March 12, 2024, is 2,281 bytes in size. The material in the XML file is incorporated herein by reference in its entirety. FIELD OF TECHNIQUE

[002] The present invention relates to bicyclic urea compounds that modulate JAK2 activity and are useful in the treatment of JAK2-related diseases, including cancer. BACKGROUND

[003] Janus kinase (JAK) 2 plays essential roles in signaling various cytokine receptors. The JAK2 V617F mutant, located in the pseudokinase domain (JH2), is the most common molecular event associated with myeloproliferative neoplasms (MPNs). Current small molecule JAK2 inhibitors used to treat MPNs are designed to target the JAK2 kinase domain (JH1). Thus, selective targeting of the JAK2 V617F mutant to the JAK2 kinase domain (JH1) may be useful for treating various pathologies while sparing essential JAK2 functions. This application is intended to address this need and others. SUMMARY

[004] The present invention relates to, among others, compounds of Formula I: H Petition 870250102588, dated 10 / 11 / 2025, page 7 / 574 2 / 492 or pharmaceutically acceptable salts thereof, wherein the constituent members are defined in this document.

[005] The present invention further provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[006] The present invention further provides methods for inhibiting the activity of the V617F variant of JAK2 kinase, comprising contacting the kinase with a compound of Formula I, or a pharmaceutically acceptable salt thereof.

[007] The present invention further provides methods of treating a disease or disorder associated with the expression or activity of the V617F variant of JAK2 kinase in a patient by administering to a patient a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

[008] The present invention further provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.

[009] The present invention further provides the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein. DETAILED DESCRIPTION

[0010] This application provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, where: Petition 870250102588, dated 10 / 11 / 2025, p. 8 / 574 3 / 492 R1 is selected from C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl groups, wherein the C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl groups of R1 are each optionally substituted by 1, 2 or 3 independently selected R1A substituents; Each R1A is selected independently of halo, oxo CN, NO2, ORa11, SRa11, NHORa11, C(O)Rb11, C(O)NRc11Rd11 C(O)NRc11(ORa11), C(O)ORa11, OC(O)Rb11, OC(O)NRc11Rd11, NRc11Rd11 NRc11NRc11Rd11, NRc11C(O)R b11 NRc11C(O)ORa11, NRc11C(O)NRc11Rd11 C(=NRe11)Rb11, C(=NRe11)NRc11Rd11, NRc11C(=NRe11)NRc11Rd11 NRc11C(=NRe11)Rb11, NRc11S(O)Rb11, NRc11S(O)NRc11Rd11 NRc11S(O)2Rb11, NRc11S(O)(=NRe11)Rb11, NRc11S(O)2NRc11Rd11 S(O)Rb11, S(O)NRc11Rd11, S(O)2Rb11, S(O)2NRc11Rd11 OS(O)(=NRe11)Rb11e OS(O)2Rb11; Each Ra11, Rb11, Rc11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra11, Rb11, Rc11, and Rd11 are each optionally replaced by 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents; each Re11 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl and C2-6 alkynyl; Cy2 is selected from C3-10 cycloalkyl and 4-12 membered heterocycloalkyl, wherein the C3-10 cycloalkyl and the 4-12 membered heterocycloalkyl are each substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2 substituents; each R2 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl, cycloalkyl C3-10 -C1-6 alkyl, (5-10 membered heteroaryl) -C1-6 alkyl, (4-10 heterocycloalkyl Petition 870250102588, dated 10 / 11 / 2025, p. 9 / 574 4 / 492 members)-alkyl-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2NRc2Rd2, NRc2NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2 NRc2C(O)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2 NRc2C(=NRe2)NRc2Rd2, NRc2C(=NRe2)Rb2, NRc2S(O)Rb2 NRc2S(O)NRc2Rd2, NRc2S(O)2Rb2, NRc2S(O)(=NRe2)Rb2 NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, S(O)2NRc2Rd2OS(O)(=NRe2)Rb2, OS(O)2Rb2, SF5, P(O)Rf2Rg2, OP(O)(O)(ORi2) P(O)(ORh2)(ORi2), and BRj2Rk2, in which alkyl C1-6, alkenyl C2-6, quinyl C2-6, aryl C6-10, cycloalkyl C3-10, heteroaryl of 5 to 10 members, heterocycloalkyl of 16-10 members, C - alkyl C1-6 - , cycloalkyl C3-10 - alkyl C1-6 - , (5- to 10-membered heteroaryl) - alkyl C1-6 - , and (heterocycloalkyl C1-6 - , and (4-10-membered heterocycloalkyl)-alkyl C1-6 - of R2, each substituted 2, 4 , 3 , commonly 5, 6, 7 or 8 independently selected R2substituents; each Ra2, Rc2, and Rd2 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10 members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkylC1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rc2e Rd2são, each amu, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R2Asubstitutes independently selected; or, any Rc2 and Rd2 groups attached to the same N atom, together with the N atom to which they are attached, form a 5- to 10-membered heteroaryl group or a 4- to 10-membered heterocycloalkyl group. Petition 870250102588, dated 10 / 11 / 2025, p. 10 / 574 5 / 492 members, wherein the 5- to 10-membered heteroaryl group or the 4- to 10-membered heterocycloalkyl group is optionally replaced by independently selected 1, 2, 3 or 4 R2A substituents; each Rb2e independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rb2são, each amu, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R2Asubstitutes independently selected; each Re2é independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rf2e Rg2é independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rh2 and Ri2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to Petition 870250102588, dated 10 / 11 / 2025, p. 11 / 574 6 / 492 members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; Each Rj2e Rk2é is selected independently from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any Rj2e Rk2 bonded to the same B atom, together with the B atom to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; each R2Ae independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 4-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa21, SRa21, NHORA21, C(O)Rb21 C(O)NRc21Rd21, OC(O)NRc21Rd21, NRc21C(O)ORa21, C(O)NRc21(ORa21), C(O)ORa21, OC(O)Rb21 NRc21Rd21, NRc21NRc21Rd21 NRc21C(O)Rb21 NRc21C(O)NRc21Rd21, C(=NRe21)Rb21 C(=NRe21)NRc21R d21 NRc21C(=NRe21)NRc21Rd21, NRc21C(=NRe21)R b21 NRc21S(O)Rb21, NRc21S(O)NRc21Rd21, NRc21S(O)2Rb21 NRc21S(O)(=NRe21)Rb21, NRc21S(O)2NRc21Rd21, S(O)Rb21 S(O)NRc21Rd21, S(O)2Rb21, S(O)2NRc21Rd21, OS(O)(=NRe21)Rb21 OS(O)2Rb21, SF5, P(O)Rf21Rg21, OP(O)(ORh21)(ORi21) P(O)(ORh21)(ORi21), and BRj21Rk21, where Ci-6 alkyl, C2-6 alkenyl C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (heterocycloalkyl of 4-10 members)-C1-6 alkyl- of R2A are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R2Bsubstituents Petition 870250102588, dated 10 / 11 / 2025, p. 12 / 574 7 / 492 independently selected; each Ra21, Rc21, and Rd21 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, heterocycloalkyl of 4 to 10 members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra21, Rc21e Rd21são each um optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2Bsubstitutes; or any Rc21 and Rd21 bonded to the same N atom, together with the N atom to which they are bonded, form a 5- to 10-membered heteroaryl group or a 4- to 10-membered heterocycloalkyl group, wherein the 5- to 10-membered heteroaryl group or the 4- to 10-membered heterocycloalkyl group is optionally substituted by independently selected 1, 2, 3 or 4 R2B substituents; each Rb21é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl- of Rb21são cada um optamente substituídos por 1, 2, 3, 4, 5, 6, 7 ou 8 R2Bsubstituintes selecionados Petition 870250102588, dated 10 / 11 / 2025, page. 13 / 574 8 / 492 independently; each Re21é independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rf21e Rg21é independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rh21 and Ri21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; Each Rj21e Rk21e is selected independently from OH, C1-6 alkoxy and C1-6 haloalkoxy; or any Rj21 and Rk21 bonded to the same B atom, together with the B atom to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; each R2Bé selected independently of halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6-membered heteroaryl, 4-7-membered heterocycloalkyl, phenyl-C cycloalkyl-C1-6 alkyl-, (heteroaryl of 5Petition 870250102588, of 10 / 11 / 2025, p. 14 / 574 9 / 492 members)-Ci-6 alkyl-, (4-7-membered heterocycloalkyl)-Ci-6 alkyl-, CN, NO2, ORa22, SRa22, NHORa22, C(O)Rb22, C(O)NRc22Rd22C(O)Rb22, C(O)NRc22Rd22C(O)Rb22, CO OC(O)Rb22, OC(O)NRc22Rd22, NRc22Rd22 NRc22NRc22Rd22NRc22C(O)Rb22, NRc22C(O)ORa22, NRc22C(O)NRc22Rd22 C(=NRe22)Rb22, C(=NRe22)NRc22Rd22, NRc22C(=NRe22)NRc22Rd22 NRc22C(=NRe22)Rb22, NRc22S(O)Rb22, NRc22S(O)NRc22Rd22 NRc22S(O)2Rb22, NRc22S(O)(=NRe22)Rb22, NRc22S(O)2NRc22Rd22 S(O)Rb22, S(O)NRc22Rd22, S(O)2Rb22, S(O)2NRc22Rd22 OS(O)(=NRe22)Rb22, and OS(O)2Rb22, in which C1-6 is alkyl, C2-6 is alkenyl C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, (4-7 member heterocycloalkyl)-C1-6 alkyl- of R2Csão each um optionally substituted by 1, 2, 3 or 4 RMsubstituents selected independently; each Ra22, Rc22, and Rd22 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra22, Rc22e Rd22são each um optionally substituted by 1, 2, 3 or 4 RMsubstituintes independently selected; or any Rc22 and Rd22 bonded to the same N atom, together with the N atom to which they are bonded, form a 5- to 6-membered heteroaryl group or a 4- to 7-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl group or the group Petition 870250102588, dated 10 / 11 / 2025, p. 15 / 574 10 / 492 4- to 7-membered heterocycloalkyl is optionally replaced by independently selected 1, 2, 3 or 4 RM substituents; each Rb22é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C16 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Rb22são each um optionally substituted by 1, 2, 3 or 4 RMsubstituintes independently selected; each Re22é independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-; R3é selected from H, halo, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; Cy4é selected from C6-10 aryl and heteroaryl of 5 to 14 members, em than to C6-10 aryl and heteroaryl of 5 to 12 members only, each one, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R4substituintes; each R4 is independently selected from halo, oxo, C16 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, (4- to 10-membered heterocycloalkyl) Petitção 870250102588, of 10 / 11 / 2025, page 16 / 574 11 / 492 bros)-Ci-6 alkyl-, CN, NO2, ORa4, SRa4, NHORa4, C(O)Rb4C(O)NRc4Rd4, C(O)NRc4(ORa4), C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4NRc4Rd4, NRc4NRc4Rd4NRc4C(O)Rb4, NRc4C(O)ORa4 NRc4C(O)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4 NRc4C(=NRe4)NRc4Rd4, NRc4C(=NRe4)Rb4, NRc4S(O)Rb4 NRc4S(O)NRc4Rd4, NRc4S(O)2Rb4, NRc4S(O)(=NRe4)Rb4 NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, S(O)2NRc4Rd4OS(O)(=NRe4)Rb4, OS(O)2Rb4, SF5, P(O)Rf4Rg4, OP(O)(ORh4)(ORi4) P(O)(ORh4)(ORi4), e BRj4Rk4, em que a Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, Ce-10 aryl-C1-e alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (5-10-membered heteroaryl)-C1-e alkyl-, e (4-10-membered heterocycloalkyl)-C1-e alkyl- of R4são, each uma, optionally substituted by 1,2, 3, 4, 5, e, 7 or 8 R4Asubstituintes sele cionados independentlyemente; each Ra4, Rc4, and Rd4é selected independently of H, C1-e alkyl, C1-e haloalkyl, C2-e alkenyl, C2-e alkynyl, Ce-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 1-10-membered heterocycloalkyl, Ce aryl-C1-e alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (5-10-membered heteroaryl)-C1-e alkyl-, and (4-10-membered heterocycloalkyl)-C1-e alkyl-, in which C1-e alkyl, C2-e alkyl, C2-alkyl, Ce-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, Ce-10 aryl-C1-e alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (5-membered heteroaryl-C1-e alkyl-) (4-10-membered heterocycloalkyl)-C1-and alkyl- of Ra4, Rc4e Rd4são, each, optionally substituted by 1, 2, 3, 4, 5, e, 7 or 8 independently selected R4Asubstituents; or any Rc4 and Rd4 bonded to the same N atom, together with the N atom to which they are bonded, form a 5- to 10-membered heteroaryl group or a 4- to 10-membered heterocycloalkyl group. Petition 870250102588, dated 10 / 11 / 2025, p. 17 / 574 12 / 492 members, wherein the 5- to 10-membered heteroaryl group or the 4- to 10-membered heterocycloalkyl group is optionally replaced by independently selected 1, 2, 3 or 4 R4A substituents; each Rb4e independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rb4são, each amu, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R4Asubstitutes independently selected; each Re4é independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rf4e Rg4é independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rh4 and Ri4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to Petition 870250102588, dated 10 / 11 / 2025, p. 18 / 574 13 / 492 members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; Each Rj4e Rk4é selected independently from OH, C1-6 alkoxy and C1-6 haloalkoxy; or any Rj4e Rk4 bonded to the same B atom, together with the B atom to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; Each R4A is independently selected from halo, oxo, C1-6 alquila, C1-6 haloalquila, C2-6 alquila, C2-6 alquinila, C6-10 aryla, C310 cycloalquila, heteroaryla from 5 to 10 members, heterocicloalquila from 4 to members, C6-10 aryl-C1-6 alquil-, C3-10 cycloalquil-C1-6 alquil-, (heterocycloalquila of 5-10 members)-C1-6 alquil-, (heterocycloalquila of 4-10 members)-C1-6 alquil-, CN, NO2, ORa41, SRa41, NHORa41, C(O)Rb41 C(O)NRc41Rd41, C(O)NRc41(ORa41), C(O)ORa41, OC(O)Rb41 OC(O)NRc41Rd41, NRc41C(O)ORa41,NRc41Rd41, NRc41NRc41Rd41NRc41C(O)NRc41Rd41, NRc41C(O)R b41 C(=NRe41)R b41 C(=NRe41)NRc41R d41NRc41C(=NRe41)NRc41Rd41, NRc41C(=NRe41)R b41 NRc41S(O)Rb41,NRc41S(O)NRc41Rd41, NRc41S(O)2Rb41 NRc41S(O)(=NRe41)Rb41, NRc41S(O)2NRc41Rd41, S(O)Rb41 S(O)NRc41Rd41, S(O)2Rb41, S(O)2NRc41Rd41, OS(O)(=NRe41)Rb41 OS(O)2Rb41, SF5, P(O)Rf41Rg41, OP(O)(ORh41)(ORi41) P(O)(ORh41)(ORi41), and BRj41Rk41, where C1-6 alkyl, C2-6 alkenyl C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (heterocycloalkyl of 4-10 members)-C1-6 alkyl- of R41 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R4Bsubstituents Petition 870250102588, dated 10 / 11 / 2025, p. 19 / 574 14 / 492 independently selected; each Ra41, Rc41, and Rd41 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, heterocycloalkyl of 4 to 10 members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra41, Rc41e Rd41são, each ame, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R4Bsubstitutes independently selected; or any Rc41 and Rd41 bonded to the same N atom, together with the N atom to which they are bonded, form a 5- to 10-membered heteroaryl group or a 4- to 10-membered heterocycloalkyl group, wherein the 5- to 10-membered heteroaryl group or the 4- to 10-membered heterocycloalkyl group is optionally substituted by independently selected 1, 2, 3 or 4 R4B substituents; each Rb41é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rb41são, each amu, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R4Bselected substitutes Petition 870250102588, dated 10 / 11 / 2025, page. 20 / 574 15 / 492 independently; each Re41é independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rf41e Rg41é independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rh41 and Ri41 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; Each Rj41e Rk41e is selected independently from OH, C1-6 alkoxy and C1-6 haloalkoxy; or any Rj41 and Rk41 bonded to the same B atom, together with the B atom to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; each R4B is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (heteroaryl of 5Petition 870250102588, dated 11 / 10 / 2025, p. 16 / 492 members)-Ci-6 alkyl-, (4-7 membered heterocycloalkyl)-Ci-6 alkyl-, CN, NO2, ORa42, SRa42, NHORa42, C(O)Rb42, C(O)NRc42Rd42C(O)NRc42(ORa42), C(O)ORa42, OC(O)Rb42, OC(O)NRc42Rd42, NRc42Rd42 NRc42NRc42Rd42NRc42C(O)Rb42, NRc42C(O)ORa42, NRc42C(O)NRc42Rd42 C(=NRe42)Rb42, C(=NRe42)NRc42Rd42, NRc42C(=NRe42)NRc42Rd42 NRc42C(=NRe42)Rb42, NRc42S(O)Rb42, NRc42S(O)NRc42Rd42 NRc42S(O)2Rb42, NRc42S(O)(=NRe42)Rb42, NRc42S(O)2NRc42Rd42 S(O)Rb42, S(O)NRc42Rd42, S(O)2Rb42, S(O)2NRc42Rd42 OS(O)(=NRe42)Rb42, and OS(O)2Rb42, wherein the C1-6 alkyl, C2-6 alkenyl C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl- of R4Csão, each one, optionally substituted by 1, 2, 3 or 4 RMsubstituents selected independently; each Ra42, Rc42, and Rd42 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra42, Rc42e Rd42são, each amu, optionally substituted by 1, 2, 3 or 4 RMsubstituintes independently selected; or any Rc42 and Rd42 bonded to the same N atom, together with the N atom to which they are bonded, form a 5- to 6-membered heteroaryl group or a 4- to 7-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl group or the group Petition 870250102588, dated 10 / 11 / 2025, p. 22 / 574 17 / 492 4- to 7-membered heterocycloalkyl is optionally replaced by independently selected 1, 2, 3 or 4 RM substituents; each Rb42é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C16 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Rb42são, each amu, optionally substituted by 1, 2, 3 or 4 RMsubstituintes independently selected; each Re42é selected independently of H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6-membered heteroaryl, 4-7-membered heterocycloalkyl, phenyl-C cycloalkyl-C1-6 alkyl-, (5-6-membered heteroaryl)-C1-6 alkyl-, and (4-7-membered heterocycloalkyl)-C1-6 alkyl-; R5é selected between alkyl C1-6 , alkenyl C2-6 , alkynyl C2-6 , cycloalkyl C3-12 , aryl C6-10 , 5-12-membered heteroaryl, 4-12-membered cycloalkyl hetero, ORw2, SRw2, NRw2Rw3, C(O)Rw2, C(O)NRw2Rw3, C(O)ORw2, OC(O)Rw2, OC(NRw3)Rw2, OC(O)NRw2Rw3, NRw3C(O)Rw2, NRw3C(O)ORw2, NRw3C(O)NRw2Rw3, NRw3S(O)Rw2, NRw3S(O)NRw2Rw3, NRw3S(O)2Rw2, S(O)Rw2, S(O)NRw2Rw3, S(O)2Rw2, and S(O)2NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl groups of R5 are each replaced by one Rw1 substituent and optionally replaced by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5A substituents; or the C6-10 aryl group of R5 is replaced by one optional Rw5 substituent. Petition 870250102588, dated 10 / 11 / 2025, p. 23 / 574 18 / 492 substituted individually and 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5A substituents; and the C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of R5 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5A substituents; Rw1 is selected from C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 5- to 12-membered heteroaryl, C6-12 aryl, 4- to 12-membered heterocycloalkyl, ORw4, NHRw4, NRw3Rw4, SRw4, S(O)2Rw4, C(O)Rw4, C(O)NHRw4, C(O)NRw3Rw4, OC(O)Rw4, S(O)Rw3, S(O)NRw3Rw3, S(O)2Rw2, and S(O)2NRw3Rw3, wherein C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 5- to 12-membered heteroaryl, C6-12 aryl, and 4- to 12-membered heterocycloalkyl of Rw1 are each optionally substituted. by 1, 2, 3, 4, 5, 6, 7 or 8 R5A substitutes selected independently; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5A substituents; each Rw3é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, e (heterocycloalkyl Petition 870250102588, dated 10 / 11 / 2025, page. 24 / 574 19 / 492 of 4-10 members)-Ci-6 alkyl- of Rw3são, each uma, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R5Asubstituintes independently selected; each Rw4é independently selected from Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-, in which a C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra51, Rc51e Rd51são, each amu, optionally substituted by 1, 2, 3, 4, 5, 6, 7 ou 8 R5Bsubstitutes independently selected; Rw5é C1-6 alkyl that is oxo-substituted, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 16-10-membered Cla heterocyclo aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10-membered heteroaryl)-C1-6 alkyl-, (4-10-membered heterocycloalkyl)-C1-6 alkylCN, NO2, ORa51, NHOR,5 C(O)NRc51Rd51 C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51 NRc51NRc51Rd51, NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rd51 C(=NRe51)Rb51, C(=NRe51)NRc51Rd51, NRc51C(=NRe51)NRc51R d51NRc51C(=NRe51)Rb51, NRc51S(O)Rb51, NRc51S(O)NRc51R d51 NRc51S(O)2Rb51, NRc51S(O)(=NRe51)Rb51, NRc51S(O)2NRc51Rd51 S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, S(O)2NRc51Rd51 OS(O)(=NRe51)Rb51, OS(O)2Rb51, SF5, P(O)Rf51Rg51 OP(O)(ORh51)(ORi51), P(O)(ORh51)(ORi51), or BRj51Rk51, in which Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, hete Petition 870250102588, of 10 / 11 / 2025, p. 25 / 574 20 / 492 5- to 10-membered roaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-Ci-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10-membered heteroaryl)-C1-6-alkyl-alkyl (heteroalkyl 4-10 members)-C1-6 alkyl- of rw5 are, each, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5Bsubstituents; each selected R5Aé independently of halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5- to 10-membered heteroaryl, 4-membered heterocycloalkyl, C6-C-C alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10-membered aryl hetero)-C1-6 alkyl-, (4-10-membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa51, SRa51, NHO C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51 OC(O)NRc51Rd51, NRc51C(O)ORa51, NRc51Rd51, NRc51NRc51Rd51 NRc51C(O)NRc51Rd51, NRc51C(O)R b51 C(=NRe51)R b51 C(=NRe51)NRc51R d51 NRc51C(=NRe51)NRc51Rd51, NRc51C(=NRe51)R b51 NRc51S(O)Rb51, NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51 NRc51S(O)(=NRe51)Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51 S(O)NRc51Rd51, S(O)2Rb51, S(O)2NRc51Rd51, OS(O)(=NRe51)Rb51 OS(O)2Rb51, SF5, P(O)Rf51Rg51, OP(O)(ORh51)(ORi51) P(O)(ORh51)(ORi51), and BRj51Rk51, in which the C1-6 alkyl, C2-6 alkenyl C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl- of R5Asão, each one, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R5Bsubstituents selected independently; each Ra51, Rc51, and Rd51é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 al Petition 870250102588, dated 10 / 11 / 2025, page. 26 / 574 21 / 492 kyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, where C1-6 alkyl, C2-6 alkenyl, C26 alkynyl, Ce-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, heterocycloalkyl 4- to 10-membered, Ce-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-e alkyl-, and (4-10 membered heterocycloalkyl)-C1-e alkyl- of Ra51, Rc51, and Rd51 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 R5B independently selected substitutes; or any Rc51 and Rd51 bonded to the same N atom, together with the N atom to which they are bonded, form a 5- to 10-membered heteroaryl group or a 4- to 10-membered heterocycloalkyl group, wherein the 5- to 10-membered heteroaryl group or the 4- to 10-membered heterocycloalkyl group is optionally substituted by independently selected 1, 2, 3 or 4 R5B substituents; each Rb51é selected independently of H, C1-e alkyl, C1-e haloalkyl, C2-e alkenyl, C2-e alkynyl, Ce-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, Ce-C-10-1 alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (5-10-membered heteroaryl)-C1-alkyl-, and (4-10-membered heterocycloalkyl) C1-e alkyl-, in which C1-e alkyl, C2-e alkene, C1-e alkyl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, Ce-10 aryl-C1-e alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (5-10-membered heteroaryl)-C1-alkyl-alkyl (heteroaryl) of 4-10 members)-C1-and alkyl- of Rb51são, each, optionally substituted by 1, 2, 3, 4, 5, e, 7 or 8 independently selected R5Bsubstituents; each Re51é independently selected from H, OH, CN, C1-e alkyl, C1-e alkoxy, C1-e haloalkyl, C1-e haloalkoxy, C2-e alkenyl, C2-e alkynyl, Ce-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl members, Ce-10 aryl-C1-e alkyl-, C3-10 Petition 870250102588, dated 10 / 11 / 2025, page. 27 / 574 22 / 492 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-; each Rf51e Rg51é independently selected from H, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; each Rh51 and Ri51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5-10 membered heteroaryl, 4-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; Each Rj51e Rk51e is selected independently from OH, C1-6 alkoxy and C1-6 haloalkoxy; or any Rj51 and Rk51 bonded to the same B atom, together with the B atom to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents selected independently from C1-6 alkyl and C1-6 haloalkyl; each R5Bé independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl, (5-membered heteroaryl)-C1-6 alkyl-, (4-7-membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa52, SRa52, NHORa52, C(O)Rb52, C(O)NRc52Rd52, C(O)NRc52(ORa52), C(O)ORa52, OC(O)Rb52, OC(O)NRc52Rd52, NRc52Rd52, NRc52NRc52Rd52NRc52C(O)Rb52, NRc52C(O)ORa52, NRc52C(O)NRc52Rd52, C(=NRe52)Rb52, C(=NRe52)NRc52Rd52, NRc52C(=NRe52)NRc52Rd52, Petition 870250102588, dated 10 / 11 / 2025, page. 28 / 574 23 / 492 NRc52C(=NRe52)Rb52, NRc52S(O)Rb52, NRc52S(O)2Rb52, NRc52S(O)(=NRe52)Rb52, S(O)Rb52, S(O)NRc52Rd52, S(O)2Rb52, NRc52S(O)NRc52Rd52, NRc52S(O)2NRc52Rd52, S(O)2NRc52Rd52, OS(O)(=NRe52)Rb52, and OS(O)2Rb52, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl- of R5Bsão, each one, optionally substituted by 1, 2, 3 or 4 RMsubstituents selected independently; each Ra52, Rc52, and Rd52 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra52, Rc52e Rd52são, each amu, optionally substituted by 1, 2, 3 or 4 RMsubstituintes independently selected; or any Rc52 and Rd52 bonded to the same N atom, together with the N atom to which they are bonded, form a 5- to 6-membered heteroaryl group or a 4- to 7-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl group or the 4- to 7-membered heterocycloalkyl group is optionally substituted by independently selected 1, 2, 3 or 4 RM substituents; each Rb52 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, Petition 870250102588, dated 10 / 11 / 2025, p. 29 / 574 24 / 492 phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, (5-6 member heteroaryl)-Ci-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenylC1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C16 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl- of Rb52são, each one, optionally substituted by 1, 2, 3 or 4 independently selected RMsubstitutes; each Re52é independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, and (4-7 member heterocycloalkyl)-C1-6 alkyl-; and each RMe independently selected from H, OH, halo, oxo, CN, C(O)OH, NH2, NO2, SF5, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5- to 10-membered heteroaryl)-C1-6 alkyl-, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-; given that: (i) Cy4 is not a triazolopyridinyl; and (ii) R5 is not a morpholinyl or piperazinyl; and (iii) when Cy4 is phenyl, R5 is not a pyridinyl or pyrimidinyl.

[0011] In some embodiments, Cy4 is selected from C6-10 aryl and heteroaryl groups of 5 to 14 members, wherein the C6-10 aryl and heteroaryl groups of 5 to 12 members of Cy4 are each optionally replaced by 1, 2, 3, or 4 independently selected R4 substituents; provided that: Petition 870250102588, dated 10 / 11 / 2025, p. 30 / 574 25 / 492 (i) Cy4 is not a triazolopyridinyl; and (ii) R5 is not a morpholinyl or piperazinyl; and (iii) when Cy4 is phenyl, R5 is not a pyridinyl or pyrimidinyl.

[0012] In some embodiments, Cy4 is selected from 5- to 14-membered phenyl and heteroaryl groups, wherein 5- to 14-membered phenyl and heteroaryl groups of Cy4 are each optionally substituted by 1, 2, 3, or 4 independently selected R4 substituents; provided that: (i) Cy4 is not a triazolopyridinyl; and (ii) R5 is not a morpholinyl or piperazinyl; and (iii) when Cy4 is phenyl, R5 is not a pyridinyl or pyrimidinyl.

[0013] In some embodiments, Cy4 is selected from phenyl, 5-6 membered monocyclic heteroaryl and 8-14 membered bicyclic heteroaryl, wherein the phenyl, 5-6 membered monocyclic heteroaryl and 8-14 membered bicyclic heteroaryl of Cy4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4 substituents; provided that: (i) Cy4 is not a triazolopyridinyl; and (ii) R5 is not a morpholinyl or piperazinyl; and (iii) when Cy4 is phenyl, R5 is not a pyridinyl or pyrimidinyl.

[0014] In some embodiments, Cy4 is selected from phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2b]pyridazinyl, pyrazol[1,5-a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-onyl and pyrazol[4,3-b]pyridinyl, wherein phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazol[1,5-a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-onyl and Cy4 pyrazol[4,3-b]pyridinil, each optionally substituted by 1, 2, 3 or 4 independently selected R4 substituents; Petition 870250102588, dated 10 / 11 / 2025, page 31 / 574 26 / 492 provided that: (i) R5 is not morpholinyl or piperazinyl; and (ii) when Cy4 is phenyl, R5 is not pyridinyl or pyrimidinyl.

[0015] In some embodiments, Cy4 is selected from phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2b]pyridazinyl and pyrazol[1,5-a]pyrimidinyl, wherein the phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl groups of Cy4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4 substituents; provided that: (i) R5 is not morpholinyl or piperazinyl; and (ii) when Cy4 is phenyl, R5 is not pyridinyl or pyrimidinyl.

[0016] In some embodiments, Cy4 is phenyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl, piperazinyl, pyridinyl or pyrimidinyl.

[0017] In some embodiments, Cy4 is selected from thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazol[1,5-a]pyrimidinyl, wherein the thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazol[1,5-a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-onyl and pyrazol[4,3-b]pyridinyl of Cy4 are each optionally substituted by 1, 2, 3 or 4 R4substituents, provided that R5 is not morpholinyl or piperazinyl.

[0018] In some embodiments, Cy4 is selected from thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazol[1,5-a]pyrimidinyl, wherein the thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl of Cy4 are each optionally substituted by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0019] In some embodiments, Cy4 is selected from among thiazolyl, Petition 870250102588, dated 10 / 11 / 2025, p. 32 / 574 27 / 492 pyrazolyl, pyridinyl and pyrimidinyl, wherein the thiazolyl, pyrazolyl, pyridinyl and pyrimidinyl groups of Cy4 are each optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0020] In some embodiments, Cy4 is thiazolyl, which is optionally replaced by 1 or 2 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0021] In some embodiments, Cy4 is pyrazolyl, which is optionally replaced by 1 or 2 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0022] In some embodiments, Cy4 is pyridinyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0023] In some embodiments, Cy4 is pirimidinyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0024] In some embodiments, Cy4 is selected from quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazol[1,5-a]pyrimidinyl, pyrrolo[3,2b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-onyl and pyrazol[4,3b]pyridinyl, wherein the quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazol[1,5a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5b]pyridin-2-onyl and pyrazol[4,3-b]pyridinyl of Cy4 are each optionally substituted by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinnyl or piperazinyl.

[0025] In some embodiments, Cy4 is selected from quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazol[1,5-a]pyrimidinyl, wherein quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazol[1,5-a]pyrimidinyl of Cy4 are each optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0026] In some forms, Cy4 is quinolinil, which is optional Petition 870250102588, dated 10 / 11 / 2025, p. 33 / 574 28 / 492 finally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0027] In some embodiments, Cy4 is imidazo[1,2-b]pyridazinyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0028] In some embodiments, Cy4 is pyrazol[1,5-a]pyrimidinyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0029] In some embodiments, Cy4 is pyrrolo[3,2-b]pyridinyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0030] In some embodiments, Cy4 is 1,3-dihydro-2Himidazo[4,5-b]pyridin-2-onyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0031] In some embodiments, Cy4 is pyrazol[4,3-b]pyridinyl, which is optionally replaced by 1, 2, 3 or 4 R4 substituents, provided that R5 is not morpholinyl or piperazinyl.

[0032] In some categories, the Formula 1 compound is a Formula 2 compound: II or a pharmaceutically acceptable salt thereof.

[0033] In some forms, the Formula I compound is a Formula IIa compound: Petition 870250102588, dated 10 / 11 / 2025, p. 34 / 574 29 / 492 or a pharmaceutically acceptable salt thereof, where m is 0, 1, 2, 3, 4, 5, 6 or 7.

[0034] In some forms, the Formula I compound is a Formula IIb compound: or a pharmaceutically acceptable salt thereof, where m is 0, 1, 2, 3, 4, 5, 6 or 7.

[0035] In some forms of Formulas IIa and IIb, m is 0, 1, 2, 3 or 4.

[0036] In some forms of Formulas IIa and IIb, m is 0, 1, 2 or 3.

[0037] In some forms of Formulas IIa and IIb, m is 0, 1 or 2. Petition 870250102588, dated 10 / 11 / 2025, p. 35 / 574 30 / 492

[0038] In some forms of Formulas IIa and Ilb, m is 0 or 1.

[0039] In some embodiments, the compound of Formula I is a compound of Formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, IIIk, IIIm, IIIn: IIIf Petition 870250102588, dated 10 / 11 / 2025, p. 36 / 574 31 / 492 Illi lllk lllm llln; or a pharmaceutically acceptable salt thereof.

[0040] In some forms, the Formula I compound is a Formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi or IIIj compound: Petition 870250102588, dated 10 / 11 / 2025, p. 37 / 574 32 / 492 IlIf lllj; or a pharmaceutically acceptable salt thereof.

[0041] In some embodiments, the compound of Formula I is a compound of Formula IIIa, or a pharmaceutically acceptable salt thereof.

[0042] In some embodiments, the compound of Formula I is a compound of Formula IIIb, or a pharmaceutically acceptable salt thereof. Petition 870250102588, dated 10 / 11 / 2025, p. 38 / 574 33 / 492

[0043] In some embodiments, the compound of Formula I is a compound of Formula IIIc, or a pharmaceutically acceptable salt thereof.

[0044] In some embodiments, the compound of Formula I is a compound of Formula IIId, or a pharmaceutically acceptable salt thereof.

[0045] In some embodiments, the compound of Formula I is a compound of Formula IIIe, or a pharmaceutically acceptable salt thereof.

[0046] In some embodiments, the compound of Formula I is a compound of Formula IIIf, or a pharmaceutically acceptable salt thereof.

[0047] In some embodiments, the compound of Formula I is a compound of Formula IIIg, or a pharmaceutically acceptable salt thereof.

[0048] In some embodiments, the compound of Formula I is a compound of Formula IIIh, or a pharmaceutically acceptable salt thereof.

[0049] In some embodiments, the compound of Formula I is a compound of Formula IIIi, or a pharmaceutically acceptable salt thereof.

[0050] In some embodiments, the compound of Formula I is a compound of Formula IIIj, or a pharmaceutically acceptable salt thereof.

[0051] In some embodiments, the compound of Formula I is a compound of Formula IIIk, or a pharmaceutically acceptable salt thereof.

[0052] In some embodiments, the compound of Formula I is a compound of Formula IIIm, or its pharmaceutically acceptable salt. Petition 870250102588, dated 10 / 11 / 2025, p. 39 / 574 34 / 492

[0053] In some embodiments, the compound of Formula I is a compound of Formula IIIn, or its pharmaceutically acceptable salt.

[0054] In some forms, the Formula I compound is a Formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVi, IVj, IVk, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu or IVv compound: Petition 870250102588, of 10 / 11 / 2025, p. 40 / 574 35 / 492 % ,cy2r^^^r4“r / X? H THEIR, R5 R1-N Cy2 N-R4 IVi THEIR, R1-N R4.4 R1-N R4 Ivj R5 Cy2 N IVk Ok Cy2r4 d5 ΉyAYR R nA XXn-''''^'X''R4 NNR H IVm IVo; R1 IVn ,5 R4 R1 R1-N R4 R5 N~~R4 IVp R5 Cy2 N R4 / R4 IVq IVr IVs Petition 870250102588, of 10 / 11 / 2025, p. 41 / 574 36 / 492 IVt IVu or a pharmaceutically acceptable salt thereof.

[0055] In some forms, the Formula I compound is a Formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVi, IVj, IVk, IVm, IVn, IVo compound: IVb IVd Petition 870250102588, dated 10 / 11 / 2025, p. 42 / 574 37 / 492 ivj R4 THE, R1-N R5 Cy2 N IVm or a pharmaceutically acceptable salt thereof.

[0056] In some disciplines, the Formula 1 compound is a Petition 870250102588, dated 10 / 11 / 2025, p. 43 / 574 38 / 492 composed of Formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh or IVi: or a pharmaceutically acceptable salt thereof. Petition 870250102588, dated 10 / 11 / 2025, p. 44 / 574 39 / 492

[0057] In some embodiments, the compound of Formula I is a compound of Formula IVa, or a pharmaceutically acceptable salt thereof.

[0058] In some embodiments, the compound of Formula I is a compound of Formula IVb, or a pharmaceutically acceptable salt thereof.

[0059] In some embodiments, the compound of Formula I is a compound of Formula IVc, or a pharmaceutically acceptable salt thereof.

[0060] In some embodiments, the compound of Formula I is a compound of Formula IVd, or a pharmaceutically acceptable salt thereof.

[0061] In some embodiments, the compound of Formula I is a compound of Formula IVe, or a pharmaceutically acceptable salt thereof.

[0062] In some embodiments, the compound of Formula I is a compound of Formula IVf, or a pharmaceutically acceptable salt thereof.

[0063] In some embodiments, the compound of Formula I is a compound of Formula IVg, or a pharmaceutically acceptable salt thereof.

[0064] In some embodiments, the compound of Formula I is a compound of Formula IVh, or a pharmaceutically acceptable salt thereof.

[0065] In some embodiments, the compound of Formula I is a compound of Formula IVi, or a pharmaceutically acceptable salt thereof.

[0066] In some embodiments, the compound of Formula I is a compound of Formula IVj, or a pharmaceutically acceptable salt thereof. Petition 870250102588, dated 10 / 11 / 2025, p. 45 / 574 40 / 492

[0067] In some embodiments, the compound of Formula I is a compound of Formula IVk, or a pharmaceutically acceptable salt thereof.

[0068] In some embodiments, the compound of Formula I is a compound of Formula IVm, or a pharmaceutically acceptable salt thereof.

[0069] In some embodiments, the compound of Formula I is a compound of Formula IVn, or a pharmaceutically acceptable salt thereof.

[0070] In some embodiments, the compound of Formula I is a compound of Formula IVo, or a pharmaceutically acceptable salt thereof.

[0071] In some embodiments, the compound of Formula I is a compound of Formula IVp, or a pharmaceutically acceptable salt thereof.

[0072] In some embodiments, the compound of Formula I is a compound of Formula IVq, or a pharmaceutically acceptable salt thereof.

[0073] In some embodiments, the compound of Formula I is a compound of Formula IVr, or a pharmaceutically acceptable salt thereof.

[0074] In some embodiments, the compound of Formula I is a compound of Formula IVs, or a pharmaceutically acceptable salt thereof.

[0075] In some embodiments, the compound of Formula I is a compound of Formula IVt, or a pharmaceutically acceptable salt thereof.

[0076] In some embodiments, the compound of Formula I is a compound of Formula IVu, or a pharmaceutically acceptable salt thereof. Petition 870250102588, dated 10 / 11 / 2025, p. 46 / 574 41 / 492

[0077] In some embodiments, the compound of Formula I is a compound of Formula IVv, or a pharmaceutically acceptable salt thereof.

[0078] In some forms, the Formula I compound is a compound of Formula Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, VIi, Vj, Vk, Vm or Vn: ox / —ORa2 HN o °VX2-(R2)m R5 K . / N R1-N R1-N V R3 X y- ΪΎ aJ Γ H Va O o hnXor- o p1 kX / Cy'(R2)m 1 Ν' H R4 Vc O o hiAor*2o . Κ'Άϊ λ}1-NI R5 R1-N R3 / V \ JN^yR4 WJ 1 H Ve O HN^ORa2 N 'm 1 3 R4 XR 1 1 N^\ H r5 Vb O HN^ORa2 / ^^'ÍR2) >1 (fX Jm . 3 R4 H Vd O HhAoRa2 1 9 -N'Cy'(R2)m A 3 r5 X^-R3 / A / N Λ-UH Vf Petition 870250102588, dated 10 / 11 / 2025, p. 47 / 574 42 / 492 Vm Petition 870250102588, dated 10 / 11 / 2025, p. 48 / 574 43 / 492 0Ra2 Vn; or a pharmaceutically acceptable salt thereof.

[0079] In some embodiments, the compound of Formula I is a compound of Formula Va, or a pharmaceutically acceptable salt thereof.

[0080] In some embodiments, the compound of Formula I is a compound of Formula Vb, or a pharmaceutically acceptable salt thereof.

[0081] In some embodiments, the compound of Formula I is a compound of Formula Vc, or a pharmaceutically acceptable salt thereof.

[0082] In some embodiments, the compound of Formula I is a compound of Formula Vd, or a pharmaceutically acceptable salt thereof.

[0083] In some embodiments, the compound of Formula I is a compound of Formula Ve, or a pharmaceutically acceptable salt thereof.

[0084] In some embodiments, the compound of Formula I is a compound of Formula Vf, or a pharmaceutically acceptable salt thereof.

[0085] In some embodiments, the compound of Formula I is a compound of Formula Vg, or a pharmaceutically acceptable salt thereof.

[0086] In some disciplines, the Formula 1 compound is a Petition 870250102588, dated 10 / 11 / 2025, p. 49 / 574 44 / 492 compound of Formula Vh, or a pharmaceutically acceptable salt thereof.

[0087] In some embodiments, the compound of Formula I is a compound of Formula VI, or a pharmaceutically acceptable salt thereof.

[0088] In some embodiments, the compound of Formula I is a compound of Formula Vj, or a pharmaceutically acceptable salt thereof.

[0089] In some embodiments, the compound of Formula I is a compound of Formula Vk, or a pharmaceutically acceptable salt thereof.

[0090] In some embodiments, the compound of Formula I is a compound of Formula Vm, or a pharmaceutically acceptable salt thereof.

[0091] In some embodiments, the compound of Formula I is a compound of Formula Vn, or a pharmaceutically acceptable salt thereof.

[0092] In some forms of the Va-Vn Formulas, m is 0, 1, 2, 3 or 4.

[0093] In some forms of the Va-Vn Formulas, m is 0, 1, 2 or 3.

[0094] In some forms of the Va-Vn Formulas, m is 0, 1 or 2.

[0095] In some embodiments of the Va-Vn Formulas, m is 0 or 1.

[0096] In rcasoma embodiments, the Formula I compound is a Formula VIa, VIb, VIc, VId, VIe, VIf, VIg, VIh, VIi, VIj, VIk, VIm or VIn compound: Petition 870250102588, dated 10 / 11 / 2025, p. 50 / 574 45 / 492 VI Petition 870250102588, dated 10 / 11 / 2025, p. 51 / 574 46 / 492 VIm Petition 870250102588, dated 10 / 11 / 2025, p. 52 / 574 47 / 492 O VIn; or a pharmaceutically acceptable salt thereof.

[0097] In some embodiments, the compound of Formula I is a compound of Formula VIa, or a pharmaceutically acceptable salt thereof.

[0098] In some embodiments, the compound of Formula I is a compound of Formula VIb, or a pharmaceutically acceptable salt thereof.

[0099] In some embodiments, the compound of Formula I is a compound of Formula VIc, or a pharmaceutically acceptable salt thereof.

[00100] In some embodiments, the compound of Formula I is a compound of Formula VId, or a pharmaceutically acceptable salt thereof.

[00101] In some embodiments, the compound of Formula I is a compound of Formula VIe, or a pharmaceutically acceptable salt thereof.

[00102] In some embodiments, the compound of Formula I is a compound of Formula VIf, or a pharmaceutically acceptable salt thereof.

[00103] In some embodiments, the compound of Formula I is a compound of Formula VIg, or a pharmaceutically acceptable salt thereof.

[00104] In some disciplines, the Formula 1 compound is a Petition 870250102588, dated 10 / 11 / 2025, p. 53 / 574 48 / 492 compound of Formula VIh, or a pharmaceutically acceptable salt thereof.

[00105] In some embodiments, the compound of Formula I is a compound of Formula VII, or a pharmaceutically acceptable salt thereof.

[00106] In some embodiments, the compound of Formula I is a compound of Formula VIj, or a pharmaceutically acceptable salt thereof.

[00107] In some embodiments, the compound of Formula I is a compound of Formula VIk, or a pharmaceutically acceptable salt thereof.

[00108] In some embodiments, the compound of Formula I is a compound of Formula VIm, or a pharmaceutically acceptable salt thereof.

[00109] In some embodiments, the compound of Formula I is a compound of Formula VIn, or a pharmaceutically acceptable salt thereof.

[00110] In some embodiments of the VIa-VIn Formulas, m is 0, 1, 2, 3 or 4.

[00111] In some embodiments of the VIa-VIn Formulas, m is 0, 1, 2 or 3.

[00112] In some embodiments of the VIa-VIn Formulas, m is 0, 1 or 2.

[00113] In some embodiments of the VIa-VIn Formulas, m is 0 or 1.

[00114] In some embodiments, the compound of Formula I is a compound of Formula VIIa, VIIb, VIIc, VIId, VIIe, VIIf, VIIg, VIIh, VIIi, VIIj, VIIk, VIIm, VIIn or VIIo: Petition 870250102588, dated 10 / 11 / 2025, p. 54 / 574 49 / 492 Village Petition 870250102588, dated 10 / 11 / 2025, p. 55 / 574 50 / 492 Petition 870250102588, dated 10 / 11 / 2025, p. 56 / 574 51 / 492 YoRa2 HN VIIn or a pharmaceutically acceptable salt thereof.

[00115] In some embodiments, the compound of Formula I is a compound of Formula VIIa, or a pharmaceutically acceptable salt thereof.

[00116] In some embodiments, the compound of Formula I is a compound of Formula VIIb, or a pharmaceutically acceptable salt thereof.

[00117] In some embodiments, the compound of Formula I is a compound of Formula VIIc, or a pharmaceutically acceptable salt thereof.

[00118] In some embodiments, the compound of Formula I is a compound of Formula VIId, or a pharmaceutically acceptable salt thereof.

[00119] In some embodiments, the compound of Formula I is a compound of Formula VIIe, or a pharmaceutically acceptable salt thereof.

[00120] In some embodiments, the compound of Formula I is a compound of Formula VIIf, or a pharmaceutically acceptable salt thereof.

[00121] In some embodiments, the compound of Formula I is a compound of Formula VIIg, or a pharmaceutically acceptable salt thereof. Petition 870250102588, dated 10 / 11 / 2025, p. 57 / 574 52 / 492

[00122] In some embodiments, the compound of Formula I is a compound of Formula VIIh, or a pharmaceutically acceptable salt thereof.

[00123] In some embodiments, the compound of Formula I is a compound of Formula VIIi, or a pharmaceutically acceptable salt thereof.

[00124] In some embodiments, the compound of Formula I is a compound of Formula VIIj, or a pharmaceutically acceptable salt thereof.

[00125] In some embodiments, the compound of Formula I is a compound of Formula VIIk, or a pharmaceutically acceptable salt thereof.

[00126] In some embodiments, the compound of Formula I is a compound of Formula VIIm, or a pharmaceutically acceptable salt thereof.

[00127] In some embodiments, the compound of Formula I is a compound of Formula VIIn, or a pharmaceutically acceptable salt thereof.

[00128] In some embodiments, the compound of Formula I is a compound of Formula VIIo, or its pharmaceutically acceptable salt.

[00129] In some forms of Formulas VIIa-VIIo, m is 0, 1, 2, 3 or 4.

[00130] In some forms of Formulas VIIa-VIIo, m is 0, 1, 2 or 3.

[00131] In some forms of Formulas VIIa-VIIo, m is 0, 1 or 2.

[00132] In some forms of Formulas VIIa-VIIo, m is 0 or 1.

[00133] In some disciplines, the Formula 1 compound is a Petition 870250102588, dated 10 / 11 / 2025, p. 58 / 574 53 / 492 composed of Formula Vllla, Vlllb, Vlllc, Vllld, Vllle, Vlllf, Vlllg, Vlllh, Vllli, Vlllj, Vlllk, Vlllm, Vllln or Vlllo: Petition 870250102588, dated 10 / 11 / 2025, p. 59 / 574 54 / 492 Petition 870250102588, dated 10 / 11 / 2025, p. 60 / 574 55 / 492 VIIn or a pharmaceutically acceptable salt thereof.

[00134] In some embodiments, the compound of Formula I is a compound of Formula VIIIa, or a pharmaceutically acceptable salt thereof.

[00135] In some embodiments, the compound of Formula I is a compound of Formula VIIIb, or a pharmaceutically acceptable salt thereof.

[00136] In some embodiments, the compound of Formula I is a compound of Formula VIIIc, or a pharmaceutically acceptable salt thereof.

[00137] In some embodiments, the compound of Formula I is a compound of Formula VIIId, or a pharmaceutically acceptable salt thereof.

[00138] In some embodiments, the compound of Formula I is a compound of Formula VIIIe, or a pharmaceutically acceptable salt thereof.

[00139] In some embodiments, the compound of Formula I is a compound of Formula VIIIf, or a pharmaceutically acceptable salt thereof.

[00140] In some embodiments, the compound of Formula I is a compound of Formula VIIIg, or a pharmaceutically acceptable salt thereof. Petition 870250102588, dated 10 / 11 / 2025, p. 61 / 574 56 / 492

[00141] In some embodiments, the compound of Formula I is a compound of Formula VIIIh, or a pharmaceutically acceptable salt thereof.

[00142] In some embodiments, the compound of Formula I is a compound of Formula VIIIi, or a pharmaceutically acceptable salt thereof.

[00143] In some embodiments, the compound of Formula I is a compound of Formula VIIIj, or its pharmaceutically acceptable salt.

[00144] In some embodiments, the compound of Formula I is a compound of Formula VIIIk, or a pharmaceutically acceptable salt thereof.

[00145] In some embodiments, the compound of Formula I is a compound of Formula VIIIm, or a pharmaceutically acceptable salt thereof.

[00146] In some embodiments, the compound of Formula I is a compound of Formula VIIIn, or a pharmaceutically acceptable salt thereof.

[00147] In some embodiments, the compound of Formula I is a compound of Formula VIII, or its pharmaceutically acceptable salt.

[00148] In some forms of Formulas VIIIa-VIIIo, m is 0, 1, 2, 3 or 4.

[00149] In some forms of Formulas VIIIa-VIIIo, m is 0, 1, 2 or 3.

[00150] In some forms of Formulas VIIIa-VIIIo, m is 0, 1 or 2.

[00151] In some forms of Formulas VIIIa-VIIIo, m is 0 or 1.

[00152] In some modes of any of the Formula 1 Petition 870250102588, dated 10 / 11 / 2025, p. 62 / 574 57 / 492 VIIIo, each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4 to 10-membered heterocycloalkyl, of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4Asubstituents.

[00153] In some embodiments of any of Formulas IVIIIo, each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl of R4 are each, optionally replaced by 1, 2, 3 or 4 independently selected R4A substitutes.

[00154] In some embodiments of any of Formulas IVIIIo, each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00155] In some embodiments of any of the Formulas IVIIIo, each R4 is selected independently from halo, C1-6 alkyl, C6-10 aryl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl Petition 870250102588, dated 10 / 11 / 2025, p. 63 / 574 58 / 492 members, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, wherein C1-6 alkyl, C6-10 aryl, 5- to 6 membered heteroaryl, 4- to 10 membered heterocycloalkyl and (4- to 10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00156] In some embodiments of any of the Formulas IVIIIo, each R4 is independently selected from halo, C1-6 alkyl, C6-10 aryl and 4- to 10-membered heterocycloalkyl, wherein the C1-6 alkyl, C6-10 aryl and 4- to 10-membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00157] In some embodiments of any of Formulas IVIIIo, each R4 is independently selected from halo, C1-6 alkyl, phenyl, 5-6 membered heteroaryl, 8-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, wherein C1-6 alkyl, phenyl, 5-6 membered heteroaryl, 8-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00158] In some embodiments of any of the Formulas IVIIIo, each R4 is independently selected from halo, C1-6 alkyl, phenyl and 8- to 10-membered heterocycloalkyl, wherein the C1-6 alkyl, phenyl and 8- to 10-membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00159] In some embodiments of any of the Formulas IVIIIo, each R4 is selected independently from fluorine, methyl, isopropyl, methoxy, morpholinylcarbonyl, phenyl, pyrazolyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein methyl, isopropyl, phenyl, pyrazolyl, piperidinyl, .... Petition 870250102588, dated 10 / 11 / 2025, p. 64 / 574 59 / 492 zolyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally replaced by 1, 2, 3 or 4 independently selected R4A substituents.

[00160] In some embodiments of any of the Formulas IVlIIo, each R4 is independently selected from fluorine, methyl, phenyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein methyl, phenyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally replaced by 1, 2, 3 or 4 independently selected R4A substituents.

[00161] In some embodiments of any of Formulas IV1IIo, R4 is selected from Ce-aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein Ce-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00162] In some embodiments of any of Formulas IV1IIo, R4 is selected from phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00163] In some embodiments of any of Formulas IVIIIo, R4 is selected from phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00164] In some modes of any of the Formula 1 Petition 870250102588, dated 10 / 11 / 2025, p. 65 / 574 60 / 492 VIIIo, R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl, and pyrazolyl groups of R4 are each optionally substituted by 1, 2, 3, or 4 independently selected R4A substitutes.

[00165] In some embodiments of any of the IVIIIo Formulas, each R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl, and pyrazolyl of R4 are each optionally replaced by 1 or 2 independently selected R4A substituents.

[00166] In some embodiments of any of the Formulas IVIIIo, each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and 5-6 membered heteroaryl, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and 5-6 membered heteroaryl of R4 is optionally replaced by 1, 2, 3 or 4 independently selected R4A substituents.

[00167] In some embodiments, R4 is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, and 5-6 membered heteroaryl, wherein each C1-6 alkyl and 5-6 membered heteroaryl of R4 is optionally replaced by 1, 2, 3 or 4 independently selected R4A substituents.

[00168] In some embodiments of any of the IVIIIo Formulas, each R4 is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00169] In some embodiments of any of the IVIIIo Formulas, each R4 is selected independently from halo, C1-6 alkyl and C1-6 haloalkyl.

[00170] In some embodiments of any of the IVIIIo Formulas, each R4 is selected independently from C1-6 haloalkyl.

[00171] In some embodiments of any of the IVIIIo Formulas, each R4 is selected independently of fluorine, methyl, triflu Petition 870250102588, dated 10 / 11 / 2025, p. 66 / 574 61 / 492 oromethyl, phenyl, pyrazolyl, tetrahydropyranyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein methyl, phenyl, pyrazolyl, tetrahydropyranyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00172] In some embodiments of any of the Formulas IVIIIo, each R4 is independently selected from fluorine, methyl, hydroxymethyl, hydroxyisopropyl, methoxy, (methylcarbonyl)piperidinyl, methylpyrazolyl, trifluoromethyl, cyanophenyl, pyrazolyl, tetrahydropyranyl, 2,3dihydrobenzo[b][1,4]dioxinyl, (difluoromethylazetidinyl)methyl and morpholinylcarbonyl.

[00173] In some embodiments of any of the IVIIIo Formulas, each R4 is independently selected from fluorine, methyl, trifluoromethyl, cyanophenyl, pyrazolyl, tetrahydropyranyl and 2,3-dihydrobenzo[b][1,4]dioxinyl.

[00174] In some embodiments of any of the Formulas IVIIIo, R4 is selected independently from fluorine, methyl, hydroxymethyl, hydroxyisopropyl, methoxy, (methylcarbonyl)piperidinyl, methylpyrazolyl, cyanophenyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, and (difluoromethylazetidinyl)methyl and morpholinylcarbonyl.

[00175] In some embodiments of any of the IVIIIo Formulas, R4 is independently selected from fluorine, methyl, cyanophenyl and 2,3-dihydrobenzo[b][1,4]dioxinyl.

[00176] In some embodiments of any of the IVIIIo Formulas, R4 is trifluoromethyl.

[00177] In some embodiments of any of the Formulas IVIIIo, each Ra4, Rb4, Rc4, and Rd4 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00178] In some embodiments of any of the IVIIIo Formulas, each Ra4e Rc4e is selected independently of H and C1-6 Petition 870250102588, dated 10 / 11 / 2025, p. 67 / 574 62 / 492 alkyl.

[00179] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa41, and C(O)Rb41.

[00180] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41.

[00181] In some embodiments of any of the IVIIIo Formulas, each Ra41e Rb41 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00182] In some embodiments of any of the IVIIIo Formulas, each Ra41 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00183] In some embodiments of any of the IVIIIo Formulas, each Ra41 is selected independently from H, C1-6 alkyl and C1-6 haloalkyl.

[00184] In some embodiments of any of the IVIIIo Formulas, each Ra41 is selected independently of H and C1-6 alkyl.

[00185] In some embodiments of any of the IVIIIo Formulas, each Rb41 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00186] In some embodiments of any of the IVIIIo Formulas, each Rb41 is selected independently from H, C1-6 alkyl and C1-6 haloalkyl.

[00187] In some embodiments of any of the IVIIIo Formulas, each Rb41 is selected independently of H and C1-6 alkyl.

[00188] In some embodiments of any of the Formulas IVIIIo, each R4A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa41, and C(O)Rb41; and each Ra41 and Rb41 is selected independently from H, C1-6 alkyl, Petition 870250102588, dated 10 / 11 / 2025, p. 68 / 574 63 / 492 C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00189] In some embodiments of any of the Formulas IVIIIo, each R4A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa41, and C(O)Rb41; and each Ra41 and Rb41 is selected independently from H, C1-6 alkyl and C1-6 haloalkyl.

[00190] In some embodiments of any of the Formulas IVIIIo, each R4A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa41, and C(O)Rb41; and each Ra41 and Rb41 is selected independently of H and C1-6 alkyl.

[00191] In some embodiments of any of the Formulas IVIIIo, each R4A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; and each Ra41 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00192] In some embodiments of any of the Formulas IVIIIo, each R4A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; and each Ra41 is selected independently from H, C1-6 alkyl and C1-6 haloalkyl.

[00193] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; and each Ra41 is selected independently of H and C1-6 alkyl.

[00194] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN.

[00195] In some modalities, each R4A is independently Petition 870250102588, dated 10 / 11 / 2025, p. 69 / 574 64 / 492 selected from C1-6 haloalkyl, CN and ORa41.

[00196] In some embodiments, each R4A is selected independently of C1-6 haloalkyl, CN and ORa41; and each Ra41 is selected independently of H and C1-6 alkyl.

[00197] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN.

[00198] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently from C1-6 alkyl, C1-6 haloalkyl and CN.

[00199] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently of C1-6 alkyl and CN.

[00200] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently from among methyl, difluoromethyl, CN, OH, and methylcarbonyl.

[00201] In some embodiments of any of the IVIIIo Formulas, each R4A is selected independently of methyl and CN.

[00202] In some forms of any of the IVIIIo Formulas, each R4A is CN.

[00203] In some embodiments, R4 is selected independently from 5-6 membered C1-6 alkyl, C1-6 haloalkyl and heteroaryl, wherein each 5-6 membered C1-6 alkyl and heteroaryl of R4 is optionally replaced by 1, 2, 3 or 4 R4A substituents; Each R4A is selected independently from C1-6 haloalkyl, CN and ORa41; and each Ra41 is selected independently from H and C1-6 alkyl.

[00204] In some embodiments of any of the IVIIIo Formulas, R4 is selected from methyl, ethyl, isopropyl, trifluoromethyl and Petition 870250102588, dated 10 / 11 / 2025, p. 70 / 574 65 / 492 pyridinyl, wherein each methyl, ethyl, isopropyl and pyridinyl of R4 is optionally replaced by 1 or 2 R4A substituents selected independently from C1-3 haloalkyl, CN, OH and C1-3 alkoxy.

[00205] In some embodiments of any of Formulas IVIIIo, R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, phenyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, ORw2, NRw2Rw3, C(O)Rw2, C(O)NRw2Rw3, C(O)Rw2, NRw3C(O)Rw2, NRw3C(O)ORw2, and NRw3S(O)2Rw2, wherein the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; and wherein C1-6 alkyl and phenyl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents;or the phenyl group of R5 is replaced by 1 Rw5 substitute and optionally replaced by 1 or 2 R5A substitutes selected independently.

[00206] In some embodiments of any of Formulas IVIIIo, R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, phenyl, triazolyl, pyrazolyl, imidazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, ORw2, NRw2Rw3, C(O)Rw2, C(O)NRw2Rw3, C(O)Rw2, NRw3C(O)Rw2, NRw3C(O)ORw2, and NRw3S(O)2Rw2, to C3-12 cycloalkyl, triazolyl, imidazolyl, pyrazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 selected R5A substituents. Petition 870250102588, dated 10 / 11 / 2025, p. 71 / 574 66 / 492 independently selected; and wherein the C1-6 alkyl and phenyl groups of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 R5A substituents selected independently; or the phenyl group of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 R5A substituents selected independently.

[00207] In some embodiments of any of Formulas IVIIIo, R5 is selected from C1-6 alkyl, C3-7 cycloalkyl, phenyl, triazolyl, pyrazolyl, imidazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptaniyl, ORw2, NHRw2, C(O)Rw2, C(O)NHRw2, C(O)Rw2, NHC(O)Rw2, NHC(O)ORw2, and NHS(O)2Rw2, where C3-12 cycloalkyl, triazolyl, imidazolyl, pyrazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are, each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; and wherein C1-6 alkyl and phenyl of R5 are, each, substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents;or the phenyl group of R5 is replaced by 1 Rw5 substitute and optionally replaced by 1 or 2 R5A substitutes selected independently.

[00208] In some embodiments of any of Formulas IVIIIo, R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents. Petition 870250102588, dated 10 / 11 / 2025, p. 72 / 574 67 / 492

[00209] In some embodiments of any of Formulas IVIIIo, R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NHRw2, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents.

[00210] In some embodiments of any of Formulas IVIIIo, R5 is selected from C1-6 alkyl, C3-7 cycloalkyl, phenyl, 5- to 10-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2; wherein the C1-6 alkyl and phenyl groups of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the phenyl group of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-7 cycloalkyl, 5- to 10-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl groups of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00211] In some embodiments of any of Formulas IVIIIo, R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl groups of R5 are each replaced by one Rw1 substituent and optionally replaced by one or two independently selected R5A substituents; or the C6-10 aryl group of R5 is replaced by one Rw5 substituent and optionally replaced by one or two independently selected R5A substituents. Petition 870250102588, dated 10 / 11 / 2025, p. 73 / 574 68 / 492 nationally substituted 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00212] In some embodiments of any of Formulas IV1IIo, R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00213] In some embodiments of any of Formulas IVlIIo, R5 is selected from -CH2Rw1, C3-7 cycloalkyl, -phenyl-Rw1, -phenylRw5, pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2, wherein C3-7 cycloalkyl, phenyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-di Petition 870250102588, dated 10 / 11 / 2025, p. 74 / 574 69 / 492 hydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00214] In some embodiments of any of the IVIIIo Formulas, R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NRw2Rw3, NRw3C(O)Rw2, NRw3C(O)ORw2, and NRw3S(O)2Rw2, wherein the triazolyl, pyrazolyl, piperidinyl and tetrahydropyranyl groups of R5 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00215] In some embodiments of any of the IVIIIo Formulas, R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NHRw2, NHC(O)Rw2, NHC(O)ORw2, and NHS(O)2Rw2, wherein the triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranyl of R5 are each optionally replaced by 1, 2, 3, or 4 independently selected R5A substituents.

[00216] In some embodiments of any of Formulas IVIIIo, R5 is selected from C3-7 cycloalkyl, 5-6 membered heteroaryl, NHRw2, and C(O)Rw2, wherein the C3-7 cycloalkyl and 5-6 membered heteroaryl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00217] In some embodiments of any of the IVIIIo Formulas, R5 is selected from cyclopropyl, pyrazolyl, imidazolyl, NHRw2, and C(O)Rw2, wherein the cyclopropyl, pyrazolyl, imidazolyl, and R5 are each optionally replaced by 1, 2, 3, or 4 independently selected R5A substituents.

[00218] In some embodiments of any of Formulas IVIIIo, Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 R5A substituents selected independently. Petition 870250102588, dated 10 / 11 / 2025, p. 75 / 574 70 / 492 you.

[00219] In some embodiments of any of the IVIIIo Formulas, Rw1 is selected from C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-7 cycloalkyl and 4-7 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3 or 4 R5A substituents selected independently.

[00220] In some embodiments of any of the IVIIIo Formulas, Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, trifluoromethoxy and cyclopentylamino.

[00221] In some embodiments of any of Formulas IVIIIo, Rw2 is selected from C3-7 cycloalkyl, 8- to 12-membered bicyclic heteroaryl, 4- to 7-membered monocyclic heterocycloalkyl and 8- to 12-membered bicyclic heterocycloalkyl, wherein the C3-7 cycloalkyl, 8- to 12-membered bicyclic heteroaryl, 4- to 7-membered monocyclic heterocycloalkyl and 8- to 12-membered bicyclic heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00222] In some embodiments of any of Formulas IVIIIo, Rw2 is selected from C3-7 cycloalkyl, 4- to 8-membered monocyclic heterocycloalkyl and 6- to 10-membered bicyclic heterocycloalkyl, wherein the C3-7 cycloalkyl, 4- to 8-membered monocyclic heterocycloalkyl and 6- to 10-membered bicyclic heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00223] In some embodiments of any of the IVIIIo Formulas, Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Petition 870250102588, dated 10 / 11 / 2025, p. 76 / 574 71 / 492

[00224] In some embodiments of any of the IVIIIo Formulas, each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents;

[00225] In some embodiments of any of the IVIIIo Formulas, each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein the C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents;

[00226] In some embodiments of any of the IVIIIo Formulas, each Rw2 is independently selected from C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl, wherein C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00227] In some embodiments of any of the IVIIIo Formulas, Rw2 is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, oxazolyl, octahydro-2H-pyrido[1,2-a]pyrazinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl, wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, oxazolyl, octahydro-2H-pyrido[1,2a]pyrazinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3 Petition 870250102588, dated 10 / 11 / 2025, p. 77 / 574 72 / 492 azabicyclo[3.1.0]hexanil, 2-oxa-5-azabicyclo[2.2.1]heptanil and 2-oxa-5azabicyclo[4.1.0]heptanil of Rw2 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00228] In some embodiments of any of the IVIIIo Formulas, Rw2 is selected from cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, octahydro-2H-pyrido[1,2-a]pyrazinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl, wherein cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, octahydro-2H-pyrido[1,2-a]pyrazinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-oxa-5-azabicyclo[2.2.1]heptanil and 2-oxa5-azabicyclo[4.1.0]heptanil of Rw2 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00229] In some embodiments of any of the IVIIIo Formulas, Rw2 is selected from cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, octahydro-2H-pyrido[1,2a]pyrazinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl, wherein cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, octahydro-2H-pyrido[1,2a]pyrazinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanil, 2-oxa-5-azabicyclo[2.2.1]heptanil and 2-oxa-5-azabicyclo[4.1.0]heptanil of Rw2 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00230] In some embodiments of any of the IVIIIo Formulas, Rw2 is selected from cyclobutyl, cyclopentyl, piperidinyl, morph Petition 870250102588, dated 10 / 11 / 2025, p. 78 / 574 73 / 492 linyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl, wherein the cyclobutyl, cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl of Rw2 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00231] In some embodiments of any of the IVIIIo Formulas, Rw2 is selected from cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptaniyl and 2-oxa-5-azabicyclo[4.1.0]heptaniyl, wherein cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptaniyl and 2-oxa-5-azabicyclo[4.1.0]heptaniyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 R5A substituents selected independently.

[00232] In some embodiments of any of the IVIIIo Formulas, Rw2 is selected from cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2H-pyrido[1,2-a]pyrazinyl, wherein cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2H-pyrido[1,2-a]pyrazinyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00233] In some embodiments of any of the IVIIIo Formulas, Rw2 is selected from cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2Hpyrido[1,2-a]pyrazinyl, wherein cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2Hpyrido[1,2-a]pyrazinyl of Rw2 are each optionally substituted Petition 870250102588, dated 10 / 11 / 2025, p. 79 / 574 74 / 492 by 1, 2, 3 or 4 R5A substitutes selected independently.

[00234] In some embodiments of any of the IVIIIo Formulas, each Rw2 is independently selected from cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranyl, wherein cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranyl of Rw2 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00235] In some embodiments of any of the IVIIIo Formulas, each Rw3 is selected independently of H and C1-6 alkyl.

[00236] In some embodiments of any of the IVIIIo Formulas, each Rw3 is H.

[00237] In some embodiments of any of the IVIIIo Formulas, each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl.

[00238] In some embodiments of any of the IVIIIo Formulas, each Rw4 is selected from C1-6 haloalkyl and C3-7 cycloalkyl.

[00239] In some embodiments of any of the IVIIIo Formulas, Rw5 is a C1-6 alkyl that is replaced by CN or ORa51.

[00240] In some embodiments of any of the IVIIIo Formulas, Rw5 is selected between cyanomethyl and hydroxymethyl.

[00241] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51NRc51NRc51Rd51 NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rd51, NRc51S(O)Rb51, NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, and S(O)2NRc51Rd51, where each C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl of R5A is optionally substituted by 1, Petition 870250102588, dated 10 / 11 / 2025, p. 80 / 574 75 / 492, 3 or 4 R5B substitutes selected independently.

[00242] In some modes, each R5B is selected independently of ORa52.

[00243] In some embodiments, each Ra52 is selected independently from H, C1-6 alkyl and C1-6 haloalkyl.

[00244] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51 NRc51NRc51Rd51 NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rd51, NRc51S(O)Rb51, NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, and S(O)2NRc51Rd51, wherein each C1-6 alkyl group of R5A is optionally replaced by OH.

[00245] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51NRc51NRc51Rd51 NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rd51, NRc51S(O)Rb51, NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, and S(O)2NRc51Rd51.

[00246] In some embodiments of any of the Formulas IVIIIo, each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, C(O)Rb51, and C(O)ORa51, wherein the C1-6 alkyl of R5A is optionally replaced by 1, 2, 3, or 4 independently selected R5B substituents.

[00247] In some embodiments of any of the Formulas IVIIIo, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, C(O)Rb51, and C(O)ORa51, wherein C1-6 alkyl Petition 870250102588, dated 10 / 11 / 2025, p. 81 / 574 76 / 492 kilo of R5A is optionally replaced by OH.

[00248] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, C(O)Rb51, and C(O)ORa51.

[00249] In some embodiments of any of the IVIIIo Formulas, each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51, wherein each C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl of R5A is optionally replaced by 1, 2, 3 or 4 independently selected R5B substituents.

[00250] In some embodiments of any of the Formulas IVIIIo, each R5A is selected independently from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51, wherein each C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl of R5A is optionally replaced by OH.

[00251] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51.

[00252] In some embodiments of any of the IVIIIo Formulas, each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein each C1-6 alkyl of R5A is optionally replaced by 1, 2, 3, or 4 independently selected R5B substituents.

[00253] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein each C1-6 alkyl of R5A is optionally replaced by OH.

[00254] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently of halo, C1-6 alkyl, Petition 870250102588, dated 10 / 11 / 2025, p. 82 / 574 77 / 492 Ci-6 haloalkyl, CN, ORa51, and NRc51Rd51.

[00255] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51.

[00256] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN and ORa51.

[00257] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently of halo, C1-6 alkyl and C(O)ORa5i.

[00258] In some embodiments of any of the IVIIIo Formulas, each R5A is independently selected from among fluorine, methyl, trideuteromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, CN, hydroxy, methoxy, amino, and ethoxycarbonyl.

[00259] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from among fluorine, methyl, trideuteromethyl, fluoromethyl, trifluoromethyl, CN, hydroxy, methoxy, amino, and ethoxycarbonyl.

[00260] In some embodiments of any of the IVIIIo Formulas, each R5A is independently selected from either fluoromethyl or ethoxycarbonyl. [0026i] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from among chlorine, fluorine, methyl, hydroxyisopropyl, difluoromethyl, trifluoromethyl, CN, methoxyl and amino.

[00262] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from fluorine, methyl, trifluoromethyl, CN, methoxy, and amino.

[00263] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently of fluorine, methyl, triacid. Petition 870250102588, 10 / 11 / 2025, p. 83 / 574 78 / 492 deuteromethyl, difluoromethyl, trifluoromethyl, CN and hydroxy.

[00264] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently from fluorine, methyl, trideuteromethyl, CN and hydroxyl.

[00265] In some embodiments of any of the Formulas IVIIIo, each Ra51, Rb51, Rc51, and Rd51 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00266] In some embodiments of any of the IVIIIo Formulas, each Ra51e Rb51 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00267] In some embodiments of any of the IVIIIo Formulas, each Ra51, Rb51, Rc51, and Rd51 is selected independently of H and C1-6 alkyl.

[00268] In some embodiments of any of the IVIIIo Formulas, each Ra51e Rb51 is selected independently of H and C1-6 alkyl.

[00269] In some embodiments of any of the IVIIIo Formulas, each Ra51 is selected independently of H and C1-6 alkyl.

[00270] In some embodiments of any of the IVIIIo Formulas, each Rb51 is selected independently of H and C1-6 alkyl.

[00271] In some embodiments of any of the IVIIIo Formulas, each Rc51 is selected independently of H and C1-6 alkyl.

[00272] In some embodiments of any of the IVIIIo Formulas, each Rd51 is selected independently of H and C1-6 alkyl.

[00273] In some forms of any of the IVIIIo Formulas: R4 is selected from C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein the C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl of R4 are each Petition 870250102588, dated 10 / 11 / 2025, p. 84 / 574 79 / 492 one optionally replaced by 1, 2, 3 or 4 R4A substitutes selected independently; each Ra4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; each R4A is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN; R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NRw2Rw3, NRw3C(O)Rw2, NRw3C(O)ORw2, and NRw3S(O)2Rw2, wherein the triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranyl of R5 are each optionally replaced by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein the C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 R5A substituents selected independently; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each R5A is selected independently of halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51NRc51NRc51Rd51 NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rd51, NRc51S(O)Rb51, NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, and S(O)2NRc51Rd51; and each Ra51, Rb51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00274] In some forms of any of the IVIIIo Formulas: Petition 870250102588, dated 10 / 11 / 2025, p. 85 / 574 80 / 492 each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4 to 10-membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4 to 10-membered heterocycloalkyl, of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4Asubstituents; each R4A is independently selected from halo, oxo, C1-6 alquila, C1-6 haloalquila, C2-6 alquila, C2-6 alquinila and CN; R5é selecionado de C1-6 alquila, C3-12 cicloalquila, C6-10 arila, heteroarila de 5 a 12 membris, pirrolidinila, piperidinila, 2,3-dihidrobenzo[b][1,4]dioxinila, 3,4-di-hidro-2H-benzo[b][1,4]oxazinila, azaspiro[2,4]heptanila, ORw2, NRw2Rw3, C(O)Rw2, e C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; Petition 870250102588, dated 10 / 11 / 2025, p. 86 / 574 81 / 492 each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein the C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51; and each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00275] In some forms of any of the IVIIIo Formulas: each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Petition 870250102588, dated 10 / 11 / 2025, page 87 / 574 82 / 492 each Rw3 is selected independently of H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00276] In some embodiments of any of the Formulas IVIIIo, each R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl, and pyrazolyl of R4 are each optionally substituted by 1 or 2 R4A substituents selected independently; and each Ra4 and Rc4 is selected independently from H and C1-6 alkyl; and each R4A is selected independently from C1-6 alkyl and CN.

[00277] In some embodiments of any of the IVIIIo Formulas, R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NHRw2, NHC(O)Rw2, NHC(O)ORw2, and NHS(O)2Rw2, wherein the triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranyl of R5 are each optionally replaced by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranil, wherein the cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranil of Rw2 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents; Each R5A is selected independently of halo, C1-6 alkyl, and C(O)ORa51; and each Ra51 is selected independently of H and C1-6 alkyl. Petition 870250102588, dated 10 / 11 / 2025, p. 88 / 574 83 / 492

[00278] In some embodiments of any of the IVIIIo Formulas, Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, ORw4, and NHRw4; and Rw4 is selected from between C1-6 haloalkyl and C3-7 cycloalkyl.

[00279] In some embodiments of any of the IVIIIo Formulas, Rw5 is a C1-6 alkyl that is replaced by CN or ORa51; and Ra51 is selected from H and C1-3 alkyl.

[00280] In some embodiments of any one of Formulas IVIII, each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51 NRc51NRc51Rd51 NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rd51, NRc51S(O)Rb51, NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, and S(O)2NRc51Rd51; and each Ra51, Rb51, Rc51, and Rd51é independently selected from H, C1–6 alkyl, C1–6 haloalkyl, C2–6 alkenyl and C2–6 alkynyl.

[00281] In some embodiments of any of the Formulas IVIIIo, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, C(O)Rb51, and C(O)ORa51; and each Ra51 and Rb51 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00282] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently of halo, C1-6 alkyl and C(O)ORa51; and each Ra51 is selected independently of H and C1-6 alkyl.

[00283] In some embodiments of any of the Formulas IVIIIo, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51; and Petition 870250102588, dated 10 / 11 / 2025, p. 89 / 574 84 / 492 each Ra51, Rc51, and Rd51 is selected independently from H and C1-6 alkyl.

[00284] In some embodiments of any of the IVIIIo Formulas, each R5A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, CN and ORa51; and each Ra51 is selected independently of H and C1-6 alkyl.

[00285] In some forms, the Formula I compound is a Formula II compound: or a pharmaceutically acceptable salt thereof, where: R4 selected from C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein the C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; each Ra4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; each R4A is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN; R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NRw2Rw3, NRw3C(O)Rw2, NRw3C(O)ORw2, and NRw3S(O)2Rw2, wherein the triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranyl of R5 are each optionally replaced by 1, 2, Petition 870250102588, dated 10 / 11 / 2025, p. 90 / 574 85 / 492 or 4 R5A independently selected substitutes; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 R5A substituents selected independently; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each R5Aé selected independently of halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51NRc51NRc51Rd51 NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rd51, NRc51S(O)Rb51, NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, and S(O)2NRc51Rd51; and each Ra51, Rb51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00286] In some embodiments of either Formula I and II, R4 is selected from phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00287] In some embodiments of either Formula I and II, R4 is selected from phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 R4Asubstitutes Petition 870250102588, dated 10 / 11 / 2025, p. 91 / 574 86 / 492 independently selected tweeters.

[00288] In some embodiments of either Formula I and II, R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl, and pyrazolyl groups of R4 are each optionally substituted by 1, 2, 3, or 4 independently selected R4A substituents.

[00289] In some embodiments of either Formula I and II, R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl, and pyrazolyl groups of R4 are each optionally substituted by 1 or 2 independently selected R4A substituents.

[00290] In some embodiments of either Formula I and II, each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00291] In some embodiments of either Formula I and II, each Ra4e Rc4 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00292] In some embodiments of either Formula I and II, each Ra4e Rc4 is selected independently of H and C1-6 alkyl.

[00293] In some embodiments of either Formula I and II, each Ra4e Rc4 is selected independently of H and C1-3 alkyl.

[00294] In some embodiments of either Formula I and II, R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl, and pyrazolyl of R4 are each optionally substituted by 1, 2, 3, or 4 R4A substituents selected independently; and each Ra4 and Rc4 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl. Petition 870250102588, dated 10 / 11 / 2025, p. 92 / 574 87 / 492

[00295] In some embodiments of either Formula I and II, each R4A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN.

[00296] In some embodiments of either Formula I and II, each R4A is selected independently from C1-6 alkyl, C1-6 haloalkyl and CN.

[00297] In some embodiments of either Formula I and II, each R4A is selected independently of C1-6 alkyl and CN.

[00298] In some embodiments of either Formula I and II, each R4A is selected independently of C1-3 alkyl and CN.

[00299] In some embodiments of either Formula I and II, each R4A is selected independently of methyl and CN.

[00300] In some embodiments of either Formula I and II, R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4, and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl, and pyrazolyl of R4 are each optionally substituted by 1 or 2 R4A substituents selected independently; and each Ra4 and Rc4 is selected independently of H and C1-6 alkyl; and each R4A is selected independently of C1-6 alkyl and CN.

[00301] In some embodiments of either Formula I and II, R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NHRw2, NHC(O)Rw2, NHC(O)ORw2, and NHS(O)2Rw2, wherein the triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranyl of R5 are each optionally replaced by 1, 2, 3, or 4 independently selected R5A substituents.

[00302] In some embodiments of either Formula I and II, each Rw2 is independently selected from C3-10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl Petition 870250102588, dated 10 / 11 / 2025, p. 93 / 574 88 / 492 bros, wherein C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00303] In some embodiments of either Formula I and II, each Rw2 is independently selected from C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl, wherein C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00304] In some embodiments of either Formula I and II, each Rw2 is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl, wherein cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl of Rw2 are each optionally replaced by 1, 2, 3, or 4 independently selected R5A substituents.

[00305] In some embodiments of either Formula I and II, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, C(O)Rb51, and C(O)ORa51.

[00306] In some embodiments of either Formula I and II, each R5A is selected independently of halo, C1-6 alkyl and C(O)ORa51.

[00307] In some embodiments of either Formula I and II, each Ra51, Rb51, Rc51, and Rd51 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00308] In some embodiments of either Formula I and II, each Ra51, Rb51, Rc51, and Rd51 is selected independently of H and C1-6 alkyl.

[00309] In some modes of any of the Formula 1 Petition 870250102588, dated 10 / 11 / 2025, p. 94 / 574 89 / 492 and II, each Ra51, Rb51, Rc51, and Rd51 is selected independently from H and C1-3 alkyl.

[00310] In some embodiments of either Formula I and II, each Ra51 and Rb51 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00311] In some embodiments of either Formula I and II, each Ra51 and Rb51 is selected independently of H and C1-6 alkyl.

[00312] In some embodiments of either Formula I and II, each Ra51 and Rb51 is selected independently of H and C1-3 alkyl.

[00313] In some embodiments of either Formula I and II, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, C(O)Rb51, and C(O)ORa51; and each Ra51 and Rb51 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00314] In some embodiments of either Formula I and II, each R5A is selected independently of halo, C1-6 alkyl and C(O)ORa51; and each Ra51 is selected independently of H and C1-6 alkyl.

[00315] In some embodiments of either Formula I and II, each R5A is selected independently from either fluoromethyl or ethoxycarbonyl.

[00316] In some embodiments of either Formula I and II, R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NHRw2, NHC(O)Rw2, NHC(O)ORw2, and NHS(O)2Rw2, wherein the triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranyl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; Petition 870250102588, dated 10 / 11 / 2025, p. 95 / 574 90 / 492 each Rw2 is independently selected from cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranil, wherein cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranil of Rw2 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents; Each R5A is selected independently of halo, C1-6 alkyl, and C(O)ORa51; and each Ra51 is selected independently of H and C1-6 alkyl.

[00317] In some forms, the Formula I compound is a Formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi or IIIj compound: IIIa IIIc IIIe IIIf Petition 870250102588, dated 10 / 11 / 2025, p. 96 / 574 91 / 492 lllj; IlIn; lllm or a pharmaceutically acceptable salt thereof, where: each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of R4 are each optionally substituted Petition 870250102588, dated 10 / 11 / 2025, page 97 / 574 92 / 492 substitutes selected independently by 1, 2, 3 or 4 R4A substitutes; each R4A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN; R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; Each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, and 4- to 12-membered heterocycloalkyl, wherein the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3, or 4 R5A substituents selected in Petition 870250102588, dated 10 / 11 / 2025, p. 98 / 574 93 / 492 depending; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; Each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R5A are each optionally replaced by ORa52 and 1, 2, 3, 4, 5, 6, or 7 halo groups independently selected; and each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; and each Ra52 is independently selected from H and C1-6 alkyl.

[00318] In some modalities of the previous modality: each R4 is independently selected from halo, oxo, C16 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5 to 10 membered heteroaryl and 4 to 10 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4Asubstituents; each R4A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN; R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, Petition 870250102588, dated 10 / 11 / 2025, page 99 / 574 94 / 492 azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; each R5A is selected independently of halo, oxo, Petition 870250102588, dated 10 / 11 / 2025, p. 100 / 574 95 / 492 C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51; and each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00319] In some forms, the Formula I compound is a Formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi or IIIj compound: IlIa IIIf Petition 870250102588, dated 10 / 11 / 2025, p. 101 / 574 96 / 492 Illi lllj; or a pharmaceutically acceptable salt thereof, where: each R4 is selected independently from halo, oxo, Ci6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl, in which the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of R4são cada uma optamente substituídas por 1, 2, 3 ou 4 R4Asubstituintes selecionados independentemen te; each R4Aé independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN; R5é selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-di-hydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each Petition 870250102588, dated 10 / 11 / 2025, p. 102 / 574 97 / 492 optionally replaced by 1, 2, 3 or 4 independently selected R5A substitutes; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein the C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51; and each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00320] In some forms, the Formula I compound is a compound of Formula Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, VIi, Vj, Vk, Vm or Vn: Petition 870250102588, dated 10 / 11 / 2025, p. 103 / 574 98 / 492 See Petition 870250102588, dated 10 / 11 / 2025, p. 104 / 574 99 / 492 Petition 870250102588, dated 10 / 11 / 2025, p. 105 / 574 100 / 492 or a pharmaceutically acceptable salt thereof, where: each R4 is independently selected from halo, oxo, C6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, (4- to 10-membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, in which the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl- of R4são cada uma optionalmente substituídas por 1, 2, 3 or 4 R4Asubstitutes independently selected; each Ra4e Rb4é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and 4-6 member heterocycloalkyl; each R4Aé independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa41, and C(O)Rb41; Each Ra41e Rb41 is selected independently from H, C1-6 alkyl and C1-6 haloalkyl; R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; Petition 870250102588, dated 10 / 11 / 2025, page 106 / 574 101 / 492 wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and Petition 870250102588, dated 10 / 11 / 2025, p. 107 / 574 102 / 492 NRcsiRdsi, where the C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl groups of R5A are each optionally replaced by ORa52 and 1, 2, 3, 4, 5, 6 or 7 halo groups selected independently; Each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; and each Ra52 is independently selected from H and C1-6 alkyl.

[00321] In some modalities of the previous modality: each R4 is independently selected from halo, oxo, C16 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5 to 10 membered heteroaryl and 4 to 10 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 R4Asubstituents independently selected; each R4A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN; R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H Petition 870250102588, dated 10 / 11 / 2025, p. 108 / 574 103 / 492 benzo[b][1,4]oxazinyl and azaspir[2,4]heptanil of R5 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51; and each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00322] In some forms, the Formula I compound is a Formula VIa, VIb, VIc, VId, VIe, VIf, VIg, VIh, VIi, VIj, VIk, VIm or VIn compound: Petition 870250102588, dated 10 / 11 / 2025, p. 109 / 574 104 / 492 VI Petition 870250102588, dated 10 / 11 / 2025, p. 110 / 574 105 / 492 VIm Petition 870250102588, dated 10 / 11 / 2025, p. 111 / 574 106 / 492 or a pharmaceutically acceptable salt thereof, where: each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, and (4- to 10-membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 selected R4Asubstituents independently; each Ra4 and Rb4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and 4-6 membered heterocycloalkyl; Each R4A is selected independently from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa41, and C(O)Rb41; Each Ra41e Rb41 is selected independently from H, C1-6 alkyl and C1-6 haloalkyl; R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; Petition 870250102588, dated 10 / 11 / 2025, page 112 / 574 107 / 492 wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and Petition 870250102588, dated 10 / 11 / 2025, p. 113 / 574 108 / 492 NRcsiRdsi, where the C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl groups of R5A are each optionally replaced by ORa52 and 1, 2, 3, 4, 5, 6 or 7 halo groups selected independently; Each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; and each Ra52 is independently selected from H and C1-6 alkyl.

[00323] In some modalities of the previous modality: each R4 is independently selected from halo, oxo, C16 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5 to 10 membered heteroaryl and 4 to 10 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 R4Asubstituents independently selected; each R4A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and CN; R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NRw2Rw3, C(O)Rw2, and C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the C6-10 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; and the C3-12 cycloalkyl, 5- to 12-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H Petition 870250102588, dated 10 / 11 / 2025, p. 114 / 574 109 / 492 benzo[b][1,4]oxazinyl and azaspir[2,4]heptanil of R5 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5- to 12-membered heteroaryl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl; Rw5 is a C1-6 alkyl group that is substituted by CN or ORa51; each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51, and NRc51Rd51; and each Ra51, Rc51, and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00324] In some embodiments, each R4 is independently selected from halo, C1-6 alkyl, C6-10 aryl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, wherein C1-6 alkyl, C610 aryl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl Petition 870250102588, dated 10 / 11 / 2025, p. 115 / 574 110 / 492 members and (4 to 10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 R4A substituents selected independently; and each Ra4 and Rb4 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl and 4 to 6 membered heterocycloalkyl.

[00325] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from halo, C1-6 alkyl, phenyl, 5- to 6-membered heteroaryl, 4- to 10-membered heterocycloalkyl, (4- to 6-membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, wherein C1-6 alkyl, phenyl, 5- to 6-membered heteroaryl, 4- to 10-membered heterocycloalkyl and (4- to 6-membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 R4A substituents

[00326] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-Vin, each Ra4e Rb4 is independently selected from C1-6 alkyl and 4- to 6-membered heterocycloalkyl.

[00327] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from halo, C1-6 alkyl, phenyl, 5- to 6-membered heteroaryl, 4- to 10-membered heterocycloalkyl, (4- to 6-membered heterocycloalkyl)-C1-6 alkyl-, ORa4, and C(O)Rb4, wherein C1-6 alkyl, phenyl, 5- to 6-membered heteroaryl, 4- to 10-membered heterocycloalkyl and (4- to 6-membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; and

[00328] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-Vin, each Ra4e Rb4 is independently selected from C1-6 alkyl and 4- to 6-membered heterocycloalkyl.

[00329] In some modalities of any of the Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is selected independently. Petition 870250102588, dated 10 / 11 / 2025, p. 116 / 574 111 / 492 halo, C1-6 alkyl, C6-10 aryl and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C6-10 aryl and 4- to 10-membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00330] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from halo, C1-6 alkyl, phenyl and 8- to 10-membered heterocycloalkyl, wherein the C1-6 alkyl, phenyl and 8- to 10-membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00331] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from halo, C1-6 alkyl, phenyl and 8- to 10-membered bicyclic heterocycloalkyl, wherein the C1-6 alkyl, phenyl and 8- to 10-membered bicyclic heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00332] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from fluorine, methyl, trideuteromethyl, isopropyl, methoxy, morpholinylcarbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein the methyl, isopropyl, phenyl, pyrazolyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

[00333] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from fluorine, methyl, phenyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein methyl, phenyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally replaced by 1, 2, 3 or 4 independently selected R4A substituents. Petition 870250102588, dated 10 / 11 / 2025, p. 117 / 574 112 / 492

[00334] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4A is selected independently from C1-6 alkyl, C1-6 haloalkyl, CN, ORa41, and C(O)Rb41.

[00335] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each Ra41e Rb41e is selected independently of H and C1-6 alkyl.

[00336] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4A is selected independently from C1-6 alkyl, C1-6 haloalkyl, CN, ORa41, and C(O)Rb41; and each Ra41 and Rb41 is selected independently from H and C1-6 alkyl.

[00337] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4A is selected from methyl, difluoromethyl, trifluoromethyl, CN, OH and methylcarbonyl.

[00338] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4A is selected independently from C1-6 alkyl, C1-6 haloalkyl and CN.

[00339] In some embodiments of any of the Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4A is CN.

[00340] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from fluorine, methyl, trideuteromethyl, isopropyl, methoxy, morpholinylcarbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein the methyl, isopropyl, phenyl, pyrazolyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; Each R4A is selected independently from C1-6 alkyl, C1-6 haloalkyl, CN, ORa41, and C(O)Rb41; and each Ra41 and Rb41 is selected independently from H and Petition 870250102588, dated 10 / 11 / 2025, p. 118 / 574 113 / 492 C1-6 alkyl.

[00341] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from fluorine, methyl, trideuteromethyl, isopropyl, methoxy, morpholinylcarbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein methyl, isopropyl, phenyl, pyrazolyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; and each R4A is selected from methyl, difluoromethyl, trifluoromethyl, CN, OH and methylcarbonyl.

[00342] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R4 is independently selected from fluorine, methyl, cyanophenyl and 2,3-dihydrobenzo[b][1,4]dioxinyl.

[00343] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, R5 is selected from C1-6 alkyl, C3-7 cycloalkyl, phenyl, 5- to 10-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2, wherein C3-7 cycloalkyl, 5- to 10-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; and wherein the C1-6 alkyl and phenyl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or the phenyl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1 or 2 independently selected R5A substituents. Petition 870250102588, dated 10 / 11 / 2025, p. 119 / 574 114 / 492

[00344] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, R5 is selected from -CH2Rw1, C3-7 cycloalkyl, -phenyl-Rw1, -phenyl-Rw5, 5- to 10-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2, where C3-7 cycloalkyl, phenyl, 5- to 10-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00345] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, R5 is selected from -CH2Rw1, C3-7 cycloalkyl, -phenyl-Rw1, -phenyl-Rw5, 5- to 10-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2, wherein C3-7 cycloalkyl, phenyl, 5- to 10-membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00346] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, R5 is selected from -CH2Rw1, C3-7 cycloalkyl, -phenyl-Rw1, -phenyl-Rw5, thiazolyl, thiopheneyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptaniyl, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2, where C3-7 cycloalkyl, phenyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and Petition 870250102588, dated 10 / 11 / 2025, p. 120 / 574 115 / 492 azaspiro[2,4]heptanil of R5 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00347] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, R5 is selected from -CH2Rw1, C3-7 cycloalkyl, -phenyl-Rw1, -phenyl-Rw5, thiazolyl, thiopheneyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2, where C3-7 cycloalkyl, phenyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00348] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw1 is selected from C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-7 cycloalkyl and 4-7 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00349] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw1 is selected from C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, ORw4, and NHRw4, wherein the C3-7 cycloalkyl and 4-7 membered heterocycloalkyl or Rw1 are each optionally substituted by 1 or 2 independently selected R5A substituents.

[00350] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, ORw4, and NHRw4.

[00351] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw4 is selected from C1-6 haloalkyl, C2-6 Petition 870250102588, dated 10 / 11 / 2025, p. 121 / 574 116 / 492 alkenyl, C2-6 alkynyl, Ce-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4 to 10-membered heterocycloalkyl.

[00352] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw4 is selected from C1-e haloalkyl, C1-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl.

[00353] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw4 is selected from C1-e haloalkyl and C3-10 cycloalkyl.

[00354] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw4 is selected from C1-e haloalkyl and C3-7 cycloalkyl.

[00355] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, ORw4, and NHRw4; and Rw4 is selected from C1-e haloalkyl and C3-10 cycloalkyl. [0035e] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, ORw4, and NHRw4; and Rw4 is selected from between C1-e haloalkyl and C3-7 cycloalkyl.

[00357] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, trifluoromethoxy and cyclopentylamino.

[00358] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw2 is selected from C3-7 cycloalkyl, 8- to 12-membered bicyclic heteroaryl, 4- to 7-membered monocyclic heterocycloalkyl and 8- to 12-membered bicyclic heterocycloalkyl, wherein the C3-7 cycloalkyl, 8- to 12-membered bicyclic heteroaryl, 4- to 7-membered monocyclic heterocycloalkyl and 8- to 12-membered bicyclic heterocycloalkyl of Rw2 are each optionally substituted Petition 870250102588, dated 10 / 11 / 2025, page 122 / 574 117 / 492 by 1, 2, 3 or 4 R5A substitutes selected independently.

[00359] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw2 is selected from cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2H-pyrido[1,2-a]pyrazinyl, wherein cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2H-pyrido[1,2-a]pyrazinyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00360] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw5 is a C1-6 alkyl that is replaced by CN or ORa51.

[00361] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each Ra51, Rb51, Rc51, and Rd51 is selected independently of H and C1-6 alkyl.

[00362] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each Ra51 is selected independently of H and C1-6 alkyl.

[00363] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each Ra51 is selected independently of H and C1-3 alkyl.

[00364] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each Ra51 is an independent C1-3 alkyl.

[00365] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw5 is a C1-6 alkyl that is replaced by CN or ORa51; and Ra51 is selected from H and C1-3 alkyl.

[00366] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, Rw5 is selected between cyanomethyl and hydroxymethyl. Petition 870250102588, dated 10 / 11 / 2025, p. 123 / 574 118 / 492

[00367] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein C1-6 alkyl is optionally replaced by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5B substituents.

[00368] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein C1-6 alkyl of R5A is optionally replaced by 1, 2, 3 or 4 independently selected R5B substituents.

[00369] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein C1-6 alkyl of R5A is optionally replaced by 1 or 2 independently selected R5B substituents.

[00370] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5B is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl and OH.

[00371] In some embodiments of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5Bé is selected independently of OH and halo.

[00372] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5Bé OH.

[00373] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein C1-6 alkyl is optionally replaced by OH and 1, 2, 3, 4, 5, 6 or 7 halo groups are selected independently.

[00374] In some modes of any of the Formula 1, Petition 870250102588, dated 10 / 11 / 2025, p. 124 / 574 119 / 492 IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is independently selected from halo, Ci-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein C1-6 alkyl of R5A is optionally replaced by OH.

[00375] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51.

[00376] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein C1-6 alkyl of R5A is optionally replaced by 1 or 2 independently selected R5B substituents; and each Ra51, Rc51, and Rd51 is independently selected from H and C1-6 alkyl.

[00377] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51, wherein C1-6 alkyl of R5A is optionally replaced by OH; and each Ra51, Rc51, and Rd51 is selected independently of H and C1-6 alkyl.

[00378] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, and NRc51Rd51; and each Ra51, Rc51, and Rd51 is selected independently of H and C1-6 alkyl.

[00379] In some embodiments of any of Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is independently selected from chlorine, fluorine, methyl, hydroxyisopropyl, hydroxyhexafluoroisopropyl, difluoromethyl, trifluoromethyl, CN, methoxy, ethoxy and amino.

[00380] In some versions of any of the Formulas I, IIIa-IIIn, Va-Vn and VIa-VIn, each R5A is selected independently. Petition 870250102588, dated 10 / 11 / 2025, p. 125 / 574 120 / 492 between chlorine, fluorine, methyl, hydroxyisopropyl, difluoromethyl, trifluoromethyl, CN, methoxyl and amino.

[00381] In some embodiments, the compound of Formula I is a compound of Formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVi, IVj, IVk, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu or IVv: Petition 870250102588, of 10 / 11 / 2025, p. 126 / 574 121 / 492 % ,cy2r^^^r4“rXt? H R4ivj IVi Ο, R1-N R4.4 IVk O Cy2R5R4'Ad H IVm Ok Cy2r4 r5 Ήy RWR R^NvL·3N ^Ν^μ-'-'''^^' NNR H IVo; R1 IVn ,5 R4 R1-N R4 IVp R5cy2 N R4 / R4 IVr Petition 870250102588, of 10 / 11 / 2025, p. 127 / 574 122 / 492 IVt IVu H IVv ou a pharmaceutically oily salt of this, em that: each R4e independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl-, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4e optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; each R4Aé independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; Each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl groups, wherein the C3-12 cycloalkyl group is a component of the cycloalkyl group. Petition 870250102588, dated 10 / 11 / 2025, p. 128 / 574 123 / 492 alkyl and 4- to 12-membered heterocycloalkyl groups of Rw2 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00382] In some forms, the Formula I compound is a Formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVi, IVj, IVk, IVm, IVn or IVo compound: IVd Petition 870250102588, dated 10 / 11 / 2025, p. 129 / 574 124 / 492 or a pharmaceutically acceptable salt thereof, where: each R4e independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl-, in which each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4e option Petition 870250102588, dated 10 / 11 / 2025, page. 130 / 574 125 / 492 finally substituted by 1, 2, 3 or 4 R4Asubstitutes independently selected; each R4Aé independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00383] In some modalities of the previous modality: each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and 56-membered heteroaryl, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and 5-6 membered heteroaryl of R4 is optionally substituted by 1, 2, 3 or 4 R4Asubstituents independently selected; each R4A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; Each Ra41 is selected independently of H, C1-6 al Petition 870250102588, dated 10 / 11 / 2025, page 131 / 574 126 / 492 kilo, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00384] In some forms, the Formula I compound is a Formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh or IVi compound: IVb IVd Petition 870250102588, dated 10 / 11 / 2025, p. 132 / 574 127 / 492 IVi; or a pharmaceutically oily salt of this, em that: each R4e independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl-, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4e optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; each R4Aé independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; Petition 870250102588, dated 10 / 11 / 2025, page. 133 / 574 128 / 492 R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00385] In some modalities of the previous modality: each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; Each R5A is selected independently of halo, C1-6 Petition 870250102588, dated 10 / 11 / 2025, p. 134 / 574 129 / 492 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00386] In some forms, the Formula 1 compound is a Formula 1 compound Vlla, Vllb, Vllc, Vlld, Vlle, Vllf, Vllg, Vllh, Vlli, Vllj, Vllk, Vllm, Vlln or Vllo: Petition 870250102588, dated 10 / 11 / 2025, p. 135 / 574 130 / 492 Petition 870250102588, dated 10 / 11 / 2025, p. 136 / 574 131 / 492 or a pharmaceutically acceptable salt thereof, where: each R4e independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl-, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4e optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; each R4Aé independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5e selected from C3-12 cycloalkyl, 5 to 12 heteroaryl Petition 870250102588, dated 10 / 11 / 2025, page. 137 / 574 132 / 492 members, NRw2Rw3, and C(O)Rw2, wherein the 5- to 12-membered C3-12 cycloalkyl and heteroaryl groups of R5 are each optionally substituted by independently selected 1, 2, 3, or 4 R5A substituents; each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00387] In some modalities of the previous modality: each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and 56-membered heteroaryl, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and 5-6 membered heteroaryl of R4 is optionally substituted by 1, 2, 3 or 4 R4Asubstituents independently selected; each R4A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; Each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl groups, wherein the C3-12 cycloalkyl group is a component of the cycloalkyl group. Petition 870250102588, dated 10 / 11 / 2025, p. 138 / 574 133 / 492 alkyl and 4- to 12-membered heterocycloalkyl groups of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00388] In some embodiments, the compound of Formula I is a compound of Formula VIIIa, VIIIb, VIIIc, VIIId, VIIIe, VIIIf, VIIIg, VIIIh, VIIIi, VIIIj, VIIIk, VIIIm, VIIIn or VIIIo: VIIIc Petition 870250102588, dated 10 / 11 / 2025, p. 139 / 574 134 / 492 R1-N HN Rb2 Cy2-(R2)m NR4 VIIj Petition 870250102588, dated 10 / 11 / 2025, p. 140 / 574 135 / 492 VlIIk VIIIm VIIIn VIIIo; or a pharmaceutically acceptable salt thereof, where: each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and C3-7 cycloalkyl-C1-6 alkyl-, wherein each of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5 to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4 is optionally substituted by 1, 2, 3 or 4 R4Asubstituents independently selected; each R4A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; Petition 870250102588, dated 10 / 11 / 2025, p. 141 / 574 136 / 492 R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; each Rw2 is independently selected from 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl, wherein the 4- to 12-membered C3-12 cycloalkyl and heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5Aé independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00389] In some modalities of the previous modality: each R4é independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and 5-membered heteroaryl, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and 5-6 membered heteroaryl of R4é optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; each R4Aé independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41é independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; R5 is selected from C3-12 cycloalkyl, 5- to 12-membered heteroaryl, NRw2Rw3, and C(O)Rw2, wherein the C3-12 cycloalkyl and 5- to 12-membered heteroaryl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents; Each Rw2 is selected independently of the C3-12 cycle. Petition 870250102588, dated 10 / 11 / 2025, p. 142 / 574 137 / 492 4- to 12-membered alkyl and heterocycloalkyl, wherein C3-12 cycloalkyl and 4- to 12-membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00390] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl-, wherein each C1-6 alkyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4 is optionally replaced by 1, 2, 3 or 4 independently selected R4A substituents.

[00391] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R4A is selected independently from C1-6 haloalkyl, CN and ORa41.

[00392] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each Ra41 is independently selected from H and C1-6 alkyl.

[00393] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl-, wherein each C1-6 alkyl, C3-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl and C3-7 ci Petition 870250102588, dated 10 / 11 / 2025, p. 143 / 574 138 / 492 cloalkyl-Ci-6 alkyl- of R4 is optionally replaced by 1, 2, 3 or 4 R4A substituents selected independently; Each R4A is selected independently from C1-6 haloalkyl, CN and ORa41; and each Ra41 is selected independently from H and C1-6 alkyl.

[00394] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, R4 is selected from methyl, ethyl, isopropyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterotetrahydropyranyl, pyridinyl and cyclopropylmethyl, wherein each methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterotetrahydropyranyl, pyridinyl and cyclopropylmethyl of R4 is optionally substituted by 1 or 2 R4A substituents selected independently from C1-3 haloalkyl, CN, OH and C1-3 alkoxy.

[00395] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R4 is selected independently from halo, C1-6 alkyl and C1-6 haloalkyl.

[00396] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R4 is selected independently from C1-6 haloalkyl.

[00397] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R4 is selected independently from C1-3 haloalkyl.

[00398] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R4 is trifluoromethyl.

[00399] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, R5 is selected from C3-7 cycloalkyl, 5-6 membered heteroaryl, NHRw2, and C(O)Rw2, wherein the C3-7 cycloalkyl and 5-6 membered heteroaryl of R5 are each optionally Petition 870250102588, dated 10 / 11 / 2025, p. 144 / 574 139 / 492 replaced by 1, 2, 3 or 4 R5A substitutes selected independently.

[00400] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, R5 is selected from cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl, pyridinyl, NHRw2, and C(O)Rw2, wherein the cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl and pyridinyl of R5 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00401] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, R5 is selected from cyclopropyl, pyrazolyl, imidazolyl, NHRw2, and C(O)Rw2, wherein the cyclopropyl, pyrazolyl, imidazolyl, of R5 are each optionally replaced by 1, 2, 3 or 4 independently selected R5A substituents.

[00402] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, Rw2 is selected from C3-7 cycloalkyl, 4- to 8-membered monocyclic heterocycloalkyl and 6- to 10-membered bicyclic heterocycloalkyl, wherein the C3-7 cycloalkyl, 4- to 8-membered monocyclic heterocycloalkyl and 6- to 10-membered bicyclic heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

[00403] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, Rw2 is selected from cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl, wherein cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 R5A substitutes selected independently.

[00404] In some modes of any of the Formula 1, Petition 870250102588, dated 10 / 11 / 2025, p. 145 / 574 140 / 492 IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN and ORa51.

[00405] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each Ra51, Rb51, Rc51, and Rd51 is selected independently of H and C1-6 alkyl.

[00406] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each Ra51 is selected independently of H and C1-6 alkyl.

[00407] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each Ra51 is selected independently of H and C1-3 alkyl.

[00408] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R5A is selected independently of halo, C1-6 alkyl, C1-6 haloalkyl, CN and ORa51; and each Ra51 is selected independently of H and C1-6 alkyl.

[00409] In some embodiments of any of Formulas I, IVa-IVv, VIIa-VIIo and VIIIa-VIIIo, each R5A is independently selected from fluorine, methyl, trideuteromethyl, CN and hydroxyl.

[00410] In some embodiments of any of the IVIIIo Formulas, R1 is C1-6 alkyl, which is optionally replaced by 1, 2 or 3 R1A substituents selected independently.

[00411] In some embodiments of any of the IVIIIo Formulas, R1 is C1-6 alkyl.

[00412] In some embodiments of any of the IVIIIo Formulas, R1 is C1-3 alkyl.

[00413] In some embodiments of any of the IVIIIo Formulas, R1 is methyl or trideuteromethyl.

[00414] In some embodiments of any of the IVIIIo Formulas, R1 is methyl. Petition 870250102588, dated 10 / 11 / 2025, p. 146 / 574 141 / 492

[00415] In some embodiments of any of the IVIIIo Formulas, R1 is trideuteromethyl.

[00416] In some embodiments of any of Formulas IVIIIo, Cy2 is selected from C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, C6-10 bicyclic cycloalkyl, 6-10 membered spirocyclic heterocycloalkyl and 5-10 membered bicyclic heterocycloalkyl, wherein the C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, C6-10 bicyclic cycloalkyl, 6-10 membered spirocyclic heterocycloalkyl and 5-10 membered bicyclic heterocycloalkyl are each substituted with 1, 2, 3 or 4 R2 substituents selected independently.

[00417] In some embodiments of any of Formulas IVIIIo, Cy2 is selected from C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4- to 7-membered monocyclic heterocycloalkyl, 6- to 10-membered spirocyclic heterocycloalkyl and 5- to 10-membered bicyclic heterocycloalkyl, wherein the C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4- to 7-membered monocyclic heterocycloalkyl, 6- to 10-membered spirocyclic heterocycloalkyl and 5- to 10-membered bicyclic heterocycloalkyl are each substituted by 1, 2, 3 or 4 independently selected R2 substituents.

[00418] In some embodiments of any of the IVIIIo Formulas, Cy2 is selected from cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl and 2-azabicyclo[2.2.1]heptanyl, wherein cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl and 2Petition 870250102588, dated 10 / 11 / 2025, page 147 / 574 142 / 492 azabicyclo[2.2.1]heptanilate of Cy2 are each optionally replaced by 1, 2, 3 or 4 independently selected R2 substituents.

[00419] In some embodiments of any of the IVIIIo Formulas, Cy2 is selected from cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl, wherein the cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl of Cy2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2 substituents.

[00420] In some embodiments of any of the IVIIIo Formulas, Cy2 is selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl, wherein cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl of Cy2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2 substituents.

[00421] In some forms of any of the IVIIIo Formulas, Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 148 / 574 143 / 492 n R2 n η where n is 0, 1, or 2.

[00422] In some forms of any of the IVIIIo Formulas, Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 149 / 574 144 / 492 where n is 0, 1, or 2.

[00423] In some forms of any of the IVIIIo Formulas, Cy2 is selected from:

[00424] In some forms of any of the IVIIIo Formulas, Cy2 is selected from Petition 870250102588, dated 10 / 11 / 2025, p. 150 / 574 145 / 492 R2R2

[00425] In some forms of any of the IVIIIo Formulas, Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 151 / 574 146 / 492

[00426] R2 In some variations of any of the IVIIIo Formulas, Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 152 / 574 147 / 492

[00427] In some forms of any of the IVIIIo Formulas, Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 153 / 574 148 / 492 R2 R2R2

[00428] In some forms of any of the IVIIIo Formulas, Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 154 / 574 149 / 492

[00429] VIIIo, Cy2 In some modes of any of the Formula I modes, you are selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 155 / 574 150 / 492

[00430] In some embodiments of any of Formulas IVIIIo, each R2 is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2, where C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, of R2 are each optionally replaced by 1, 2, 3 or 4 R2A substitutes selected independently.

[00431] In some embodiments of any of the Formulas IVIIIo, each R2 is independently selected from halo, C1-6 alkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

[00432] In some embodiments of any of the Formulas IVIIIo, each R2 is selected independently from halo, C1-6 alkyl, CN, C(O)Rb2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3, or 4 R2A substituents selected independently Petition 870250102588, dated 10 / 11 / 2025, p. 156 / 574 151 / 492 dentemente.

[00433] In some embodiments of any of the Formulas IVIIIo, each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

[00434] In some embodiments of any of Formulas IVIIIo, each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

[00435] In some embodiments of any of Formulas IVIIIo, each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl, wherein the C1-6 alkyl, phenyl, C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

[00436] In some embodiments of any of the Formulas IVIIIo, each Ra2, Rb2, Rc2, and Rd2 is selected independently from H, methyl, trideuteromethyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, wherein methyl, ethyl, propynyl, cyclopropyl, cyclobutyl Petition 870250102588, dated 10 / 11 / 2025, p. 157 / 574 152 / 492 butyl, phenyl and tetrahydropyranyl groups of Ra2, Rb1, Rc2, and Rd2 are each optionally replaced by 1, 2, 3 or 4 independently selected R2A substituents.

[00437] In some embodiments of any of the IVIIIo Formulas, each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, wherein the methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl of Ra2, Rb1, Rc2, and Rd2 are each optionally replaced by 1, 2, 3, or 4 independently selected R2A substituents.

[00438] In some embodiments of any of the Formulas IVIIIo, each R2 is independently selected from halo, C1-6 alkyl, CN, C(O)Rb2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; and each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 R2A substituents independently selected.

[00439] In some embodiments of any of the Formulas IVIIIo, each R2 is independently selected from halo, C1-6 alkyl, CN, C(O)Rb2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; and Petition 870250102588, dated 10 / 11 / 2025, p. 158 / 574 153 / 492 each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4- to 10-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

[00440] In some embodiments of any of the Formulas IVIIIo, each R2 is independently selected from halo, C1-6 alkyl, CN, C(O)Rb2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; and each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl, wherein the C1-6 alkyl, phenyl, C3-7 cycloalkyl, 5- to 6-membered heteroaryl and 4- to 7-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

[00441] In some embodiments of any of Formulas IVIIIo, each R2 is independently selected from halo, C1-6 alkyl, CN, C(O)Rb2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; and each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, wherein the methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; and each Ra2, Rb1, Rc2, and Rd2 is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl. Petition 870250102588, dated 10 / 11 / 2025, p. 159 / 574 154 / 492 finally replaced by 1 or 2 independently selected R2A substitutes.

[00442] In some embodiments of any of the Formulas IVIIIo, each R2A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa21, wherein C16 alkyl, C2-6 alkenyl and C2-6 alkynyl of R2A are each optionally replaced by 1, 2, 3 or 4 independently selected R2B substituents.

[00443] In some embodiments of any of the IVIIIo Formulas, each R2A is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa21.

[00444] In some modes of any of the IVIIIo Formulas, each R2A is selected independently of halo and ORa21.

[00445] In some embodiments of any of the Formulas IVIIIo, each Ra21, Rb21, Rc21, and Rd21 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

[00446] In some embodiments of any of the IVIIIo Formulas, each Ra21, Rb21, Rc21, and Rd21 is selected independently of H and C1-6 alkyl.

[00447] In some embodiments of any of the IVIIIo Formulas, each Ra21, Rb21, Rc21, and Rd21 is selected independently of H and C1-3 alkyl.

[00448] In some embodiments of any of the IVIIIo Formulas, each Ra21 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

[00449] In some embodiments of any of the IVIIIo Formulas, each Ra21 is selected independently of H and C1-6 alkyl.

[00450] In some embodiments of any of the IVIIIo Formulas, each Ra21 is selected independently of H and C1-3 alkyl.

[00451] In some modes of any of the Formula 1 Petition 870250102588, dated 10 / 11 / 2025, p. 160 / 574 155 / 492 VIIIo, each Ra21 is selected independently of H and methyl.

[00452] In some embodiments of any of the Formulas IVIIIo, each R2A is selected independently of halo and ORa21; and each Ra21 is selected independently of H and C1-6 alkyl.

[00453] In some embodiments of any of the IVIIIo Formulas, each R2A is selected independently from fluorine, hydroxyl, and methoxyl.

[00454] In some embodiments of any of the Formulas IVIIIo, each R2A is selected independently from between fluorine and methoxy.

[00455] In some embodiments of any of the Formulas IVIIIo, R3 is selected from between H and C1-6 alkyl.

[00456] In some embodiments of any of the IVIIIo Formulas, R3 is selected from H and C1-3 alkyl.

[00457] In some embodiments of any of the IVIIIo Formulas, R3 is H.

[00458] In some forms of any of the IVIIIo Formulas: R1é selected from C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; Cy2é selected from C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4-7 member monocyclic heterocycloalkyl, C6-10 bicyclic cycloalkyl, 6-10 member spirocyclic heterocycloalkyl and 5-10 member bicyclic heteroalkyl, in which C3-10 monocyclic cycloalkyl, C6-10 bicyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4-7 member monocyclic heteroalkyl, 6-10 member spirocyclic heteroalkyl and 5-10 member bicyclic heteroalkyl are, each one, substituted by 1, 2, 3 or 4 independently selected R2substitutes; Petition 870250102588, dated 10 / 11 / 2025, page. 161 / 574 156 / 492 each R2 is selected independently from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl of R2 are each optionally replaced by 1, 2, 3 or 4 independently selected R2A substitutes; each of Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl and 4 to 10-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 R2Asubstituents independently selected; each R2A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa21; Each Ra21 is selected independently of H and C1-6 alkyl; and R3 is selected from H and C1-6 alkyl.

[00459] In some embodiments of the preceding embodiment, Cy2 is selected from C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4- to 7-membered monocyclic heterocycloalkyl, 6- to 10-membered spirocyclic heterocycloalkyl and 5- to 10-membered bicyclic heterocycloalkyl, wherein the C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4- to 7-membered monocyclic heterocycloalkyl, 6- to 10-membered spirocyclic heterocycloalkyl and 5- to 10-membered bicyclic heterocycloalkyl are each substituted by 1, 2, 3 or 4 R2 substituents selected in Petition 870250102588, dated 10 / 11 / 2025, page 162 / 574 157 / 492 dependently;

[00460] In some forms of any of the IVIIIo Formulas: R1 is selected from C1-6 alkyl; Cy2 is selected from C3-10 monocyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, C6-10 bicyclic cycloalkyl, 6 to 10 membered spirocyclic heterocycloalkyl and 5 to 10 membered bicyclic heterocycloalkyl, wherein the C3-10 cycloalkyl monocyclic, C6-10 bicyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4 to 7 membered monocyclic heterocycloalkyl, 6 to 10 membered spirocyclic heterocycloalkyl and 5 to 10 membered bicyclic heterocycloalkyl are each substituted by 1, 2, 3 or 4 independently selected R2 substituents; each R2 is independently selected from halo, C1-6 alkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; Each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 7-membered heterocycloalkyl, wherein the C1-6 alkyl, phenyl, C3-7 cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 7-membered heterocycloalkyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; each R2A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa21; Each Ra21 is selected independently of H and C1-6 alkyl; and R3é H. Petition 870250102588, dated 10 / 11 / 2025, page 163 / 574 158 / 492

[00461] In some modalities of the previous modality: Cy2 is selected from C3-10 monocyclic cycloalkyl, Ce-w spirocyclic cycloalkyl, 4- to 7-membered monocyclic heterocycloalkyl, 6- to 10-membered spirocyclic heterocycloalkyl, and 5- to 10-membered bicyclic heterocycloalkyl, wherein C3-10 monocyclic cycloalkyl, Ce-10 cycloalkyl spirocyclic, 4- to 7-membered monocyclic heterocycloalkyl, 6 to 10-membered spirocyclic heterocycloalkyl and 5 to 10-membered bicyclic heterocycloalkyl are each substituted by 1, 2, 3 or 4 independently selected R2 substituents; and each R2 is independently selected from halo, C1-6 alkyl, CN, C(O)Rb2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally replaced by 1, 2, 3, or 4 independently selected R2A substituents.

[00462] In some forms of any of the IVlIIo Formulas: R1 is C1-3 alkyl; Cy2 is selected from cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptaniyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl, wherein cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptaniyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl of Cy2 are each a optionally replaced by 1, 2, 3 or 4 independently selected R2 substitutes; Each R2 is selected independently from halo, C1-6 alkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2C(O)Rb2, Petition 870250102588, dated 10 / 11 / 2025, p. 164 / 574 159 / 492 NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally replaced by 1, 2, 3 or 4 independently selected R2A substituents; Each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, methyl, trideuteromethyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, wherein the methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl groups of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; Each R2A is selected independently of halo and R2A21; each R2A is selected independently of H and C1-6 alkyl; and R3é H.

[00463] In some modalities of the previous modality: Cy2 is selected from cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl, wherein the cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl of Cy2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2 substituents; Each R2 is independently selected from halo, C1-6 alkyl, CN, C(O)Rb2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; and each Ra2, Rb2, Rc2, and Rd2 is independently selected Petition 870250102588, dated 10 / 11 / 2025, page 165 / 574 160 / 492 of H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl and tetrahydropyranyl, wherein methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl and tetrahydropyranyl of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

[00464] In some embodiments, the compound provided here is selected from: ethyl2-((3'-cyano-5-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-6-yl)amino)-[1,1'biphenyl]-3-yl)amino)oxazol-5-carboxylate; methyl ((1R,3R)-3-(6-((3'-cyano-5-(4-fluorotetrahydro-2H-pyran-4carboxamido)-[1,1'-biphenyl]-3-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1 Himidazo[4,5-c]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R,3R)-3-(3-(methyl-d3)-6-((4-(1-methyl-1,6-diazaspiro[3.3]heptane6-carbonyl)-8-(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(4-(hydroxymethyl)-3-methylphenyl)pyridin-2-yl)amino)-3methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R,3R)-3-(6-((6'-methoxy-[2,3'-bipyridin]-6-yl)amino)-3-methyl-2-oxo2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(4-cyanopiperidine-1-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((6-(3-methyl-1 H-indazol-5-yl)pyridin-2yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxina-6-yl)pyridin-2yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; Petition 870250102588, 10 / 11 / 2025, pág. 166 / 574 161 / 492 methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-(quinolin-6-yl)pyridin-2-yl)amino)2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(1-hydroxy-3-azabicyclo[3.1.0]hexano-3-carbonyl)8-(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((6-(4-methyl-3,4-di-hidro-2 Hbenzo[ b ][1,4]oxazin-7-yl)pyridin-2-yl)amino)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(2-oxa-5-azabicyclo[2.2.1 ]heptane-5-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-himidazolazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(2-oxa-5-azabicyclo[4.1.0]heptane-5-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-himidazolazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl (3-((1-((1 R ,3 R )-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H1,2,3-triazol-4-yl)phenyl)carbamate; methyl (3-((1-((1 R ,3 R )-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methylpiperidin4-yl)phenyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(3,3-difluoropiperidine-1-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-(( R )-2,2-difluorocyclopropane-1-carboxamido)-5(tetra-hidro-2 H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-((3,3-difluorocyclopentyl)amino)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-(cyclobutanecarboxamido)-5-(tetrahydro-2 H-pyran Petition 870250102588, 10 / 11 / 2025, pág. 167 / 574 162 / 492 4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-(methyl-d3)-6-((6-(1-methyl-1 H-pyrazol-4-yl)-8(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c ]pyridin-1-yl)cyclopentyl)carbamate; methyl (3-((1-((1 R ,3 R )-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(tetra-hidro-2 Hpyran-3-yl)phenyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-((4-cyanocyclo-hexyl)óxi)pyridin-2-yl)amino)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-(quinolin-6-ylóxi)pyridin-2-yl)amino)2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl (3-((1-((1 r,3 r)-3-(cyclopropanecarboxamido)cyclobutyl)-3-methyl-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 Hpyrazol-4-yl)phenyl)carbamate; methyl (3-((1-(6-((ethoxycarbonyl)amino)espiro[3.3]heptan-2-yl)-3-methyl-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 Hpyrazol-4-yl)phenyl)carbamate; methyl (3-((1-(6-(cyclopropanosulfonamido)espiro[3.3]heptan-2-yl)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl1H-pyrazol-4-yl)phenyl)carbamate; methyl 6-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)-2azaspiro[3.3]heptane-2-carboxylate; methyl (3-((1-((1r,3r)-3-cyanocyclobutyl)-3-methyl-2-oxo-2,3-di-himidazole-1 Himidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate; methyl (3-((1-((1 r,3r)-3-((methoxycarbonyl)amino)-3-methylcyclobutyl)-3-methyl2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H Petition 870250102588, 10 / 11 / 2025, pág. 168 / 574 163 / 492 pyrazol-4-yl)phenyl)carbamate; methyl (R )-(3-((1-(3,3-difluorocyclopentyl)-3-methyl-2-oxo-2,3-di-hihydro-1 Himidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate; methyl (3-((1-((1 R ,3 S )-3-fluorocyclopentyl)-3-methyl-2-oxo-2,3-di-hihydro-1 Himidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((6-(1-methyl-1 H-pyrazol-4-yl)quinolin-2yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((8-(1-methyl-1 H-pyrazol-4-yl)quinolin-2yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((3-(1-methyl-1 H-pyrazol-4-yl)imidazo[1,2b]pyridazin-6-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((2-(1-methyl-1 H-pyrazol-4-yl)pyrazolo[1,5a]pyrimidin-5-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((3-(1-methyl-1 H-pyrazol-4-yl)pyrazolo[1,5a]pyrimidin-5-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-((tetra-hidro-2 H-pyran-4yl)óxi)pyridin-2-yl)amino)-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-6-((3-(1-methyl-1 H-imidazol-5-yl)imidazo[1,2b]pyridazin-6-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl (1R,5S)-6-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-3 Petition 870250102588, 10 / 11 / 2025, pág. 169 / 574 164 / 492 azabicyclo[3.1.0]hexane-3-carboxylate; methyl (3-((1-(2-acetyl-2-azabicyclo[2.2.1 ]heptan-5-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-((3,3-difluorocyclobutane)-1-sulfonamido)-5(tetra-hidro-2 H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl (3-((1-(4-((methoxycarbonyl)amino)-4-methylcyclo-hexyl)-3-methyl-2-oxo2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate; 2-methoxyethyl ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl1H-pyrazol-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(tetra-hidro-2 Hpyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; cyclobutyl ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1 Hpyrazol-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; ethyl ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; prop-2-yin-1-yl ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl1H-pyrazol-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; tetra-hydro-2H-pyran-4-yl ((1 R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)5-(1-methyl-1 H-pyrazol-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; 4-fluorophenyl ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl1H-pyrazol-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5 Petition 870250102588, 10 / 11 / 2025, pág. 170 / 574 165 / 492 c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-cyclopropylpyridin-2-yl)amino)-3-(methyl-d3)-2-oxo2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(3-cyanophenyl)-4-(1-methyl-1 H-pyrazol-4-yl)pyridin-2yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R,3R)-3-(6-((3-cyclopropylimidazo[1,2-b]pyridazin-6-yl)amino)-3(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-((cyclopropoxycarbonyl)amino)-5methoxyphenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin1 -yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1 Hpyrazol-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-(cyclopropanecarboxamido)-5-(1-methyl-1 Hpyrazol-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-(methyl-d3)-6-((8-(1-methylcyclopropyl)quinolin-2yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-(3-fluoro-1-(methyl-d3)-1 H-pyrazol-4-yl)imidazo[1,2b]pyridazin-6-yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; Petition 870250102588, 10 / 11 / 2025, pág. 171 / 574 166 / 492 methyl ((1 R ,3 R )-3-(6-((4-(cyclobutoxymethyl)-6-(2,3-dihydrobenzo[ b ][1,4]dioxina-6-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(3-aminopyrrolidin-1-yl)pyridin-2-yl)amino)-3-methyl2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-((cyclopentylamino)methyl)-6-(2,3-dihydrobenzo[ b ][1,4]dioxina-6-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((2-(piperidin-1-yl)pyrimidin-4-yl)amino)2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((2'-methoxy-4-methyl-[2,4'-bipyridin]-6-yl)amino)-3methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((4-(pyridin-4-yl)thiazol-2-yl)amino)-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-fluoro-6'-(trifluoromethyl)-[2,3'-bipyridin]-6yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxina-6-yl)-4-(((S)-3fluoropyrrolidin-1-yl)methyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(4-(cyanomethyl)phenyl)-5-fluoropyridin-2-yl)amino)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(4-cyclopropylphenyl)-5-fluoropyridin-2-yl)amino)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((5-fluoro-6-(4-(trifluoromethoxy)phenyl)pyridin-2yl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclomatopentyl)carbatopyl Petition 870250102588, dated 10 / 11 / 2025, p. 172 / 574 167 / 492 methyl ((1 R ,3 R )-3-(6-(((6-(2,3-di-hydrobenzo[ b ][1,4]dioxin-6-yl)-4(morpholinomethyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-Hymida-dizo-hydro-2,3-2 ]pyridine-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((2-(2-methoxypyridin-4-yl)pyrimidine-4-yl)amino)-3(methyl-d3)-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(2,3-di-hydrobenzo[ b ][1,4]dioxin-6-yl)-4(octahydro-2 H-pyrido[1,2-um ]pyrazine-2-carbonyl)pyridin-2-yl)amino)-3)-2,3-oxo-d3 H-imidazo[4,5-c ]pyridine-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((2-(5-azaspiro[2.4]heptan-5-yl)pyrimidin-4-yl)amino)3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-4-yl)amino)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((2-(4-(trifluoromethyl)piperidin-1yl)pyrimidin-4-yl)amino)-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxina-6-yl)-4-(( R )-3fluoropyrrolidine-1-carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((1-(pyridin-4-yl)-1 H-pyrazol-3yl)amino)-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxina-6-yl)-4(morpholine-4-carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((2-((3,3-difluorocyclopentyl)amino)pyrimidin-4yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1 Petition 870250102588, 10 / 11 / 2025, pág. 173 / 574 168 / 492 (il)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((2-(3,3-difluoropyrrolidin-1-yl)-6-methylpyrimidin-4yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((2-((tetra-hidro-2 H-pyran-4yl)amino)pyrimidin-4-yl)amino)-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-(piperidine-1-carbonyl)pyridin-2yl)amino)-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; and methyl ((1 R,3R)-3-(6-((6-(cyclo-hexylcarbamoyl)pyridin-2-yl)amino)-3-methyl2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; or a sal pharmaceutically aceitável do mesmo.

[00465] In some ways, this application provides a selected composition of: cyclobutyl (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-6-yl)amino)-5-(1-methyl-1H-pyrazol-4-yl)phenyl)carbamate; cyclobutyl (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-6-yl)amino)-5-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)carbamate; cyclobutyl (3-(1-cyclopropyl-1H-pyrazol-4-yl)-5-((3-methyl-2-oxo-1-(tetrahydrofuran-3-yl)-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6yl)amino)phenyl)carbamate; methyl ((1 R ,3 R )-3-(6-((1-(2-methoxyethyl)-3-(1-(trifluoromethyl)-1 H-pyrazol-4yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-1-methyl-2-oxo7-(4-(trifluoromethyl)pyridin-3-yl)-2,3-di-hidro-1 H-imidazo[4,5-b ]pyridin-5yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; N-(6-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline Petition 870250102588, 10 / 11 / 2025, pág. 174 / 574 169 / 492 2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)espiro[3.3]heptan-2-yl)cyclopropanecarboxamide; N-((1 s, 4 s )-1-methyl-4-(3-(methyl-d3)-6-((2-methyl-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclo-hexyl)cyclopropanecarboxamide; N-((1 S ,3 R )-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hidroxypropan-2-yl)pyridin-2yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1metilcyclopentyl)cyclopropanecarboxamide; methyl ((1 R ,3 R )-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hydroxypropan-2-yl)pyridin2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(1-methyl-1 H-pyrazol-4-yl)8-(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluoromethyl)thiazol-5yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((8-(2-cyanopropan-2-yl)-4-(morpholine-4carbonyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-2-methyl-8-(4(trifluoromethyl)pyridin-3-yl)imidazo[1,2-b ]pyridazin-6-yl)amino)-3-(methyl-d3)2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-3d)carbamate; methyl ((1 R ,3 R )-3-(6-((5-methoxy-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4-methylpyridin2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-1yl)cyclopentyl)carbamate; Petition 870250102588, 10 / 11 / 2025, pág. 175 / 574 170 / 492 methyl ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-((3-(difluoromethyl)azetidin-1-yl)methyl)-6-(5(trifluoromethyl)thiazol-2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-cyclobutoxy-5-(1-methyl-1 H-pyrazol-4-yl)-4(morpholine-4-carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((2-(5-(difluoromethyl)thiophen-2-yl)-6(hidroxymethyl)pyrimidin-4-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(difluoromethyl)thiophen-2-yl)-4-(morpholine-4carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(1-acetylpiperidin-4-yl)-6-(5-(trifluoromethyl)thiazol2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; 6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridin3-yl)imidazo[1,2-b ]pyridazin-6-yl)amino)-1-((1 r,3 r)-3-(2-hidroxypropan-2yl)cyclobutyl)-3-(metil-d3)-1,3-di-hidro-2 H-imidazo[4,5-c ]pyridin-2-ona; methyl ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4-(1-methyl-1 Hpyrazol-4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-(methyl-d3)-2-oxo-6-((6-(4-(trifluoromethyl)-1 H-pyrazol1 -yl)pyridin-2-yl)amino)-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2 H-pyran-4-yl)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)-hydro-hydro-5-yl) H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; Petition 870250102588, of 10 / 11 / 2025, p. 176 / 574 171 / 492 methyl ((1 R,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-3-(methyl-2-3-3-2-o H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((3 R )-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2 H-pyran-4-yl)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-dihydrohydro-1,5-H ]pyridine-1-yl)cyclopentyl-1- d) carbamate; methyl ((3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl-4-d)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)-hydro-5-yl)-hydro H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((3 R )-3-(6-((1-(1-cyanocyclopropyl)-3-(1-(trifluoromethyl)-1 H-pyrazol4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d )carbamate; methyl ((1 R ,3 R )-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(difluoromethyl)1H-pyrazol-4-yl)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-b ]pyridin-5-yl)amino)3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-7-(2hidroxypropan-2-yl)-2-methyl-3 H-imidazo[4,5-b ]pyridin-5-yl)amino)-3-(metild3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; N-((1 R ,3 R )-1-methyl-3-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)cyclopropanecarboxamide; N-((1 S ,3 R )-3-(6-((7-(hydroxymethyl)-2-methyl-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1methylcyclopentyl)cyclopropanecarboxamide; methyl ((1 R,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; Petition 870250102588, 10 / 11 / 2025, pág. 177 / 574 172 / 492 N-((1 S ,3 R )-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1methylcyclopentyl)cyclopropanecarboxamide; N-((1 s ,4 s )-4-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1-methylcyclohexyl)cyclopropanecarboxamide; N-((1 S ,3 R )-3-(6-((2-((1 s ,3 s )-3-hidroxycyclobutyl)-3-(1-(trifluorometil)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(metil-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1metilcyclopentyl)cyclopropanecarboxamide; methyl ((1 R,3R)-3-(6-((2-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; N-((1 S ,3 R )-3-(6-((2-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1methylcyclopentyl)cyclopropanecarboxamide; methyl ((3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; N-((1 s ,4 s )-4-(6-((1-((1 r,4 r)-4-hidroxiciclo-hexyl)-3-(1-(trifluorometil)-1 Hpirazol-4-yl)-1 H-pyrazolo[4,3-b ]piridin-5-yl)amino)-3-(metil-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]piridin-1-yl)-1-metilciclohexyl)cyclopropanecarboxamide; N-((1 s ,4 s )-1-methyl-4-(3-(methyl-d3)-6-((2-methyl-7-(morpholine-4-carbonyl)-3 Petition 870250102588, 10 / 11 / 2025, pág. 178 / 574 173 / 492 (1-(trifluoromethyl)-1 H-pyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclohexyl)cyclopropanecarboxamide; methyl ((1 S,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1-methylcyclopentyl)carbamate; N-((1 S ,3 R )-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1-methylcyclopentyl)acetamida; methyl ((3 R )-3-(6-((7-(2-hydroxypropan-2-yl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-1-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrrolo[2,3-b ]pyridin-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((3 R )-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2 H-pyran-4-yl)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((3 R )-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((3 R )-3-(6-((2-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((1 R ,3 R )-3-(3-(methyl-d3)-6-((6-methyl-4-(morpholine-4-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate; N-((1 S ,3 R )-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hidroxipropan-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1methylcyclopentyl)acetamida; Petition 870250102588, 10 / 11 / 2025, pág. 179 / 574 174 / 492 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-N(methyl-d3)bicyclo[2.2.2]octano-1-carboxamide; N-cyclopropyl-4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c ]pyridin-1-yl)bicyclo[2.2.2]octano-1-carboxamide; 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)bicyclo[2.2.2]octano-1-carboxamide; N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)bicyclo[2.2.2]octan-1-yl)acetamida; 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)bicyclo[2.2.1 ]heptane-1-carboxamide; N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3 )-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)bicyclo[2.2.1 ]heptan-1-yl)acetamida; N-((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)-1-methylcyclopentyl)propionamide; methyl ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(2-hydroxypropan-2yl)thiazol-2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(1,1,1,3,3,3-hexafluoro-2-hidroxypropan-2yl)thiazol-2-yl)-4-(2-hidroxypropan-2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; N-((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluoromethyl)thiazol-5yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)-1-methylcyclopentyl)acetamida; Petition 870250102588, 10 / 11 / 2025, pág. 180 / 574 175 / 492 methyl ((1 R ,3 R )-3-(6-((6-(5-(1,1,1,3,3,3-hexafluoro-2-hidroxypropan-2yl)thiazol-2-yl)-4-(2-hidroxypropan-2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4-methylpyridin2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl-1-d)carbamate; methyl ((1 R ,3 R )-3-(6-((5-fluoro-6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4methylpyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-1-d)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4-(methyld3)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-1-d)carbamate; N-((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-isopropoxythiazol-5yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)-1-methylcyclopentyl)acetamida; N-((1 S ,3 R )-3-(6-((4-(2-hidroxipropan-2-yl)-6-(2-methoxythiazol-5-yl)pyridin2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)1-methylcyclopentyl)acetamida; N-((1 S ,3 R )-3-(6-((6-(2-ethoxythiazol-5-yl)-4-(2-hidroxypropan-2-yl)pyridin-2yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1metilcyclopentyl)acetamida; methyl ((1 R ,3 R )-3-(6-((6'-(5-(difluoromethyl)thiophen-2-yl)-4-(trifluoromethyl)[3,4'-bipyridin]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 S ,2 S ,4 S )-2-hydroxy-4-(6-((4-(2-hydroxypropan-2-yl)-6-(5(trifluoromethyl)thiazol-2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-3-d)carbamate; Petition 870250102588, 10 / 11 / 2025, pág. 181 / 574 176 / 492 methyl ((1 R ,3 R )-3-(3-(methyl-d3)-6-((4-(1 -methylpiperidin-4-yl)-6-(5(trifluoromethyl)thiazol-2-yl)pyridin-2-yl)amino)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-1-d)carbamate; methyl ((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((1 S ,3 R )-3-(6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-2-methyl-8-(4(trifluoromethyl)pyridin-3-yl)imidazo[1,2-b ]pyridazin-6-yl)amino)-3-(methyl-d3)2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1d)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(2-hidroxypropan-2-yl)thiazol-2-yl)-4-(tetra-hidro2 H-pyran-4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(2-hidroxypropan-2-yl)thiazol-2-yl)-4-(tetra-hidro2 H-pyran-4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((1 S ,3 R )-3-(6-((6-(5-(2-hidroxypropan-2-yl)thiazol-2-yl)-4-(tetra-hidro2 H-pyran-4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((1 R ,3 R )-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4(trifluoromethyl)-[3,4'-bipyridin]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d )carbamate; methyl ((1 S ,3 R )-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4(trifluoromethyl)-[3,4'-bipyridin]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d )carbamate; methyl ((1 R ,3 R )-3-(6-((6-(5-(2-hidroxipropan-2-yl)thiazol-2-yl)-4-(1methylpiperidin-4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H Petition 870250102588, 10 / 11 / 2025, pág. 182 / 574 177 / 492 imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) carbamate; methyl ((1 R ,3 R )-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-2(trifluoromethyl)-[3,4'-bipyridin]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d )carbamate; N-((1S,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2-methyl-8-(4(trifluoromethyl)pyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl)amino)-3-(methyl-d3)2-oxo-2,3-dihydro-1 H-imidazo[4,5-c]pyridin-1-yl)-1methylcyclopentyl)acetamide; and methyl ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-(2hydroxypropan-2-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)amino)-3-(methyld3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1d)carbamate or a pharmaceutically acceptable salt thereof.

[00466] It is further recognized that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, several features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

[00467] In several places in this descriptive report, divalent linking substituents are described. Specifically, each divalent linking substituent is intended to include both the forward and backward forms of the linking substituent. For example, -NR(CR'R'')n- includes both -NR(CR'R'')n- and -(CR'R'')nNR-. When the structure clearly requires a linking group, the Markush variables listed for that group are understood to be linking groups.

[00468] The term n-members, where n is an integer, typically describes the number of ring-forming atoms in a fraction where the number of ring-forming atoms is n. For example Petition 870250102588, dated 10 / 11 / 2025, p. 183 / 574 178 / 492 plo, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydronaphthalene is an example of a 10-membered cycloalkyl group.

[00469] As used herein, the phrase optionally substituted means not substituted or substituted. Substituents are selected independently and substitution can occur at any chemically accessible position. As used herein, the term substituted means that a hydrogen atom is removed and replaced by a substituent. A single divalent substituent, for example, oxo, can substitute for two hydrogen atoms. It should be understood that substitution at a given atom is limited by valence.

[00470] As used here, the phrase each 'variable' is selected independently of means substantially the same as in which, on each occurrence, 'variable' is selected from.

[00471] Throughout the definitions, the term Cn-m indicates a range that includes the evaluation criteria, where neither are whole numbers and indicate the number of carbons. Examples include C1-3, C1-4, C1-6 and the like.

[00472] As used in this document, the term Cn-m alkyl, employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be linear or branched chain, having n-m carbons. Examples of alkyl groups include, but are not limited to, chemical groups such as methyl (Me), ethyl (Et), n-propyl (n-Pr), isopropyl (iPr), n-butyl, tert-butyl, isobutyl, seg-butyl; higher homologues such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl and the like. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or from 1 to 2 carbon atoms. Petition 870250102588, dated 10 / 11 / 2025, p. 184 / 574 179 / 492 carbon. The term Cn-m alkyl is understood to include deuterated analogs of alkyl groups as defined herein, including, but not limited to, groups such as trideuteromethyl (CD3), pentadeuteroethyl (CD2CD3), and the like.

[00473] As used herein, Cn-m alkenyl refers to an alkyl group with one or more carbon-carbon double bonds and with nam carbons. Examples of alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, seg-butenyl, and the like. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. The term Cn-m alkenyl is understood to include deuterated analogs of alkenyl groups as defined herein, including, but not limited to, groups such as trideuteroethenyl (-CD=CD2), tetradeuteropropenyl (-CD=CD-CD2), and the like.

[00474] As used herein, Cn-m alkynyl refers to an alkyl group with one or more carbon-carbon triple bonds and with nam carbons. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl (e.g., propyn-1-yl, propyn-2-yl, prop2-yn-1-yl), and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. The term Cnm alkynyl is understood to include deuterated analogs of alkynyl groups as defined herein, including, but not limited to, groups such as deuteroethynyl (-C^CD), trideuteropropyn-1-yl (-C^CCD3), and the like.

[00475] As used herein, the term Cn-m alkoxy, employed alone or in combination with other terms, refers to a group of formula -O-alkyl, in which the alkyl group has n-m carbons. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g., n-butoxy and tert-butoxy), and the like. In some forms Petition 870250102588, dated 10 / 11 / 2025, p. 185 / 574 180 / 492 alkoxy groups, the alkyl group has from 1 to 6, 1 to 4, or 1 to 3 carbon atoms. The term Cn-m alkoxy is understood to include deuterated analogs of the alkyl moiety of the alkoxy group as defined herein, including, but not limited to, groups such as trideuteromethoxy (-OCD3), pentadeuteroethoxy (-OCD2CD3), and the like.

[00476] As used in this document, the term amino refers to a group of the formula -NH2.

[00477] As used herein, the term aryl, employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or polycyclic (e.g., with 2, 3, or 4 fused rings). The term Cn-m aryl refers to an aryl group with nam carbon atoms in the ring. Aryl groups include, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, the aryl groups have 5 to 10 carbon atoms. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl is phenyl. The term aryl is understood to include deuterated analogs of aryl groups as defined herein, including, but not limited to, groups such as pentadeuterophenyl (i.e., perdeuterophenyl, phenyl-d5), perdeuteronaphthyl, and the like.

[00478] As used herein, halo refers to F, Cl, Br, or I. In some embodiments, a halo is F, Cl, or Br. In some embodiments, a halo is F or Cl. In some embodiments, a halo is F. In some embodiments, a halo is Cl.

[00479] As used herein, Cn-m haloalkoxy refers to a group of formula -O-haloalkyl with nam carbon atoms. Examples of haloalkoxy groups include OCF3 and OCHF2. In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. The term Cn-m haloalkoxy is understood to include deuterated analogs. Petition 870250102588, dated 10 / 11 / 2025, p. 186 / 574 181 / 492 of the haloalkyl fraction of the haloalkoxy group as defined herein, including, but not limited to, groups such as deuterodifluoromethoxy (OCDF2), dideuterofluoromethoxy (-OCD2F) and the like.

[00480] As used herein, the term Cn-m haloalkyl, employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+1 halogen atoms which may be the same or different, where s is the number of carbon atoms in the alkyl group, wherein the alkyl group has from nam carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the alkyl group has from 1 to 6, from 1 to 4, or from 1 to 3 carbon atoms. Examples of haloalkyl groups include CF3, C2F5, CHF2, CH2F, CCl3, CHCb, C2Cl5, and the like. The term Cn-m haloalkyl is understood to include deuterated analogs of the haloalkyl group as defined herein, including, but not limited to, groups such as deuterodifluoromethyl (-CDF2), dideuterofluoromethyl (-CD2F) and the like.

[00481] As used herein, the term carbonyl, employed alone or in combination with other terms, refers to a C(O)- group.

[00482] As used herein, the term Cn-m alkylcarbonyl refers to a group of formula -C(O)-alkyl, in which the alkyl group has nam carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[00483] As used herein, the term Cn-m alkylsulfonyl refers to a group of formula -S(O)2-alkyl, in which the alkyl group has nam carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[00484] As used herein, the term carboxy refers to a group with the formula -C(O)OH.

[00485] As used herein, the term di(Cn-m alkyl)amino refers to Petition 870250102588, dated 10 / 11 / 2025, p. 187 / 574 182 / 492 refers to a group of formula -N(alkyl)2, wherein the two alkyl groups each independently have nam carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[00486] As used herein, cycloalkyl refers to non-aromatic cyclic hydrocarbons, including cyclized alkyl and alkenyl groups. Cycloalkyl groups may include mono- or polycyclic groups (e.g., with 2 fused rings), spirocycles, and bridging rings (e.g., a bridging bicycloalkyl group). Ring-forming carbon atoms of a cycloalkyl group may optionally be substituted with oxo or sulfide (e.g., C(O) or C(S)). Also included in the definition of cycloalkyl are fractions having one or more fused aromatic rings (i.e., having a common bond with) the cycloalkyl ring, for example, benzo- or thienyl derivatives of cyclopentane, cyclohexane, and the like. A cycloalkyl group containing a fused aromatic ring may be linked through any ring-forming atom, which includes a ring-forming atom of the fused aromatic ring.Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (i.e., C3-10). In some embodiments, the cycloalkyl is a C3-10 monocyclic or bicyclic cycloalkyl. In some embodiments, the cycloalkyl is a C3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4-10 spirocycle or bridged cycloalkyl (e.g., a bridged bicycloalkyl group). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, azaspiro[2.4]heptanyl, and the like. Petition 870250102588, dated 10 / 11 / 2025, p. 188 / 574 183 / 492 lares. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. The term cycloalkyl is understood to include deuterated analogs of cycloalkyl groups as defined herein, including, but not limited to, groups such as perterocyclopropyl, perterocyclobutyl, perterocyclopentyl, perterocyclohexyl, and the like.

[00487] As used herein, heteroaryl refers to a monocyclic or polycyclic aromatic heterocycle (e.g., with 2 fused rings) with at least one heteroatom ring member selected from N, O, S, and B. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S, and B. In some embodiments, any ring-forming N in a heteroaryl moiety may be an N-oxide. In some embodiments, the heteroaryl is a 5- to 10-membered monocyclic or bicyclic heteroaryl with 1, 2, 3, or 4 heteroatom ring members selected independently from N, O, S, and B. In some embodiments, the heteroaryl is a 5- to 10-membered monocyclic or bicyclic heteroaryl with 1, 2, 3, or 4 heteroatom ring members selected independently from N, O, S, and B. In some embodiments, the heteroaryl is a 5- to 6-membered monocyclic heteroaryl with 1 or 2 heteroatom ring members selected independently from N, O, S, and B.In some embodiments, the heteroaryl is a 5- to 6-membered monocyclic heteroaryl with 1 or 2 heteroatom ring members selected independently from N, O, and S. In some embodiments, the heteroaryl group contains 3 to 10, 4 to 10, 5 to 10, 5 to 7, 3 to 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to 4 ring-forming heteroatoms, 1 to 3 ring-forming heteroatoms, 1 to 2 ring-forming heteroatoms, or 1 ring-forming heteroatom. When the heteroaryl group contains more than one hetero-ring member... Petition 870250102588, dated 10 / 11 / 2025, p. 189 / 574 184 / 492 heteroatom, heteroatoms can be the same or different.Examples of heteroaril grupos include tienila (ou tiofenil), furil (ou furanil), pirrolila, imidazolila, tiazolila, oxazolila, pirazolila, isotiazolila, isoxazolila, 1,2,3-triazolila, tetrazolila, 1,2,3-tiadiazolila, 1,2,3-oxadiazolila, 1,2,4-triazolila, 1,2,4-tiadiazolila, 1,2,4-oxadiazolila, 1,3,4-triazolila, 1,3,4-tiadiazolila, 1,3,4-oxadiazolila e 1,2-di-hidro-1,2azaborina, piridinila, pyrimidinila, pirazinila, piridazinila, azolila, triazolila, tiadiazolila, quinolinila, isoquinolinila, indolila, benzotiofenila, benzofuranila, benzisoxazolila, imidazo[1,2-b]tiazolila, purinila, triazinila, tieno[3,2-b]piridinila, imidazo[1,2-a]piridinila, 1,5-naftiridinila, 1Hpirazolo[4,3-b]piridinila, triazolo[4,3-a]piridinila, 1H-pirrolo[3,2b]piridinila, 1H-pirrolo[2,3-b]piridinila, pirazolo[1,5-a]piridinila, pirazolo[1,5-a]pirimidinila, indazolila, imidazo[1,2-b]pyridazinyl, pyrazol[1,5a]pyrimidinyl, and similar.The term heteroaryl is understood to include deuterated analogues of heteroaryl groups as defined herein, including, but not limited to, groups such as perdeuteropyridinyl, perdeuteropyrazinyl, perdeuteropyrimidinyl, and the like.

[00488] As used herein, heterocycloalkyl refers to monocyclic or polycyclic heterocycles having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more ring-forming carbon atoms of the heterocycloalkyl are replaced by a heteroatom selected from N, O, S and B, and wherein the carbon atoms and ring-forming heteroatoms of a heterocycloalkyl group may optionally be replaced by one or more oxo or sulfide groups (e.g., C(O), S(O), C(S) or S(O)2, etc.). When a ring-forming carbon atom or heteroatom of a heterocycloalkyl group is optionally replaced by one or more oxo or sulfide groups, the O or S of said group is added to the number of ring-forming atoms specified herein (for example, a 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl is a 6-ring-forming heterocycloalkyl group). Petition 870250102588, dated 10 / 11 / 2025, p. 190 / 574 185 / 492 members, in which a ring-forming carbon atom is replaced by an oxo group, and in which the 6-membered heterocycloalkyl group is further replaced by a methyl group). Heterocycloalkyl groups include monocyclic and polycyclic systems (e.g., with 2 fused rings). Included in heterocycloalkyl are monocyclic and polycyclic heterocycloalkyl groups of 3 to 10, 4 to 10, 5 to 10, 4 to 7, 5 to 7, or 5 to 6 members. Heterocycloalkyl groups may also include spirocycles and bridging rings (e.g., a 5 to 10-membered bridging biheterocycloalkyl ring having one or more ring-forming carbon atoms replaced by a heteroatom selected independently from N, O, S, and B). The heterocycloalkyl group may be linked through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group occurs with 0 to 3 double bonds.In some embodiments, the heterocycloalkyl group contains from 0 to 2 double bonds. The term heterocycloalkyl is understood to include deuterated analogues of heterocycloalkyl groups as defined herein, including, but not limited to, groups such as perteteroazetidinyl, perteteropyrrolidinyl, perteteropiperidinyl, and the like.

[00489] Also included in the definition of heterocycloalkyl are moieties having one or more fused aromatic rings (i.e., having a common bond with) the non-aromatic heterocyclic ring, for example, benzo- or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring may be linked via any ring-forming atom, including a ring-forming atom of the fused aromatic ring.In some embodiments, the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group... Petition 870250102588, dated 10 / 11 / 2025, p. 191 / 574 186 / 492 has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. In some embodiments, the heterocycloalkyl is a 4- to 6-membered monocyclic heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, S, and B and having one or more oxidized ring members. In some embodiments, the heterocycloalkyl is a 5- to 10-membered monocyclic or bicyclic heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from N, O, S, and B and having one or more oxidized ring members. In some embodiments, the heterocycloalkyl is a 5- to 10-membered monocyclic or bicyclic heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and having one or more oxidized ring members. In some embodiments, the heterocycloalkyl is a 5- to 6-membered monocyclic heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and having one or more oxidized ring members.

[00490] Examples of heterocycloalkyl groups include pyrrolidin-2-one (or 2-oxopyrrolidinyl), 1,3-isoxazolidin-2-one, pyranyl, tetrahydropyranyl, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, 1,2,3,4-tetrahydroisoquinoline, benzazapene, azabicyclo[3.1.0]hexanyl, chloro[2.1.1]hexanyl, chloro[2.2.1]heptanyl, chloro[3.1.1]heptanyl, diazabicyclo[3.1.0]hexanyl, oxobiziabicyclo[2.2.1]heptanyl, diazabiziabicyclo[3.1. 1 ]heptanyl, diazabiciazabicyclo[3.2.1 ]octanyl, deazabici clo[3.2.1 ]octanyl, oxobicyclo[2.2.2]octanyl, azabicyclo[2.2.2]octanyl, azaadamantanyl, diazaadamantanyl, oxo-adamantanyl, azaspiro[3.3]heptanyl, diazaspiro[3.3]heptanyl, oxo-azaspiro[3.3]heptanyl, azaspiro[3.4]octanyl, diazaspiro[3.4]octanyl, oxo azaspiro[3.4]octanyl, azaspiro[2.5]octanyl, diazaspiro[2.5]octanyl,. Petition 870250102588, dated 10 / 11 / 2025, p. 192 / 574 187 / 492 azaspiro[4.4]nonanyl, diazaspiro[4.4]nonanyl, oxoazaspiro[4.4]nonanyl, azaspiro[4.5]decanyl, diazaspiro[4.5]decanyl, diazaspiro[4.4]nonanyl, oxo-diazaspiro[4.4]nonanyl, oxo-dihydropyridazinyl, oxo-2,6-diazaspiro[3.4]octanyl, oxohexahydropyrrolo[1,2-a]pyrazinyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 3oxopiperazinyl, oxo-pyrrolidinyl, oxo-pyridinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 1,6-diazaspiro[3.3]heptanyl, 3azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5azabicyclo[4.1.0]heptanyl, and the like.

[00491] As used herein, Co-pCycloalkyl-Cn-m alkyl- refers to a cycloalkyl-alkylene-formula group, wherein the cycloalkyl has oap carbon atoms and the alkylene linking group has nam carbon atoms.

[00492] As used here Co-p aryl-Cn-m alkyl- refers to a group of formula aryl-alkylene-, wherein the aryl has oap carbon atoms and the alkylene linking group has nam carbon atoms.

[00493] As used herein, heteroaryl-Cn-m alkyl- refers to a heteroaryl-alkylene-formula group, in which the alkylene linking group has nam carbon atoms.

[00494] As used herein, heterocycloalkyl-Cn-m alkyl- refers to a heterocycloalkyl-alkylene- group of formula, in which the alkylene linking group has nam carbon atoms.

[00495] As used herein, an alkyl linking group is a linear or branched chain divalent alkyl linking group (alkylene group). For example, Co-p-cycloalkyl-Cn-m-alkyl-, Co-p-aryl-Cn-m-alkyl-, phenyl-Cn-m-alkyl-, heteroaryl-Cn-m-alkyl-, and heterocycloalkylCn-m-alkyl- contain alkyl linking groups. Examples of alkyl linking groups or alkylene groups include methylene, ethan-1,1-di-yl, Petition 870250102588, dated 10 / 11 / 2025, p. 193 / 574 188 / 492 ethan-1,2-di-yl, propan-1,3-dilyl, propan-1,2-di-yl, propan-1,1-di-yl and the like. The terms alkyl linking group and alkylene linking group are understood to include deuterated analogues of alkylene groups as defined herein.

[00496] In certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings may be attached to any ring member, provided the valence of the atom is not exceeded. For example, an azetidine ring may be attached to any position on the ring, whereas a pyridin-3-yl ring is attached at position 3.

[00497] As used herein, the term oxo refers to an oxygen atom (i.e., =O) as a divalent substituent, forming a carbonyl group when bonded to a carbon (e.g., C=O or C(O)), or bonded to a nitrogen or sulfur heteroatom forming a nitroso, sulfinyl, or sulfonyl group.

[00498] As used herein, the term independently selected means that each occurrence of a variable or substitute (e.g., each RM) is independently selected from each occurrence in the applicable list.

[00499] The compounds described in this document may be asymmetric (e.g., with one or more stereocenters). All stereoisomers, as well as enantiomers and diastereomers, are directed unless otherwise indicated. The compounds of this disclosure containing asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms. Methods for preparing optically active forms from optically inactive feedstocks are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and similar compounds are also known. Petition 870250102588, dated 10 / 11 / 2025, p. 194 / 574 189 / 492 Similar isomers may also be present in the compounds described in this document, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separate isomeric forms. In some embodiments, the compound has the (R) configuration. In some embodiments, the compound has the (S) configuration. The Formulas (e.g., Formula I, Formula Ia, etc.) provided herein include stereoisomers of the compounds.

[00500] The dissolution of racemic mixtures of compounds can be carried out by any of the numerous methods known in the art. One example method includes fractional recrystallization using a chiral dissolving acid, which is an optically active organic acid formed from a salt. Suitable dissolving agents for fractional recrystallization methods are, for example, optically active acids such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, or the various optically active camphorsulfonic acids such as β-camphorsulfonic acid. Other suitable resolving agents for fractional crystallization methods include stereoisomerically pure forms of α-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.

[00501] The dissolution of racemic mixtures can also be carried out by elution in a packed column with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). The appropriate elution solvent composition can be determined by a person skilled in the art.

[00502] The compounds provided in this document also include Petition 870250102588, dated 10 / 11 / 2025, page 195 / 574 190 / 492 in tautomeric forms. Tautomeric forms result from the exchange of a single bond for an adjacent double bond along with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers, which are isomeric protonation states with the same empirical formula and total charge. Examples of prototropic tautomers include ketone-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, 2-hydroxypyridine and 2-pyridone, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically blocked in a form by appropriate substitution.

[00503] All pharmaceutically acceptable compounds and salts of these can be found together with other substances, such as water and solvents (e.g., hydrates and solvates), or can be isolated.

[00504] In some embodiments, the preparation of compounds may involve the addition of acids or bases to affect, for example, the catalysis of a reaction or the formation of desired salt forms, such as acid addition salts.

[00505] In some embodiments, the compounds provided herein, or their salts, are substantially isolated. By substantially isolated it is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation may include, for example, a composition enriched in the compounds provided herein. Substantial separation may include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight. Petition 870250102588, dated 10 / 11 / 2025, p. 196 / 574 191 / 492 of the compounds provided in this document, or salt thereof.

[00506] The term compound, as used in this document, is intended to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures represented. Compounds identified in this document by name or structure as a particular tautomeric form are intended to include other tautomeric forms, unless otherwise specified.

[00507] The term pharmaceutically acceptable is used in this document to refer to those compounds, materials, compositions and / or dosage forms that are, within the scope of reliable medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problem or complication, assessed in accordance with a reasonable risk / benefit ratio.

[00508] This application also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, pharmaceutically acceptable salts refers to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acidic or basic fraction into its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkaline or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of this disclosure include conventional non-toxic salts of the parent compound formed, for example, from non-toxic organic or inorganic acids. The pharmaceutically acceptable salts of this disclosure may be synthesized from the parent compound containing a basic or acidic fraction by conventional chemical methods.Generally, these salts can be prepared by reacting the free acid or base forms of these compounds with... Petition 870250102588, dated 10 / 11 / 2025, p. 197 / 574 192 / 492 a stoichiometric amount of the appropriate base or acid in water, or in an organic solvent, or in a mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, alcohols (e.g., methanol, ethanol, isopropanol, or butanol), or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. Synthesis

[00509] As will be recognized by those skilled in the art, the compounds provided in this document, including salts and stereoisomers thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of the numerous possible synthetic routes.

[00510] Compounds of Formula (I) can be prepared, for example, using a process as illustrated in Scheme 1. In the process described in Scheme 1, compounds of formula 1-1, where L1 is a halogen (e.g., F, Cl or Br), can react with compounds 1-2 via aromatic nucleophilic substitution reactions (e.g., in the presence of a base such as N,N-diisopropylethylamine) followed by reduction of the nitro group in compound 1-3 (e.g., under reducing conditions such as treatment with Zn powder, H2O and NH4Cl) resulting in the formation of compounds of formula 1-4. Compounds of formula 1-4 can be converted into cyclic urea 1-5 under standard conditions (e.g., in the presence of succinimidyl N-carbonate). Compounds of formula 1-5 can be further transformed into compounds of formula 1-6 via CN bond formation (e.g., in the presence of an alkyl halide (e.g., iodomethane) and a base (e.g., cesium carbonate)).Compounds with formula 1-6, where L2 is a halogen. Petition 870250102588, dated 10 / 11 / 2025, page 198 / 574 193 / 492 (e.g., Cl or Br), are further joined to compounds of formula 1-7 via Buchwald-Hartwig cross-coupling reactions (e.g., in the presence of tris(dibenzylideneacetone)dipalladium(0), Xanthos and cesium carbonate) to produce compounds of Formula I.

[00511] Alternatively, compounds of formula 1-6 can be used to prepare compounds of formula 1-8 via Buchwald-Hartwig cross-coupling reactions (e.g., in the presence of tris(dibenzylideneacetone)dipalladium(0), BrettPhos and cesium carbonate) followed by NH deprotection of the protecting group (e.g., treatment with HCl or TFA). Then, compounds of formula 1-8 can be coupled with compounds of formula 1-9, where X is a halogen (e.g., Cl or Br), under Buchwald-Hartwig cross-coupling reactions (e.g., in the presence of tris(dibenzylideneacetone)dipalladium(0), Xantfos and cesium carbonate) to give compounds of Formula I. Diagram 1. Li I 3 Substitution of SNAr y YG + H2N—Cy2 * °2 1-1 1-2 o py2 c „ Γ-n Coupling RN.A R3 .____-_______ Ri-r L JL / CY\ cv4N r5 'r5 Formula I 17 °a Cy2 c . r~N Coupling RNyA^R3 -__________ Ri-r Ü JL zCyí. Cv4 SANZ ^R5 χ / Cy\R5 Π Formula I 19 .Cy2 .Cy2 HN Reduction hn y NyAyR2 _____► HjNy.R3 ^n^l2 1-3 1-4 Urea Formation >. ή^τ2 ή^τ2 1-6 1-5 η Coupling 2) NH Deprotection ) Cy2 / -N ^γΛγρ3 ή^ήη2 1-8 Petition 870250102588, dated 10 / 11 / 2025, p. 199 / 574 194 / 492

[00512] When Cy4 is a 6-membered aryl or heteroaryl ring, compounds of formula 1-7 and 1-9 can be prepared using a process as illustrated in Scheme 2. Compounds of formula 2-1, where X is a halogen (e.g., Cl, Br, or I), can react with compounds 2-2 (M is B(OR)2, Sn(alkyl)3, Zn-hal, etc.) under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand), to give compounds of formula 2-3. After manipulations of functional groups (e.g., amide coupling, cross-coupling, Grignard addition, etc.) in compound 2-3, compounds of formula 1-7 can be prepared.

[00513] Alternatively, compounds of formula 2-4, where X is a halogen (e.g., Cl, Br, or I), can be converted into compounds 2-5 (M is B(OR)2, Sn(alkyl)3, etc.) under standard conditions (e.g., in the presence of a palladium catalyst and a suitable ligand). Compounds of formula 2-5 can be further transformed into compounds of formula 2-7 (1-9) via cross-coupling reaction with compounds of formula 2-6 under standard conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base). After manipulations of functional groups (e.g., amide coupling, cross-coupling, Grignard addition, etc.) in compound 2-7, compounds of formula 1-7 can be prepared.

[00514] Compounds of formula 1-9 can also be prepared from compounds of formula 2-4, where X is a halogen (e.g., Cl, Br, or I), through aromatic nucleophilic substitution reactions with compounds 2-8 (e.g., in the presence of a Petition 870250102588, dated 10 / 11 / 2025, page 200 / 574 195 / 492 base, such as N,N-diisopropylethylamine) followed by manipulations of functional groups (e.g., amide coupling, cross-coupling, Grignard addition, etc.) in compound 2-9. In Scheme 2, at least one RQ group corresponds to the R5 variable as defined herein, and each additional RQ group corresponds to the H or R4 variable as defined herein. Diagram 2. rq-m 2-2 Coupling Functional group Manipulation R5 Functional group Manipulation Transmetalation SiNAr Replacement rq-x· 2-6 Functional group Coupling Manipulation ά4\5 R5 1-9 2-8 2-9

[00515] When Cy4 is 1H-pyrrolo[3,2-b]pyridine or 1H-pyrazolo[4,3b]pyridine ring, compounds of formula 1-7 and 1-9 can be prepared using a process as illustrated in Scheme 3. Compounds of formula 3-1 can undergo a halogenation reaction (e.g., in the presence of N-iodosuccinimide) followed by an alkylation reaction with compound 2-2 (L are halogens, MOs, etc.) to give compounds of formula 3-3. Compounds of formula 3-3 can react with compounds 3-4 (e.g., M is B(OR)2) under standard cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base) to give a derivative of formula 3-5. After manipulations of functional groups (by Petition 870250102588, dated 10 / 11 / 2025, page 201 / 574 196 / 492 example, amide coupling, cross coupling, Grignard addition etc.) in compound 3-5, compounds of formula 1-7 (if Y = NHPG) and 1-9 (if Y = halogens) can be prepared. In Scheme 3, at least one RQ group corresponds to the variable R5 as defined here and each additional RQ group corresponds to H or variable R4 as defined here. Diagram 3. l) Iodination 2) Alkylation R°-L 3-2 R°-M 3-4 Coupling Functional group Manipulation 3-5 Y = NHPG Y _ halogens / Cyí N R5 1-7

[00516] When Cy4 is 3 H-imidazo[4,5-b]pyridine or 1,3-dihydro-2 Himidazo[4,5-b]pyridine-2-one ring, compounds of formula 1-9 can be prepared using a process as illustrated in Scheme 4. Compounds of formula 4-1, where Li is a halogen (e.g., F, Cl, or Br), can react with compounds 4-2 via aromatic nucleophilic substitution reactions (e.g., in the presence of a base such as N,N-diisopropylethylamine) to give compounds of formula 4-3. Reduction of the nitro group in compound 4-3 (e.g., under reducing conditions such as treatment with Zn powder, H2O, and NH4CD followed by cyclization reaction (e.g., in the presence of CDI or methyl orthoformate)) produces compounds of formula 4-4. After manipulations of functional groups (e.g., amide coupling, cross-coupling, Grignard addition, etc.) in compound 4... [Petition 870250102588, 10 / 11 / 2025, p. 202 / 574] 197 / 492 4, compounds 1-9 can be prepared. In Scheme 4, at least one RQ group corresponds to the variable R5 as defined here and each additional RQ group corresponds to H or variable R4 as defined here. Diagram 4. SiNAr Replacement Rq-NH2 4-2 η | Nitro reduction 2) Cycling 4-4 Functional group Manipulation 1-9

[00517] When Cy4 is an imidazo[1,2-b] pyridazine ring, the compounds of formula 1-7 can be prepared using a process as illustrated in Scheme 5. The compounds of formula 5-1 can couple to compounds 5-2 (e.g., M is B(OR)2 Zn-hal, etc.) under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand), to generate the compound of formula 5-3. Iodination of compound 5-3 (e.g., in the presence of N-iodosuccinimide) yields the compound of formula 5-4. The compounds of formula 5-4 can react with compounds 5-5 (e.g., M is B(OR)2) under standard conditions of aco Petition 870250102588, dated 10 / 11 / 2025, page 203 / 574 198 / 492 Cross coupling (e.g., in the presence of a palladium catalyst and a suitable ligand / base) to give compounds of formula 5-6 (1-9). The compounds of formula 5-6 can be elaborated into compounds of formula 1-7 by Buchwald-Hartwig cross coupling reactions (e.g., in the presence of a palladium catalyst and a suitable ligand) followed by NH deprotection of the protecting group (e.g., treatment with HCl or TFA). In Scheme 5, at least one RQ group corresponds to the variable R5 as defined herein and each additional RQ group corresponds to H or the variable R4 as defined herein. Diagram 5. Iodination rq-m 5-5 Coupling Cv4h2n^ 'r5 1-7 pQ 1) Buchwald coupling X 2) NH3 deprotection Rq Rq

[00518] The reactions for the preparation of compounds described in this document can be carried out in suitable solvents that can be easily selected by a person skilled in the art of organic synthesis. Suitable solvents can be substantially unreactive with the starting materials (reagents), intermediates or products at the temperatures at which the reactions are carried out (for example, temperatures that can range from the freezing point of the solvent to the boiling point of the solvent). Petition 870250102588, dated 10 / 11 / 2025, page 204 / 574 199 / 492 A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, solvents suitable for that particular reaction step can be selected by someone skilled in the art.

[00519] The expressions ambient temperature or ambient temperature or rt as used herein, are understood in the art and generally refer to a temperature, for example, a reaction temperature, which is approximately the temperature of the environment in which the reaction is carried out, for example, a temperature of about 20 °C to about 30 °C.

[00520] The preparation of the compounds described herein may involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be easily determined by a specialist in the field. The chemistry of protecting groups can be found, for example, in TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd Ed., Wiley & Sons, Inc., New York (1999).

[00521] Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LCMS), or thin-layer chromatography (TLC). Compounds can be purified by those skilled in the art by a variety of methods, including high-performance liquid chromatography (HPLC) and normal-phase silica chromatography. Methods of use Petition 870250102588, dated 10 / 11 / 2025, page 205 / 574 200 / 492

[00522] The compounds described herein can inhibit the activity of the V617F variant of the JAK2 protein tyrosine kinase (i.e., V617F or JAK2V617F). Compounds that inhibit V617F are useful for providing a means of preventing growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. Therefore, the compounds disclosed are expected to be useful in the treatment or prevention of proliferative disorders, such as cancers. In particular, tumors with activating mutants of tyrosine kinase receptors or upregulation of tyrosine kinase receptors may be particularly sensitive to the inhibitors.

[00523] In certain embodiments, the disclosure provides a method for treating a V617F-related disorder in a patient who needs it, comprising the step of administering to said patient a compound of the disclosure, or a pharmaceutically acceptable composition thereof.

[00524] Myeloproliferative diseases (MPDs) are multipotent disorders of hematopoietic stem cells characterized by the overproduction of various blood cells. MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF). The JAK2 V617F mutation is reported in approximately 95% of patients with PV, in 35% to 70% of patients with ET, and in 50% of patients with IMF. Furthermore, exon 12 mutations of JAK2 are detected in some patients with PV V617F-negative (Ma et al., J. Mol. Diagn., 11: 49-53, 2009). In some modalities, the compounds of the dissemination may be useful in the treatment of myeloproliferative disorders (e.g., myeloproliferative neoplasms) in a patient who requires them, such as polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), systemic disease Petition 870250102588, dated 10 / 11 / 2025, page 206 / 574 201 / 492 of mast cells (SMCD) and similar.

[00525] In some modalities, the myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis.

[00526] In some forms, myeloproliferative disorder is a myeloproliferative neoplasm.

[00527] In some forms, the myeloproliferative disorder is myelofibrosis (e.g., primary myelofibrosis (PMF) or post-polycythemia vera / essential thrombocythemia myelofibrosis (post-PV / ETMF)).

[00528] In some forms, the myeloproliferative disorder is primary myelofibrosis (PMF).

[00529] In some forms, the myeloproliferative disorder is post-essential thrombocythemia myelofibrosis (Post-ET MF).

[00530] In some forms, the myeloproliferative disorder is post-polycythemia vera myelofibrosis (Post-PV MF).

[00531] In some modalities, the myeloproliferative disorder is selected from primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET).

[00532] In some forms, myeloproliferative neoplasia is primary myelofibrosis (PMF).

[00533] In some forms, myeloproliferative neoplasm is polycythemia vera (PV).

[00534] In some forms, myeloproliferative neoplasia is essential thrombocythemia (ET).

[00535] Myeloproliferative diseases include disorders of a type of cell derived from the bone marrow or lymph nodes, such as a white blood cell. A myeloproliferative disease can manifest as abnormal cell division, resulting in an abnormal level of a specific population of hematological cells. Abnormal cell division Petition 870250102588, dated 10 / 11 / 2025, p. 207 / 574 202 / 492 underlying a proliferative hematological disorder is normally inherent to the cells and not a normal physiological response to infection or inflammation. Leukemia is a type of myeloproliferative disease. Exemplary myeloproliferative diseases include, but are not limited to, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), hairy cell leukemia, leukemic manifestations of lymphomas, multiple myeloma, polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF), hypereosinophilic syndrome (HES), chronic neutrophilic leukemia (CNL), myelofibrosis with myeloid metaplasia (MMM), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia, chronic basophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis (SM), and unclassified myeloproliferative diseases (UMPD or MPDNC).Lymphoma is a type of proliferative disease that primarily involves lymphoid organs, such as lymph nodes, liver, and spleen. Exemplary proliferative lymphoid disorders include lymphocytic lymphoma (also called chronic lymphocytic leukemia), follicular lymphoma, large cell lymphoma, Burkitt lymphoma, marginal zone lymphoma, and lymphoblastic lymphoma (also called acute lymphoblastic lymphoma).

[00536] For example, the compounds in the disclosure are useful in the treatment of cancer. Examples of cancer include bladder cancer (e.g., urothelial carcinoma, squamous cell carcinoma, adenocarcinoma), breast cancer (e.g., hormone R positive, triple negative), cervical cancer, colorectal cancer, small bowel cancer, colon cancer, rectal cancer, anal cancer, endometrial cancer, gastric cancer (e.g., gastrointestinal stromal tumors), head and neck cancer (e.g., larynx, hypopharynx, nasopharynx, oropharynx, lip and mouth cancers, squamous cell carcinomas of the head and neck), kidney cancer (e.g., carcinoma of Petition 870250102588, dated 10 / 11 / 2025, page 208 / 574 203 / 492 renal cells, urothelial carcinoma, sarcoma, Wilms' tumor), liver cancer (e.g., hepatocellular carcinoma, cholangiocellular carcinoma (e.g., intrahepatic, hilar or perihilar, distal extrahepatic), hepatic angiosarcoma, hepatoblastoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, vulvar cancer, esophageal cancer, gallbladder cancer, pancreatic cancer (e.g., exocrine pancreatic carcinoma), stomach cancer, thyroid cancer, parathyroid cancer, neuroendocrine cancer (e.g., pheochromocytoma, Merkel cell carcinoma, carcinoma neuroendocrine), skin cancer (e.g., squamous cell carcinoma, Kaposi's sarcoma,Merkel cell skin cancer) and brain cancer (e.g., astrocytoma, medulloblastoma, ependymoma, neuroectodermal tumors, pineal tumors).

[00537] Other examples of cancer include hematopoietic malignancies such as leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, acute myeloid leukemia (AML), B-cell lymphoma, cutaneous T-cell lymphoma, acute myeloid leukemia, Hodgkin's or non-Hodgkin's lymphoma, myeloproliferative neoplasms (e.g., 8p11 myeloproliferative syndrome, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)), myelodysplastic syndrome, chronic eosinophilic leukemia, Waldenstrom's macroglobulinemia, hairy cell lymphoma, chronic myelogenous lymphoma, acute lymphoblastic lymphoma, AIDS-related lymphomas, and Burkitt's lymphoma.

[00538] In certain modalities, a method of cancer treatment is provided here which comprises administering to a patient necessary Petition 870250102588, dated 10 / 11 / 2025, page 209 / 574 204 / 492 cites a therapeutically effective amount of a disclosure compound. In certain modalities, the cancer is selected from among T-lymphoblastic lymphoma, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, and osteosarcoma.

[00539] Other cancers treatable with disclosure compounds include eye tumors, glioblastoma, melanoma, leiomyosarcoma, and urothelial carcinoma (e.g., ureter, urethra, bladder, urachus).

[00540] The compounds in the dissemination process may also be useful in inhibiting tumor metastases.

[00541] In some embodiments, the compounds disclosed, as described herein, may be used to treat Alzheimer's disease, HIV, or tuberculosis.

[00542] In some embodiments, the compounds of the disclosure may be useful in the treatment of myelodysplastic syndrome (MDS) in a patient who requires it. In some embodiments, the patient with myelodysplastic syndrome (MDS) is dependent on red blood cell transfusion.

[00543] As used herein, myelodysplastic syndromes are intended to encompass heterogeneous and clonal hematopoietic disorders that are characterized by ineffective hematopoiesis in one or more of the major myeloid cell lineages. Myelodysplastic syndromes are associated with bone marrow failure, peripheral blood cytopenias, and a propensity for progression to acute myeloid leukemia (AML). In addition, clonal cytogenetic abnormalities can be detected in approximately 50% of MDS cases. In 1997, the World Health Organization (WHO), in conjunction with the Society of Hematopathology (SH) and the European Association of Hematopathology (EAHP), proposed new classifications for hematopoietic neoplasms (Harris, et al., J Clin Oncol 1999;17:3835-3849; Vardiman, et al., Blood 2002;100:2292-2302). For the MDS, the WHO did not use... Petition 870250102588, dated 10 / 11 / 2025, page 210 / 574 205 / 492 not only the morphological criteria of the Franco-American-British (FAB) classification, but also incorporated available genetic, biological and clinical characteristics to define subsets of MDS (Bennett, et al., Ir. J. Hematol. 1982;51:189-199). In 2008, the WHO classification for MDS (Table 1) was further refined to allow for a precise and prognostically relevant subclassification of unilineage dysplasia, incorporating new clinical and scientific information (Vardiman, et al., Blood 2009;114:937-951; Swerdlow, et al., WHO Classification of Hematopoietic and Lymphoid Tissue Tumors. 4th Edition. Lyon, France: IARC Press; 2008:88-103; Bunning and Germing, Myelodysplastic Syndromes / Neoplasms in Chapter 5, Swerdlow, et al., eds. WHO Classification of Hematopoietic and Lymphoid Tissue Tumors. (4th edition): Lyon, France: IARC Press; 2008:88-103). Table 1. 2008 WHO Classification for New-Developed Myelodysplastic Syndrome Subtype Blood Bone marrow Refractory cytopenia with unilineage dysplasia (RCUD) Single or Bicytopenia Dysplasia in > 10% of 1 cell lineage, < 5% bursts Refractory anemia with ring sideroblasts (RARS) Anemia, without bursts > 15% of erythroid precursors with ring sideroblasts, only erythroid dysplasia, < 5% bursts Refractory cytopenia with multilineage dysplasia Cytopenia(s), < 1 x 109 / L monocytes Dysplasia in > 10% of cells in > 2 hematopoietic lineages, ± 15% ring sideroblasts, < 5% bursts Refractory anemia with excess blasts-1 (RAEB-1) Cytopenia(s), < 2% to 4% blasts, < 1 x 109 / L monocytes Uni- or multilineage dysplasia, without Auer rods, 5% 9% of blasts Petition 870250102588, dated 10 / 11 / 2025, page 211 / 574 206 / 492 Subtype Blood Bone marrow Refractory anemia with excess blasts-2 (RAEB-2) Cytopenia(s), < 5% to 19% blasts, < 1 x 109 / L monocytes Uni- or multilineage dysplasia, ± Auer rods, 10% to 19% blasts Myelodysplastic syndrome not classified (MDS-U) Cytopenias Unilineage or without dysplasia, but with cytogenetics characteristic of MDS, < 5% blasts MDS associated with isolated del(5q) Anemia, normal or increased platelets Unilineage erythroid. Del(5q) alone, < 5% blasts

[00544] In some forms, myelodysplastic syndrome is refractory cytopenia with unilineage dysplasia (RCUD).

[00545] In some forms, myelodysplastic syndrome is refractory anemia with ring sideroblasts (RARS).

[00546] In some forms, myelodysplastic syndrome is a refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T).

[00547] In some forms, myelodysplastic syndrome is refractory cytopenia with multilineage dysplasia.

[00548] In some forms, myelodysplastic syndrome is refractory anemia with excess blasts-1 (RAEB-1).

[00549] In some forms, myelodysplastic syndrome is refractory anemia with excess blasts-2 (RAEB-2).

[00550] In some forms, myelodysplastic syndrome is unclassified myelodysplastic syndrome (MDS-U).

[00551] In some forms, the myelodysplastic syndrome is a myelodysplastic syndrome associated with isolated del(5q).

[00552] In some forms, myelodysplastic syndrome is refractory to erythropoiesis-stimulating agents.

[00553] In some forms, the compounds of disclosure po Petition 870250102588, dated 10 / 11 / 2025, page 212 / 574 207 / 492 may be useful in the treatment of myeloproliferative disorder / myelodysplastic overlap syndrome (MPD / MDS).

[00554] In some modalities, the compounds of the dissemination may be useful in the treatment of leukemia.

[00555] In some modalities, the compounds of the disclosure may be useful in the treatment of acute myeloid leukemia (AML).

[00556] In addition to oncogenic neoplasms, the compounds of the disclosure may be useful in the treatment of skeletal and chondrocyte disorders, including, but not limited to, achondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson gyrated cutis syndrome, Pfeiffer syndrome, and craniosynostosis syndromes.

[00557] The compounds provided here may also be useful in the treatment of fibrotic diseases, such as when a symptom or disorder of the disease is characterized by fibrosis. Examples of fibrotic diseases include liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, and wound healing.

[00558] In some embodiments, the compounds provided herein may be used in the treatment of a hypophosphatemia disorder, such as, for example, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets and autosomal dominant hypophosphatemic rickets, or tumor-induced osteomalacia.

[00559] In some embodiments, a method is provided here for increasing survival or progression-free survival in a patient, comprising administering a compound provided herein to the patient. In some embodiments, the patient has cancer. In some embodiments, the patient has a disease or disorder described herein. As used herein, progression-free survival Petition 870250102588, dated 10 / 11 / 2025, page 213 / 574 Progression refers to the period of time during and after treatment of a solid tumor in which a patient lives with the disease, but it does not worsen. Progression-free survival may refer to the period of time from the first administration of the compound until death or disease progression, whichever occurs first. Disease progression may be defined by RECIST v. 1.1 (Response Assessment Criteria in Solid Tumors), as assessed by an independent centralized radiology review committee. In some modalities, administration of the compound results in progression-free survival that is greater than approximately 1 month, approximately 2 months, approximately 3 months, approximately 4 months, approximately 5 months, approximately 6 months, approximately 8 months, approximately 9 months, approximately 12 months, approximately 16 months, or approximately 24 months.In some modalities, administration of the compound results in progression-free survival that is at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months, or about 12 months; and less than about 24 months, about 16 months, about 12 months, about 9 months, about 8 months, about 6 months, about 5 months, about 4 months, about 3 months, or about 2 months. In some modalities, administration of the compound results in an increase in progression-free survival that is at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months, or about 12 months; and less than about 24 months, about 16 months, about 12 months, about 9 months, about 8 months, about 6 months, about 5 months, about 4 months, about 3 months, or about 2 months.

[00560] This disclosure also provides a compound described herein, or a pharmaceutically acceptable salt thereof, for use in Petition 870250102588, dated 10 / 11 / 2025, page 214 / 574 209 / 492 any of the methods described here.

[00561] This disclosure further provides the use of a compound described herein, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein.

[00562] As used in this document, the term cell refers to a cell that is in vitro, ex vivo, or in vivo. In some embodiments, an ex vivo cell may be part of a tissue sample taken from an organism, such as a mammal. In some embodiments, an in vitro cell may be a cell in a cell culture. In some embodiments, an in vivo cell is a cell that lives in an organism, such as a mammal.

[00563] As used in this document, the term "contact" refers to bringing together the indicated chemical moieties in an in vitro system or in an in vivo system. For example, contacting a V617F variant with a compound described herein includes administering a compound described herein to an individual or patient, such as a human, having a V617F variant, as well as, for example, introducing a compound described herein into a sample containing a cell preparation or purified sample containing the V617F variant.

[00564] As used in this document, the term individual or patient, used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, or primates and, more preferably, human beings.

[00565] As used in this document, the term therapeutically effective amount refers to the amount of active compound or pharmaceutical agent, such as an amount of any of its solid forms or salts, as disclosed. Petition 870250102588, dated 10 / 11 / 2025, page 215 / 574 210 / 492 in this document, which elicits the biological or medicinal response in a tissue, system, animal, individual, or human being being sought by a researcher, veterinarian, physician, or other clinician. An appropriate effective amount in any individual case can be determined using techniques known to a specialist in the field.

[00566] The term pharmaceutically acceptable is used in this document to refer to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problem or complication proportionate to a reasonable risk / benefit ratio.

[00567] As used in this document, the term pharmaceutically acceptable vehicle or excipient refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or vehicles are generally safe, nontoxic, and neither biologically nor otherwise und...

Claims

1. A compound characterized by having Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl of R1 are each optionally substituted by 1, 2 or 3 independently selected substituents R1A; Each R1A is independently selected from halo, oxo CN, NO2, ORa11, SRa11, NHORa11, C(O)Rb11, C(O)NRc11Rd11 C(O)NRc11(ORa11), C(O)ORa11, OC(O)Rb11, OC(O)NRc11Rd11, NRc11Rd11 NRc11NRc11Rd11, NRc11C(O)Rb11, NRc11C(O)ORa11, NRc11C(O)NRc11Rd11 C(=NRe11)Rb11, C(=NRe11)NRc11Rd11, NRc11C(=NRe11)Rb11, NRc11S(O)Rb11, NRc11 S(O)2Rb11, NRc11 S(O)(=NRe11)Rb11, NRc11C(=NRe11)NRc11Rd11 S(O)Rb11, S(O)NRc11Rd11, S(O)2Rb11, NRc11S(O)NRc11Rd11 NRc11S(O)2NRc11Rd11 S(O)2NRc11Rd11 OS(O)(=NRe11)Rb11, and OS(O)2Rb11; each Ra11, Rb11, Rc11 and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl,wherein C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl of Ra11, Rb11, Rc11 and Rd11 are each optionally replaced by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected RM substituents; each Re11 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl and C2-6 alkynyl; Petition 870250102588, dated 10 / 11 / 2025, p. 499 / 574 2 / 71 Cy2 is selected from 4-12 membered C3-10 cycloalkyl and heterocycloalkyl, wherein C3-10 cycloalkyl and 4-12 membered heterocycloalkyl are each substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2 substituents; each R2 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C1-10 aryl-C1-e alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (5-10 membered heteroaryl)-C1-e alkyl-,(4-10 membered heterocycloalkyl)-C1-e alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2 C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2 NRc2Rd2, NRc2NRc2Rd2 NRc2C(O)Rb2, NRc2C(O)ORa2 NRc2C(O)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2 NRc2C(=NRe2)NRc2Rd2, NRc2C(=NRe2)Rb2, NRc2S(O)Rb2 NRc2S(O)NRc2Rd2, NRc2S(O)2Rb2, NRc2S(O)(=NRe2)Rb2 NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, S(O)2NRc2Rd2 OS(O)(=NRe2)Rb2, OS(O)2Rb2, SF5, P(O)Rf2Rg2, OP(O)(ORh2)(ORi2) P(O)(ORh2)(ORi2), and BRj2Rk2, where C1-e alkyl, C2-e alkenyl, C2-e alkynyl, Ce-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-10 aryl-C1-e alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (5-10 membered heteroaryl)-C1-e alkyl- and (4-10 membered heterocycloalkyl)-C1-e alkyl- of R2 are each optionally substituted by 1, 2, 3, 4, 5, and 7 or 8 independently selected R2A substituents; each Ra2, Rc2 and Rd2 is independently selected from H,C1-e alkyl, C1-e haloalkyl, C2-e alkynyl, C2-e alkynyl, Ce-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-10 aryl-C1-e alkyl-, C3-10 cycloalkyl-C1-e alkyl-, (heteroaryl of 5-10 members)-C1-e alkyl- and (4-10 member heterocycloalkyl)-C1-e alkyl-, where C1-e alkyl, C2-e alkenyl, C2-e alkyn Petition 870250102588, of 11 / 10 / 2025, p. 500 / 574 3 / 71 la, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rc2 and Rd2 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2A substituents; or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached,It forms a 5-10-membered heteroaryl group or a 4-10-membered heterocycloalkyl group, i.e. a 5-10-membered heteroaryl group or a 4-10-membered heterocycloalkyl group, optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents; each Rb2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl- and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl- and (4-10 member heterocycloalkyl)-C1-6 alkyl- of Rb2 são, cada uma,optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2A substituents; each Re2 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl, and (4-10 member heterocycloalkyl)-C1-6 alkyl-; Petition 870250102588, dated 10 / 11 / 2025, page. 501 / 574 4 / 71 each Rf2 and Rg2 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-,(5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; each Rh2 is Ri2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; Each Rj2 and Rk2 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any Rj2 and Rk2 bonded to the same atom B, together with the atom B to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; each R2A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl,heteroaryl of 5-10 members, heterocycloalquila of 4-10 members, C6-10 aryl-C1-6 alquila-, C3-10 cycloalquil-C1-6 alquila-, (heteroaryl of 5-10 members)-C1-6 alquila-, (heterocycloalquila of 4-10 members)-C1-6 alquila-, CN, NO2, ORa21, SRa21, NHORa21, C(O)Rb21 C(O)NRc21Rd21, OC(O)NRc21Rd21, NRc21C(O)ORa21, C(O)NRc21(ORa21), C(O)ORa21, OC(O)Rb21NRc21Rd21, NRc21NRc21Rd21 NRc21C(O)Rb21 NRc21 C(O)NRc21 Rd21, C(=NRe21)Rb21 C(=NRe21)NRc21R d21 NRc21C(=NRe21)NRc21Rd21, NRc21C(=NRe21)R b21 NRc21S(O)Rb21, NRc21S(O)NRc21Rd21, NRc21S(O)2Rb21 Petição 870250102588, dated 10 / 11 / 2025, pág. 502 / 574 5 / 71 NRc21S(O)(=NRe21)Rb21, NRc21S(O)2NRc21Rd21, S(O)Rb21, S(O)NRc21Rd21, S(O)2Rb21, S(O)2NRc21Rd21, OS(O)(=NRe21)Rb21, OS(O)2Rb21, SF5, P(O)Rf21Rg21, OP(O)(ORh21)(ORi21), P(O)(ORh21)(ORi21), and BRj21Rk21, with C1-6 alquila, C2-6 alquila, C2-6 alquinila, C6-10 aryla, C3-10 cycloalquila, heteroaryla de 5-10 members, heterocycloalquila of 4-10 members, C6-10 aryl-C1-6 alquila-,C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A alone, each optionally substituted by 1,2, 3, 4, 5, 6, 7 or 8 selected R2B substituents independently; each Ra21, Rc21, and Rd21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkylC1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl- of Ra21, Rc21 and Rd21 are, each one,optionally replaced by 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2B substituents; or, any Rc21 and Rd21 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or the 4-10 membered heterocycloalkyl group is optionally replaced by 1, 2, 3, or 4 independently selected R2B substituents; each Rb21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 Petition 870250102588, dated 10 / 11 / 2025, p. 503 / 574 6 / 71 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 heterocycloalkyl members)-C1-6 alkyl-, where C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C610 aryl,C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rb21 são, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2B substitutes; each Re21 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-; each Rf21 and Rg21 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl,4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; Each Rh21 and Ri21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; each Rj21 and Rk21 is independently selected from OH, C1-6 alkoxy and C1-6 haloalkoxy; Petition 870250102588, dated 10 / 11 / 2025, p. 504 / 574 7 / 71 or any Rj21 and Rk21 bonded to the same B atom, together with the B atom to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2,3 or 4 substituents independently selected from Ci-6 alkyl and C1-6 haloalkyl; each R2B is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, (4-7 member heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa22, SRa22, NHORa22, C(O)Rb22, C(O)NRc22Rd22, C(O)NRc22(ORa22), C(O)ORa22, OC(O)Rb22, OC(O)NRc22Rd22, NRc22Rd22 NRc22NRc22Rd22 NRc22C(O)Rb22 , NRc22C(O)ORa22, NRc22C(O)NRc22Rd22 C(=NRe22)Rb22, C(=NRe22)NRc22Rd22, NRc22C(=NRe22)NRc22Rd22 NRc22C(=NRe22)Rb22, NRc22S(O)Rb22, NRc22S(O)NRc22Rd22 NRc22S(O)2Rb22, NRc22S(O)(=NRe22)Rb22, NRc22S(O)2NRc22Rd22 S(O)Rb22, S(O)NRc22Rd22, S(O)2Rb22, S(O)2NRc22Rd22 OS(O)(=NRe22)Rb22 and OS(O)2Rb22, in which Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl,4-7-membered heterocycloalkyla, phenyl-C1-6 alkyla-, C3-7 cycloalkyl-C1-6 alkyla-, (5-6-membered heteroaryl)-C1-6 alkyla-, (4-7-membered heterocycloalkyl)-C1-6 alkyla- of R2C only, each unit, optionally substituted by 1, 2, 3 or 4 independently selected RM substitutes; each Ra22, Rc22 and Rd22 is independently selected from H, Ci-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 47 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 Petition 870250102588, of 10 / 11 / 2025, page. 505 / 574 8 / 71 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-,(5-6 membered heteroaryl)-C1-6 alkyl- and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra22, Rc22 and Rd22 are each optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; or, any Rc22 and Rd22 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or the 4-7 membered heterocycloalkyl group is optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; each Rb22 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (heteroaryl of 5-6 members)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl-, where C1-6 alkyl, C2-6 alkenyl,C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenylC1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)C1-6 alkyl- and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Rb22 are each optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; each Re22 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl, C3-7 cycloalkyl-C16 alkyl, (5-6 membered heteroaryl)-C1-6 alkyl- and (4-7 membered heterocycloalkyl)-C1-6 alkyl-; R3 is selected from H, halo, C1-6alkyl, C2-6alkenyl and C2-6alkynyl; Petition 870250102588, dated 11 / 10 / 2025, p. 506 / 574 9 / 71 Cy4 is selected from C6-10 aryl and heteroaryl cells with 5-14 members.em that C6-10 aryl and heteroaryl of 5-12 members only, each one, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R4 substituents; each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, (4-10 member heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa4, SRa4, NHORa4, C(O)Rb4, C(O)NRc4Rd4, C(O)NRc4(ORa4), C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4NRc4Rd4 , NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(O)NRc4Rd4, C(=NRe4)Rb4, NRc4C(=NRe4)Rb4, NRc4S(O)2Rb4, NRc4C(O)ORa4 C(=NRe4)NRc4Rd4 NRc4S(O)Rb4 NRc4S(O)(=NRe4)Rb4 NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, S(O)2NRc4Rd4, OS(O)(=NRe4)Rb4, OS(O)2Rb4, SF5, P(O)Rf4Rg4, OP(O)(ORh4)(ORi4), P(O)(ORh4)(ORi4), and BRj4Rk4,in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl- and (4-10 member heterocycloalkyl)-C1-6 alkyl- of R4 are, each one, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R4A substituents; each Ra4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 al Petition 870250102588, of 10 / 11 / 2025, page. 507 / 574 10 / 71 quinyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl,4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra4, Rc4 and Rd4 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R4A substituents; or, any Rc4 and Rd4, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R4A substituents; each Rb4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-,(5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl- of Rb4 are, each one, optionally substituted by 1, 2, 3, 4, 5, 6, 7, or 8 R4A substituents independently selected; each Re4 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl, (4-10 member heterocycloalkyl)-C1-6 alkyl-; Petition 870250102588, dated 10 / 11 / 2025,p. 508 / 574 11 / 71 each Rf4 and Rg4 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, heterocycloalkyl of 4-10 members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-; Each Rh4 and Ri4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl, C3-10 cycloalkyl-C1-6 alkyl, (5-10 membered heteroaryl)-C1-6 alkyl, and (4-10 membered heterocycloalkyl)-C1-6 alkyl; each Rj4 and Rk4 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any Rj4 and Rk4 bonded to the same atom B, together with the atom B to which they are bonded.form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; each R4A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)NRc41Rd41, OC(O)NRc41Rd41, NRc41C(O)ORa41, C(=NRe41)NRc41Rd41, NRc41S(O)Rb41, CN, NO2, ORa41, SRa41, NHORa41, C(O)Rb41 C(O)NRc41(ORa41), C(O)ORa41, NRc41Rd41, NRc41NRc41Rd41, NRc41C(O)NRc41Rd41, OC(O)Rb41 NRc41C(O)Rb41 C(=NRe41)Rb41 NRc41C(=NRe41)NRc41Rd41, NRc41C(=NRe41)Rb41 NRc41S(O)NRc41Rd41, NRc41S(O)2Rb41 Petition 870250102588, dated 10 / 11 / 2025, page. 509 / 574 12 / 71 NRc41S(O)(=NRe41)Rb41, NRc41S(O)2NRc41Rd41, S(O)Rb41, S(O)NRc41Rd41,S(O)2Rb41, S(O)2NRc41Rd41, OS(O)(=NRe41)Rb41, OS(O)2Rb41, SF5, P(O)Rf41Rg41, OP(O)(ORh41)(ORi41), P(O)(ORh41)(ORi41) e BRj41Rk41, em que C1-6 alkylates, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- e (heterocycloalkyl of 4-10 members)-C1-6 alkyl- of R41 são, each uma, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R4B substituents; each Ra41, Rc41 and Rd41 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 alkyl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra41, Rc41 and Rd41 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R4B substituents; or, any Rc41 and Rd41, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R4B substituents; each Rb41 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, Petition 870250102588, 10 / 11 / 2025, p. 510 / 574 13 / 715-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl members)-C1-6 alkyla- of Rb41 são, each uma, optionally substituted by 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R4B substituents; each Re41 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-waryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-,(5-10 membered heteroaryl)-C1-6 alkyl, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; each Rf41 and Rg41 are independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; each Rh41 and Ri41 and independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C310 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl, C3-10 alkyl cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; each Rj41 and Rk41 is independently selected from OH, C1-6 alkoxy and C1-6 haloalkoxy; Request 870250102588,from 10 / 11 / 2025, page 511 / 574 14 / 71 or any Rj41 and Rk41 bonded to the same atom B, together with the atom B to which they are bonded, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; each R4B is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl-, (4-7 member heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa42, SRa42, NHORa42, C(O)Rb42, C(O)NRc42Rd42 C(O)NRc42(ORa42), C(O)ORa42, OC(O)Rb42, OC(O)NRc42Rd42, NRc42Rd42 NRc42NRc42Rd42 NRc42C(O)Rb42 , NRc42C(O)ORa42, NRc42C(O)NRc42Rd42 C(=NRe42)Rb42, C(=NRe42)NRc42Rd42, NRc42C(=NRe42)NRc42Rd42 NRc42C(=NRe42)Rb42, NRc42S(O)Rb42, NRc42S(O)NRc42Rd42 NRc42S(O)2Rb42,NRc42S(O)(=NRe42)Rb42, NRc42S(O)2NRc42Rd42 S(O)Rb42, S(O)NRc42Rd42, S(O)2Rb42, S(O)2NRc42Rd42 OS(O)(=NRe42)Rb42 and OS(O)2Rb42, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl- of R4C são, each one, substituted by 1,2, 3 or 4 independently selected RM substituents; each Ra42, Rc42 and Rd42 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl,4-7 member heterocycloalkyl Petition 870250102588, dated 10 / 11 / 2025, page 512 / 574 15 / 71 members, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl- of Ra42, Rc42 and Rd42 are each optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; or, any Rc42 and Rd42 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or the 4-7 membered heterocycloalkyl group is optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; each Rb42 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-,C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenylC1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl- of Rb42 are, each one, optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; each Re42 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl-; R5 is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,C3-12 cycloalkyl, C6-10 aryl, 5-12 membered heteroaryl, 4-12 membered heterocycloalkyl, ORw2, SRw2, NRw2Rw3, C(O)Rw2, Petition 870250102588, dated 10 / 11 / 2025, p. 513 / 574 16 / 71 C(O)NRw2Rw3, C(O)ORw2, OC(O)Rw2, OC(NRw3)Rw2, OC(O)NRw2Rw3, NRw3C(O)Rw2, NRw3C(O)ORw2, NRw3C(O)NRw2Rw3, NRw3S(O)Rw2, NRw3S(O)NRw2Rw3, NRw3S(O)2Rw2, S(O)Rw2, S(O)NRw2Rw3, S(O)2Rw2 and S(O)2NRw2Rw3; wherein C1-6 alkyl and C1-1 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5A substituents; or C1-1 aryl of R5 is substituted by 1 Rw5 substituent and optionally substituted by 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R5A substituents; and C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 5-12 membered heteroaryl and 4-12 membered heterocycloalkyl of R5 are each optionally substituted by 1, 2, 3, 4, 5, 6,7 or 8 independently selected R5A substitutes; Rw1 is selected from C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 5-12 membered heteroaryl, C6-12 aryl, 4-12 membered heterocycloalkyl, ORw4, NHRw4, NRw3Rw4, SRw4, S(O)2Rw4, C(O)Rw4, C(O)NHRw4, C(O)NRw3Rw4, OC(O)Rw4, S(O)Rw3, S(O)NRw3Rw3, S(O)2Rw2 and S(O)2NRw3Rw3, where C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 5-12 membered heteroaryl, C6-12 aryl and 4-12 membered heterocycloalkyl of Rw1 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5-12 membered heteroaryl and 4-12 membered heterocycloalkyl, wherein the C3-12 cycloalkyl, 5-12 membered heteroaryl and 4-12 membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3, 4, 5, 6,7 or 8 independently selected R5A substitutes; each Rw3 is independently selected from H, C1-6 Petition 870250102588, dated 10 / 11 / 2025, p. 514 / 574 17 / 71 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C610 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 heterocycloalkyl members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rw3 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5A substituents; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl,C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl- and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl bros)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra51, Rc51 and Rd51 são, each uma, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5B substituents; Rw5 is C1-6 alkyl that is substituted by oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C610 aryl-C1-6 alkyl, C3-10 cycloalkyl-C1-6 alkyl-,(5-10-membered heteroaryl)-C1-6 alkyl-, (4-10-membered heterocycloalkyl)-C1-6alkyl-, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRa51, C(O)Rb51, C(O)NRa51, C(ONRa51), C(ONRa51), C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51, NRc51NRc51Rd51, NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRa51, PetitRd51 870250102588, of 10 / 11 / 2025, p. 515 / 574 18 / 71 C(=NRe51)Rb51, C(=NRe51)NRc51 Rd51, NRc51 C(=NRe51)Rb51, NRc51 S(O)Rb51, NRc51 S(O)2Rb51, NRc51 S(O)(O)Rb51, NRc51 S(O)(Rb51,51) NRc51C(=NRe51)NRc51Rd51, NRc51S(O)NRc51Rd51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51, S(O)251Rd51, S(O)251Rd51, OS(O)(=NRe51)Rb51, OS(O)2Rb51, SF5, P(O)Rf51Rg51, OP(O)(ORh51)(ORi51), P(O)(ORh51)(ORi51) or BRj51Rk51, in which C1-6 is alkylated, C6-C2, alkyne, C-26 C6-10 aryl, C3-10 cycloalkyl, 5-10-membered heteroaryl, 4-10-membered heterocycloalkyl, C6-10 arylC1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10-membered alkyl-C1-6 heteroaryl) (4-10-membered heterocycloalkyl)-C1-6 alkyl- of Rw5 are,each, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5B substituents; each R5A is independently selected between halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5-10-membered heteroaryl, 4-10-membered heterocycloalkyl, C-C-C-106 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (heteroary la of 5-10 members)-C1-6 alkyl-, (heterocycloalkyl of 4-10 members)-C1-6 alkyl-, CN, NO2, ORa51, SRa51, NHO2, CHO(151) C(O)NRc51Rd51, C(O)NRc51(ORa51), C(O)ORa51, OC(O)Rb51 OC(O)NRc51Rd51, NRc51C(O)ORa51, NRc51Rd51, NRc51NRc51Rd51 NRc51Rd51(ONRa51) NRc51C(O)R b51 C(=NRe51)R b51 C(=NRe51)NRc51R d51 NRc51C(=NRe51)NRc51Rd51, NRc51C(=NRe51)R b51 NRc51S(O)Rb51, NRc51S(ONRe5151,51) NRc51S(O)2Rb51 NRc51S(O)(=NRe51)Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51 S(O)NRc51Rd51, S(O)2Rb51, S(O)2NRc51Rb51, S(O)2NRc51Rd51(RbO51) OS(O)2Rb51, SF5, P(O)Rf51Rg51,OP(O)(ORh51)(ORi51) P(O)(ORh51)(ORi51) e BRj51Rk51, em que C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (heteroci Petitção 870250102588, de 10 / 11 / 2025, p. 516 / 574 19 / 71 4-10 cloalkyl members)-Ci-6 alkyl- of R5A são, each uma, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5B substituents; each Ra51, Rc51 and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl- and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl,C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra51, Rc51 and Rd51 are each optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5B substituents; or, any Rc51 and Rd51 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3 or 4 independently selected R5B substituents; each Rb51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl- and (4-10 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl- and (heterocycloalkyl of Petition 870250102588, of 10 / 11 / 2025, page. 517 / 574 20 / 71 4-10 members)-Ci-6 alkyla- of Rb51 são, each unit, optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R5B substituents; each Re51 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl members, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-,(5-10 member heteroaryl)-C1-6 alkylate (4-10 member heterocycloalkyl)-C1-6 alkylate-; each Rf51 and Rg51 are independently selected from H, C1-6 alkylate, C1-6 alkoxy, C1-6 haloalkylate, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkylate, 5-10 member heteroaryl, 4-10 member heterocycloalkylate, C6-10 aryl-C1-6 alkylate-, C3-10 cycloalkyl-C1-6 alkylate-, (5-10 member heteroaryl)-C1-6 alkylate- and (4-10 member heterocycloalkyl)-C1-6 alkylate-; each Rh51 and Ri51 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 member heteroaryl)-C1-6 alkyl-, and (4-10 member heterocycloalkyl)-C1-6 alkyl-; each Rj51 and Rk51 are independently selected from OH,C1-6 alkoxy and C1-6 haloalkoxy; or any Rj51 and Rk51 attached to the same atom B, together with the atom B to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl; each R5B is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 Petition 870250102588, dated 10 / 11 / 2025, p. 518 / 574 21 / 71 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa52, SRa52, NHORa52, C(O)Rb52, C(O)NRc52Rd52 C(O)NRc52(ORa52), C(O)ORa52, OC(O)Rb52, OC(O)NRc52Rd52, NRc52Rd52 NRc52NRc52Rd52 NRc52C(O)Rb52, NRc52C(O)ORa52, NRc52C(O)NRc52Rd52 C(=NRe52)Rb52, C(=NRe52)NRc52Rd52, NRc52C(=NRe52)NRc52Rd52 NRc52C(=NRe52)Rb52,NRc52S(O)Rb52, NRc52S(O)NRc52Rd52 NRc52S(O)2Rb52, NRc52S(O)(=NRe52)Rb52, NRc52S(O)2NRc52Rd52 S(O)Rb52, S(O)NRc52Rd52, S(O)2Rb52, S(O)2NRc52Rd52 OS(O)(=NRe52)Rb52 and OS(O)2Rb52, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (heteroaryl of 5-6 members)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl- of R5B são, each uma, optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; each Ra52, Rc52 and Rd52 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,Phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl- and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra52, Rc52 and Rd52 are each optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; or, any Rc52 and Rd52 attached to the same N atom, together with the N atom to which they are attached, form a Petition 870250102588, dated 10 / 11 / 2025, p. 519 / 574 22 / 71 5-6 membered heteroaryl group or a 47 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or the 4-7 membered heterocycloalkyl group is optionally replaced by 1, 2, 3 or 4 independently selected RM substituents; each Rb52 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl,4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)-C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl-, in which C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenylC1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 member heteroaryl)C1-6 alkyl- and (4-7 member heterocycloalkyl)-C1-6 alkyl- of Rb52 are, each one, optionally substituted by 1, 2, 3 or 4 independently selected RM substituents; each Re52 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C16 alkyl,(5-6 membered heteroaryl)-C1-6 alkyl- and (4-7 membered heterocycloalkyl)-C1-6 alkyl-; each RM is independently selected from H, OH, halo, oxo, CN, C(O)OH, NH2, NO2, SF5, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C310 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; provided that: (i) Cy4 is not triazolopyridinyl; and Petition 870250102588, dated 10 / 11 / 2025, pp. 520 / 574 23 / 71 (ii) R5 is neither morpholinyl nor piperazinyl; and (iii) when Cy4 is phenyl, R5 will not be pyridinyl nor pyrimidinyl., 2. Compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that the compound of Formula I is a compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein: R4 is selected from C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, ORa4 and NRc4C(O)ORa4, wherein C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; each Ra4, Rc4 and Rd4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; Each R4A is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and CN;R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NRw2Rw3, NRw3C(O)Rw2, NRw3C(O)ORw2 and NRw3S(O)2Rw2, wherein triazolyl, pyrazolyl, piperidinyl and tetrahydropyranyl of R5 are each optionally substituted with 1, 2, 3 or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl, 5-12 member heteroaryl and 4-12 member heterocycloalkyl. Petition 870250102588, dated 10 / 11 / 2025, p. 521 / 574 24 / 71 members, wherein C3-12 cycloalkyl, 5-12 member heteroaryl and 4-12 member heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl;each R5A is independently selected between halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, NO2, ORa51, SRa51, NHORa51, C(O)Rb51, C(O)NRc51, C(O)Rb51, C(O C(O)ORa51, OC(O)Rb51, OC(O)NRc51Rd51, NRc51Rd51NRc51NRc51Rd51 NRc51C(O)Rb51, NRc51C(O)ORa51, NRc51C(O)NRc51Rb51, NRc51Rb51, NRc51Rb51 NRc51S(O)NRc51Rd51, NRc51S(O)2Rb51, NRc51S(O)2NRc51Rd51, S(O)Rb51, S(O)NRc51Rd51, S(O)2Rb51 and S(O)2NRc51Rd51; and each Ra51, Rb51, Rc51 and Rd51 is independently selected between H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.; 3. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that R4 is selected from phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, ORa4 and NRc4C(O)ORa4, wherein the phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R4 are each substituted by 1, 2, 3 or 4 independently selected R4A substituents.

4. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that R4 is selected from phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, ORa4 and NRc4C(O)ORa4, wherein the phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R4 are each optionally substituted with 1, 2, 3 or 4 independently selected R4A substituents. Petition 870250102588, dated 10 / 11 / 2025, p. 522 / 574 25 / 71 5. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4 and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl and pyrazolyl groups of R4 are each optionally substituted with 1, 2, 3 or 4 independently selected R4A substituents; and each Ra4 and Rc4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

6. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, characterized in that each R4A is independently selected from C1-6 alkyl, C1-6 haloalkyl and CN.

7. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, characterized in that each R4A is independently selected from C1-6 alkyl and CN.

8. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, characterized in that each R4A is independently selected from methyl and CN.

9. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that R4 is selected from phenyl, tetrahydropyranyl, pyrazolyl, ORa4 and NRc4C(O)ORa4, wherein the phenyl, tetrahydropyranyl and pyrazolyl groups of R4 are each optionally substituted with one or two independently selected R4A substituents; and each Ra4 and Rc4 is independently selected from H and C1-6 alkyl; and each R4A is independently selected from C1-6 alkyl and CN. Petition 870250102588, dated 10 / 11 / 2025, pp. 523 / 574 26 / 71 10. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NHRw2, NHC(O)Rw2, NHC(O)ORw2 and NHS(O)2Rw2, wherein triazolyl, pyrazolyl, piperidinyl and tetrahydropyranyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, characterized in that each Rw2 is independently selected from C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

12. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, characterized in that each Rw2 is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl, wherein cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl of Rw2 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents.

13. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, characterized in that each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51, C(O)Rb51 and C(O)ORa51; and each Ra51 and Rb51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

14. Compound, according to any of the claims Petition 870250102588, of 10 / 11 / 2025, p. 524 / 574 27 / 71 tions 1 to 12, or a pharmaceutically acceptable salt thereof, characterized in that R5A is independently selected from halo, C1-6 alkyl and C(O)ORa51; and each Ra51 is independently selected from H and C1-6 alkyl.

15. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, characterized in that each R5A is independently selected from between fluoromethyl and ethoxycarbonyl.

16. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from triazolyl, pyrazolyl, piperidinyl, tetrahydropyranyl, NHRw2, NHC(O)Rw2, NHC(O)ORw2 and NHS(O)2Rw2, wherein triazolyl, pyrazolyl, piperidinyl and tetrahydropyranyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw2 is independently selected from cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranyl, wherein cyclopropyl, cyclobutyl, oxazolyl and tetrahydropyranyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Each R5A is independently selected from halo, C1-6 alkyl, and C(O)ORa51; and each Ra51 is independently selected from H and C1-6 alkyl.

17. Compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that Cy4 is selected from thiazolyl, pyrazolyl, pyridinyl and pyrimidinyl, wherein thiazolyl, pyrazolyl, pyridinyl and pyrimidinyl of Cy4 are each optionally substituted by 1, 2, 3 or 4 R4 substituents selected pendingly.

18. Compound according to claim 1 or 17, characterized in that the compound of Formula I is a compound of Formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, IIIk, IIIm or IIIn; or a pharmaceutically acceptable salt thereof.

19. A compound according to any one of claims 1, 17 and 18, or a pharmaceutically acceptable salt thereof, characterized in that: each R4 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, ORa4 and C(O)Rb4, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl and (4-10 membered heterocycloalkyl)-C1-6 alkyl- The C1-6 alkyl groups of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; Petition 870250102588, dated 10 / 11 / 2025, page 527 / 574 30 / 71 each Ra4 and Rb4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl and 4-6 membered heterocycloalkyl;Each R4A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa41 and C(O)Rb41; each Ra41 and Rb41 is independently selected from H, C1-6 alkyl and C1-6 haloalkyl; R5 is selected from C1-6 alkyl, C3-12 cycloalkyl, C6-10 aryl, 5-12 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2Hbenzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, ORw2, NRw2Rw3, C(O)Rw2 and C(O)NRw2Rw3; wherein the C1-6 alkyl and C6-10 aryl of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or C6-10 arila of R5 is replaced by 1 Rw5 substitute and optionally replaced by 1 or 2 independently selected R5A substitutes;and C3-12 cycloalkyl, 5-12 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; Rw1 is selected from C3-12 cycloalkyl, 4-12 membered heterocycloalkyl, ORw4 and NHRw4, wherein C3-12 cycloalkyl and 4-12 membered heterocycloalkyl or Rw1 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 ci Petition 870250102588, dated 10 / 11 / 2025, page 528 / 574 31 / 71 cycloalkyl, 5-12 membered heteroaryl and 4-12 membered heterocycloalkyl, wherein C3-12 cycloalkyl, 5-12 membered heteroaryl and 4-12 membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents;Each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; each Rw4 is independently selected from C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl; Rw5 is C1-6 alkyl that is substituted by CN or ORa51; Each R5A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa51 and NRc51Rd51, wherein C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl of R5A are each optionally substituted by ORa52 and 1, 2, 3, 4, 5, 6 or 7 halo groups independently selected; each Ra51, Rc51 and Rd51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl; and each Ra52 is independently selected from H and C1-6 alkyl.

20. A compound according to any one of claims 1 and 17 to 19, or a pharmaceutically acceptable salt thereof, characterized in that each R4 is independently selected from halo, C1-6 alkyl, C6-10 aryl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, ORa4 and C(O)Rb4, wherein the C1-6 alkyl, C6-10 aryl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; and Petition 870250102588, dated 10 / 11 / 2025, page 529 / 574 32 / 71 each Ra4 and Rb4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl and 4-6 membered heterocycloalkyl.

21. A compound according to any one of claims 1 and 17 to 19, or a pharmaceutically acceptable salt thereof, characterized in that R4 is independently selected from halo, C1-6 alkyl, phenyl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-C1-6 alkyl-, ORa4 and C(O)Rb4, wherein the C1-6 alkyl, phenyl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl and (4-6 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents; and each Ra4 and Rb4 is independently selected from C1-6 alkyl and 4-6 membered heterocycloalkyl.

22. A compound according to any one of claims 1 and 17 to 19, or a pharmaceutically acceptable salt thereof, characterized in that each R4 is independently selected from fluorine, methyl, trideuteromethyl, isopropyl, methoxy, morpholinylcarbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl, wherein methyl, isopropyl, phenyl, pyrazolyl, piperidinyl and 2,3-dihydrobenzo[b][1,4]dioxinyl of R4 are each optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

23. A compound according to any one of claims 1 and 17 to 22, or a pharmaceutically acceptable salt thereof, characterized in that each R4A is independently selected from C1-6 alkyl, C1-6 haloalkyl, CN, ORa41 and C(O)Rb41; and each Ra41 and Rb41 is independently selected from H and C1-6 alkyl.

24. Compound, according to any of the claims Petition 870250102588, of 10 / 11 / 2025, p. 530 / 574 33 / 71 tions 1 and 17 to 22, or a pharmaceutically acceptable salt thereof, characterized in that each R4A is selected from methyl, difluoromethyl, trifluoromethyl, CN, OH and methylcarbonyl.

25. A compound according to any one of claims 1 and 17 to 19, or a pharmaceutically acceptable salt thereof, characterized in that each R4 is independently selected from fluorine, methyl, hydroxymethyl, hydroxy-isopropyl, methoxy, (methylcarbonyl)piperidinyl, methylpyrazolyl, cyanophenyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, (difluoromethylazetidinyl)methyl and morpholinylcarbonyl.

26. A compound according to any one of claims 1 and 17 to 25, or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from C1-6 alkyl, C3-7 cycloalkyl, phenyl, 5-10 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, ORw2, NHRw2, C(O)Rw2 and C(O)NHRw2; wherein the C1-6 alkyl and phenyl groups of R5 are each substituted by 1 Rw1 substituent and optionally substituted by 1 or 2 independently selected R5A substituents; or phenyl of R5 is replaced by 1 Rw5 substituent and optionally replaced by 1 or 2 independently selected R5A substituents; and C3-7 cycloalkyl, 5-10 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2.4]heptanil groups of R5 are each optionally replaced by 1, 2, 3, or 4 independently selected R5A substituents.

27. Compound, according to any one of claims 1 and 17 to 25, or a pharmaceutically acceptable salt thereof, Petition 870250102588, dated 10 / 11 / 2025, p. 531 / 574 34 / 71 characterized in that R5 is selected from -CH2Rw1, C3-7 cycloalkyl, -phenyl-Rw1, -phenyl-Rw5, 5-10 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, ORw2, NHRw2, C(O)Rw2, and C(O)NHRw2, where C3-7 cycloalkyl, phenyl, 5-10 membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl and azaspiro[2,4]heptanyl of R5 are each optionally substituted by 1, 2, 3, or 4 independently selected R5A substituents.

28. A compound according to any one of claims 1 and 17 to 27, or a pharmaceutically acceptable salt thereof, characterized in that Rw1 is selected from C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, ORw4 and NHRw4, wherein C3-7 cycloalkyl and 4-7 membered heterocycloalkyl or Rw1 are each optionally substituted by 1 or 2 independently selected R5A substituents.

29. A compound according to any one of claims 1 and 17 to 27, or a pharmaceutically acceptable salt thereof, characterized in that Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, ORw4 and NHRw4; and Rw4 is selected from C1-6 haloalkyl and C3-7 cycloalkyl.

30. A compound according to any one of claims 1 and 17 to 27, or a pharmaceutically acceptable salt thereof, characterized in that Rw1 is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, trifluoromethoxy and cyclopentylamino.

31. A compound according to any one of claims 1 and 17 to 30, or a pharmaceutically acceptable salt thereof, characterized in that Rw2 is selected from C3-7 cycloalkyl, 8-12 membered bicyclic heteroaryl, 4-7 membered monocyclic heterocycloalkyl and 8-12 membered bicyclic heterocycloalkyl, wherein the C3-7 cycloalkyl, 8-12 membered bicyclic heteroaryl, 4-7 membered monocyclic heterocycloalkyl and 8-12 membered bicyclic heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

32. A compound according to any one of claims 1 and 17 to 30, or a pharmaceutically acceptable salt thereof, characterized in that Rw2 is selected from cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2H-pyrido[1,2-a]pyrazinyl, wherein cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl and octahydro-2H-pyrido[1,2-a]pyrazinyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

33. A compound according to any one of claims 1 and 17 to 32, or a pharmaceutically acceptable salt thereof, characterized in that Rw5 is C1-6 alkyl which is substituted by CN or ORa51; and Ra51 is selected from H and C1-3 alkyl.

34. A compound according to any one of claims 1 and 17 to 32, or a pharmaceutically acceptable salt thereof, characterized in that Rw5 is selected from between cyanomethyl and hydroxymethyl.

35. Compound, according to any one of claims 1 and 17 to 34, or a pharmaceutically acceptable salt thereof, characterized in that R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, ORa51 and NRc51Rd51, wherein C1-6 alkyl is optionally substituted by OH and 1, 2, 3, 4, 5, 6 or 7 halo groups independently selected; and each Ra51, Rc51 and Rd51 is independently selected from H and C1-6 alkyl.

36. A compound according to any one of claims 1 and 17 to 34, or a pharmaceutically acceptable salt thereof, characterized in that each R5A is independently selected from chlorine, fluorine, methyl, hydroxyisopropyl, hydroxyhexafluoroisopropyl, difluoromethyl, trifluoromethyl, CN, methoxy, ethoxy, and amino.

37. Compound according to claim 1, or a pharmaceutically acceptable salt thereof, characterized in that Cy4 is selected from quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein quinolinyl, imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl are each optionally substituted by 1, 2, 3 or 4 independently selected R4 substituents.

38. Compound according to claim 1 or 37, characterized in that the compound of Formula I is a compound of Formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVi, IVj, IVk, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu or IVv: Petition 870250102588, 10 / 11 / 2025, p. 534 / 574 37 / 71 ivj IVm IVo; Petition 870250102588, 10 / 11 / 2025, p. 535 / 574 38 / 71 or a pharmaceutically acceptable salt thereof.

39. Compound according to any one of claims 1, 37 and 38, or a pharmaceutically acceptable salt thereof, characterized in that: each R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl-, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 Petition 870250102588, dated 10 / 11 / 2025, page. 536 / 574 39 / 71 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4 is optionally replaced by 1, 2, 3 or 4 independently selected R4A substituents; each R4A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa41; each Ra41 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl;R5 is selected from C3-12 cycloalkyl, 5-12 membered heteroaryl, NRw2Rw3 and C(O)Rw2, wherein the C3-12 cycloalkyl and 5-12 membered heteroaryl of R5 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw2 is independently selected from C3-12 cycloalkyl and 4-12 membered heterocycloalkyl, wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents; each Rw3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl; Each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa51; and each Ra51 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl.

40. A compound according to any one of claims 1 and 37 to 39, or a pharmaceutically acceptable salt thereof, characterized in that R4 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl and C3-7 cycloalkyl-C16 alkyl-, wherein each C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl- of R4 is optionally substituted by 1, 2, 3 or 4 independently selected R4A substituents.

41. A compound according to any one of claims 1 and 37 to 39, or a pharmaceutically acceptable salt thereof, characterized in that R4 is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl, wherein each C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl and C3-7 cycloalkyl-C1-6 alkyl of R4 is optionally substituted by 1, 2, 3 or 4 R4A substituents; each R4A is independently selected from C1-6 haloalkyl, CN and ORa41; and each Ra41 is independently selected from H and C1-6 alkyl.

42. A compound according to any one of claims 1 and 37 to 39, or a pharmaceutically acceptable salt thereof, characterized in that R4 is selected from methyl, ethyl, isopropyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterotetrahydropyranyl, pyridinyl and cyclopropylmethyl, wherein each methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterotetrahydropyranyl, pyridinyl and cyclopropylmethyl of R4 is optionally substituted by 1 or 2 R4A substituents independently selected from C1-3 haloalkyl, CN, OH and C1-3 alkoxy.

43. Compound according to any one of claims 1 and 37 to 42, or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from C3-7 cycloalkyl, 5-6 membered heteroaryl, NHRw2 and C(O)Rw2, wherein the C3-7 cycloalkyl and 5-6 membered heteroaryl of R5 are each optionally substituted by 1, 2, 3 or 4 R5A substituents regardless of whether Petition 870250102588, dated 10 / 11 / 2025, pp. 538 / 574 41 / 71 administered.

44. A compound according to any one of claims 1 and 37 to 42, or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl, pyridinyl, NHRw2 and C(O)Rw2, wherein cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl and pyridinyl of R5 are each optionally substituted with 1, 2, 3 or 4 independently selected R5A substituents.

45. A compound according to any one of claims 1 and 37 to 44, or a pharmaceutically acceptable salt thereof, characterized in that Rw2 is selected from C3-7 cycloalkyl, 4-8 membered monocyclic heterocycloalkyl and 6-10 membered bicyclic heterocycloalkyl, wherein the C3-7 cycloalkyl, 4-8 membered monocyclic heterocycloalkyl and 6-10 membered bicyclic heterocycloalkyl of Rw2 are each optionally substituted by 1, 2, 3 or 4 independently selected R5A substituents.

46. ​​A compound according to any one of claims 1 and 37 to 44, or a pharmaceutically acceptable salt thereof, characterized in that Rw2 is selected from cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspir[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl, wherein cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspir[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5azabicyclo[2.2.1]heptanyl and 2-oxa-5-azabicyclo[4.1.0]heptanyl of Rw2 are, each one, optionally replaced by 1, 2, 3 or 4 independently selected R5A substitutes.

47. A compound according to any one of claims 1 and 37 to 46, or a pharmaceutically acceptable salt thereof, characterized in that each R5A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN and ORa51; and Petition 870250102588, dated 10 / 11 / 2025, pp. 539 / 574 42 / 71 each Ra51 is independently selected from H and C1-6 alkyl.

48. A compound according to any one of claims 1 and 37 to 46, or a pharmaceutically acceptable salt thereof, characterized in that each R5A is independently selected from fluorine, methyl, trideuteromethyl, difluoromethyl, trifluoromethyl, CN and hydroxyl.

49. A compound according to any one of claims 1 to 48, or a pharmaceutically acceptable salt thereof, characterized in that R1 is C1-6 alkyl, which is optionally substituted by independently selected 1, 2 or 3 R1A substituents.

50. Compound according to any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, characterized in that R1 is C1-6 alkyl.

51. A compound according to any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, characterized in that R1 is methyl or trideuteromethyl.

52. A compound according to any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, characterized in that Cy2 is selected from C3-10 monocyclic cycloalkyl, C6-10 bicyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, 6-10 membered spirocyclic heterocycloalkyl and 5-10 membered bicyclic heterocycloalkyl, wherein C3-10 monocyclic cycloalkyl, C6-10 bicyclic cycloalkyl, C6-10 spirocyclic cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, 6-10 membered spirocyclic heterocycloalkyl and 5-10 membered bicyclic heterocycloalkyl are each substituted by 1, 2, 3 or 4 R2 substituents. independently selected.

53. Compound, according to any of claims 1 to 51, or a pharmaceutically acceptable salt thereof, characterizing Petition 870250102588, dated 10 / 11 / 2025, page. 540 / 574 43 / 71 characterized by the fact that Cy2 is selected from cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptaniyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptaniyl, wherein cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptaniyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptaniyl, 3-azabicyclo[3.1.0]hexanyl, 2azaspiro[3.3]heptaniyl and 2-azabicyclo[2.2.1]heptanilates of Cy2 are each optionally replaced by 1, 2, 3 or 4 independently selected R2 substituents.

54. Compound, according to any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, characterized in that Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, p. 541 / 574 44 / 71 and / ή , where n is 0, 1 or 2.

55. Compound, according to any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, characterized in that Cy2 is selected from: Υκ Ah Λα / a O xwx / ' ^1 ' LA—70 \ \ l A \4z AAA / / -¾ ^^70 7J '-n 73 73 Y k> 73 io m - - IO - . Ax ' / ΛΖ Vb, Ax A / 73 I \---τη \ \ / / \ \ IO / \ k> L / \ V--Ά ' π A / io '—73 73 . σ - 73 A N3 >o IO - - Petition 870250102588, dated 10 / 11 / 2025, p. 542 / 574 45 / 71 56. Compound, according to any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, characterized in that Cy2 is selected from: Petition 870250102588, dated 10 / 11 / 2025, pp. 543 / 574 46 / 71 57. A compound according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, characterized in that each R2 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2 and S(O)2NRc2Rd2, where C1-6 alkyl, C2-6 The alkenyl, C2-6 alkynyl, and R2 groups are each optionally replaced by 1, 2, 3, or 4 independently selected R2A substituents.

58. A compound according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, characterized in that each R2 is independently selected from halo, C1-6 alkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2 and NRc2S(O)2Rb2, wherein the C1-6 alkyl of R2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

59. Compound, according to any of claims 1 to 58, or a pharmaceutically acceptable salt thereof, characterizing Petition 870250102588, dated 10 / 11 / 2025, p. 544 / 574 47 / 71 characterized by the fact that each Ra2, Rb2, Rc2 and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl of Ra2, Rb1, Rc2 and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

60. A compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, characterized in that each Ra2, Rb2, Rc2 and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of Ra2, Rb1, Rc2 and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

61. A compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, characterized in that each Ra2, Rb2, Rc2 and Rd2 is independently selected from H, methyl, trideuteromethyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl and tetrahydropyranyl, wherein methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl and tetrahydropyranyl of Ra2, Rb1, Rc2 and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents.

62. Compound, according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, characterized in that each R2 is independently selected from halo, C1-6 alkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2 and NRc2S(O)2Rb2, wherein C1-6 alkyl of Petition 870250102588, 10 / 11 / 2025, pp. 545 / 574 48 / 71 R2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents; and each Ra2, Rb2, Rc2 and Rd2 is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl and tetrahydropyranyl, wherein methyl, trideuteromethyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl and tetrahydropyranyl of Ra2, Rb1, Rc2 and Rd2 are each optionally replaced by 1 or 2 independently selected R2A substituents.

63. A compound according to any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof, characterized in that each R2A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa21.

64. A compound according to any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof, characterized in that each R2A is independently selected from between halo and ORa21; and each Ra21 is independently selected from between H and C1-6 alkyl.

65. A compound, according to any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof, characterized in that each R2A is independently selected from fluorine, hydroxyl, and methoxyl.

66. A compound according to any one of claims 1 to 65, or a pharmaceutically acceptable salt thereof, characterized in that R3 is selected from H and C1-6 alkyl.

67. Compound according to any one of claims 1 to 65, or a pharmaceutically acceptable salt thereof, characterized in that R3 is H.

68. Compound, according to any of the claims Petition 870250102588, of 10 / 11 / 2025, pp. 546 / 574 49 / 71 tions 1 to 48, or a pharmaceutically acceptable salt thereof, characterized in that: R1 is selected from C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; Cy2 is selected from C3-10 monocyclic cycloalkyl, C6-10 bicyclic cycloalkyl, C6-10 spore-cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, 6-10 membered spore-cycloalkyl and 5-10 membered bicyclic heterocycloalkyl, wherein C3-10 monocyclic cycloalkyl, C6-10 bicyclic cycloalkyl, C6-10 spore-cycloalkyl, 4-7 membered heterocycloalkyl, 6-10 membered spore-cycloalkyl and 5-10 membered bicyclic heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R2 substituents;Each R2 is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2 and S(O)2NRc2Rd2, where C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl of R2 are each optionally substituted by 1, 2, 3 or 4 selected R2A substituents. independently; each Ra2, Rb2, Rc2 and Rd2 is selected independently from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, where C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl of Ra2, Rb1, Rc2 and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents;Each R2A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa21; each Ra21 is independently selected from H and C1-6 alkyl; and R3 is selected from H and C1-6 alkyl.

69. Compound according to any one of claims 1 to 48, or a pharmaceutically acceptable salt thereof, characterized in that: R1 is selected from C1-6 alkyl; Cy2 is selected from C3-10 monocyclic cycloalkyl, C6-10 bicyclic cycloalkyl, C6-10 spore-cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, 6-10 membered spore-cycloalkyl and 5-10 membered bicyclic heterocycloalkyl, wherein C3-10 monocyclic cycloalkyl, C6-10 bicyclic cycloalkyl, C6-10 spore-cycloalkyl, 4-7 membered heterocycloalkyl, 6-10 membered spore-cycloalkyl and 5-10 membered bicyclic heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R2 substituents;Each R2 is independently selected from halo, C1-6 alkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2 and NRc2S(O)2Rb2, where C1-6 alkyl of R2 are each optionally replaced by 1, 2, 3 or 4 independently selected R2A substituents; Each Ra2, Rb2, Rc2 and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein C1-6 alkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of Ra2, Rb1, Rc2 and Rd2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents; each R2A is independently selected from halo, C1-6 Petition 870250102588, dated 10 / 11 / 2025, p. 548 / 574 51 / 71 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN and ORa21; each Ra21 is independently selected from H and C1—6 alkyl; and R3 is H.; 70. Compound according to any one of claims 1 to 48, or a pharmaceutically acceptable salt thereof, characterized in that: R1 is C1-3 alkyl; Cy2 is selected from cyclobutyl, cyclopentyl, deuterocyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl and 2-azabicyclo[2.2.1]heptanyl, wherein cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl and 2-azabicyclo[2.2.[1] heptanilic groups of Cy2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2 substituents; each R2 is independently selected from halo, C1-6 alkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2C(O)Rb2, NRc2C(O)ORa2 and NRc2S(O)2Rb2, where C1-6 alkyl groups of R2 are each optionally substituted by 1, 2, 3 or 4 independently selected R2A substituents; Each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, wherein the methyl, trideuteromethyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl groups of Ra2, Rb1, Rc2, and Rd2 are each optionally substituted by 1, 2, 3, or 4 independently selected R2A substituents; each R2A is independently selected from halo and ORa21; Petition 870250102588, 10 / 11 / 2025, p. 549 / 574 52 / 71 each Ra21 is independently selected from H and C1-6 alkyl; and R3 is H.

71. Compound, according to indication 1, characterized by the fact that it is selected among: 2-((3'-cyano-5-((1-((1 R ,3 R )-3-((methoxicarbonyl)amino)cyclopentyl)-3methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-[1,1'biphenyl]-3-yl)amino)oxazol-5-ethyl carboxylate; ((1 R ,3 R )-3-(6-((3'-cyano-5-(4-fluorotetra-hidro-2 H-pyran-4carboxamido)-[1, 1 '-biphenyl]-3-yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-(methyl-d3)-6-((4-(1-methyl-1,6-diazaspiro[3.3]heptane-6carbonyl)-8-(trifluorometil)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(4-(hydroxymethyl)-3-methylphenyl)pyridin-2-yl)amino)-3methyl-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate demethyl;((1 R ,3 R )-3-(6-((6'-methoxy-[2,3'-bipyridin]-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-(4-cyanopiperidine-1-carbonyl)-8(trifluorometil)quinolin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-6-((6-(3-methyl-1 H-indazol-5-yl)pyridin-2-yl)amino)-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxin-6-yl)pyridin-2yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-(quinolin-6-yl)pyridin-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl)carbamate demethyl;Petition 870250102588, de 10 / 11 / 2025, pág. 550 / 574 53 / 71 ((1 R ,3 R )-3-(6-((4-(1-hidróxi-3-azabiciclo[3.1.0]hexano-3-carbonyl)-8(trifluorometil)quinolin-2-il)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]piridin-1-il)ciclopentil)carbamato de methyla; ((1 R ,3 R )-3-(3-methyl-6-((6-(4-methyl-3,4-di-hidro-2 H-benzo[ b ][1,4]oxazin7-yl)pyridin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-(2-oxa-5-azabicyclo[2.2.1 ]heptane-5-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-(2-oxa-5-azabicyclo[4.1.0]heptane-5-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl;(3-((1-((1 R ,3 R )-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-1,2,3-triazol4-yl)phenyl)carbamate de methyl; (3-((1-((1 R ,3 R )-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methylpiperidin-4yl)phenyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-(3,3-difluoropiperidine-1-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-(( R )-2,2-difluorocyclopropane-1-carboxamido)-5(tetra-hidro-2 H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-((3,3-difluorocyclopentyl)amino)-8(trifluorometil)quinolin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]piridin-1-yl)cyclopentyl)carbamato de methyl;((1 R ,3 R )-3-(6-((3-(cyclobutanocarboxamido)-5-(tetra-hidro-2 H-pyran-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-1yl)cyclopentyl)carbamato de methyl; Petition 870250102588, 10 / 11 / 2025, pág. 551 / 574 54 / 71 ((1 R ,3 R )-3-(3-(methyl-d3)-6-((6-(1-methyl-1 H-pyrazol-4-yl)-8(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; (3-((1-((1 R ,3 R )-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(tetra-hidro-2 H-pyran-3yl)phenyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-((4-cyanocyclo-hexyl)óxi)pyridin-2-yl)amino)-3-methyl-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-(quinolin-6-ylóxi)pyridin-2-yl)amino)-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl;(3-((1-((1 r,3 r)-3-(cyclopropanecarboxamido)cyclobutyl)-3-methyl-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate de methyl; (3-((1-(6-((ethoxycarbonyl)amino)spiro[3.3]heptan-2-yl)-3-methyl-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate de methyl; (3-((1-(6-(cyclopropanesulfonamido)spiro[3.3]heptan-2-yl)-3-methyl-2-oxo2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamato de methyl; 6-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-2azaspiro[3.3]heptano-2-carboxylato de methyl; (3-((1-((1 r,3r)-3-cyanocyclobutyl)-3-methyl-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate de methyl;(3-((1-((1r,3r)-3-(((methoxycarbonyl)amino)-3-methylcyclobutyl)-3-methyl-2-oxo2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 demethyl-1 H-matho)pyrazol (R )-(3-((1-(3,3-difluorocyclopentyl)-3-methyl-2-oxo-2,3-di-hydro-1 H Petition 870250102588, dated 10 / 11 / 2025, p. 552 / 574- imidazo 51 / 41 ]pyridine-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)methyl carbamate; (3-((1-((1 R ,3 S )-3-fluorocyclopentyl)-3-methyl-2-oxo-2,3-di-hydro-1 Himidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)methyl)carbamate; ((1 R ,3 R )-3-(3-methyl-6-((6-(1-methyl-1 H-pyrazol-4-yl)quinoline-2-yl)amino)-2oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl methyl)carbamate; ((1 R ,3 R )-3-(3-methyl-6-((8-(1-methyl-1 H-pyrazol-4-yl)quinoline-2-yl)amino)-2oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl methyl)carbamate;((1 R ,3 R )-3-(3-methyl-6-((3-(1-methyl-1 H-pyrazol-4-yl)imidazo[1,2b]pyridazin-6-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-6-((2-(1-methyl-1 H-pyrazol-4-yl)pyrazolo[1,5a]pyrimidin-5-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-6-((3-(1-methyl-1 H-pyrazol-4-yl)pyrazolo[1,5a]pyrimidin-5-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-((tetra-hidro-2 H-pyran-4-yl)óxi)pyridin-2yl)amino)-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate; ((1 R ,3 R )-3-(3-methyl-6-((3-(1-methyl-1 H-imidazol-5-yl)imidazo[1,2b]pyridazin-6-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate demethyl;(1R ,5 S )-6-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-3azabicyclo[3.1.0]hexane-3-carboxylate de methyl; (3-((1-(2-acetyl-2-azabiciclo[2.2.1 ]heptan-5-yl)-3-methyl-2-oxo-2,3-di Petição 870250102588, de 10 / 11 / 2025, pág. 553 / 574 56 / 71 hidro-1 H-imidazo[4,5-c ]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate de methyl; (1R ,3 R )-3-(6-((3-((3,3-difluorocyclobutane)-1-sulfonamido)-5-(tetrahydro-2 H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hydro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; (3-((1-(4-((methoxycarbonyl)amino)-4-methylcyclo-hexyl)-3-methyl-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c]pyridin-6-yl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de 2-methoxyethyl;((1 R ,3 R )-3-(6-((3-((ciclobutoxycarbonil)amino)-5-(tetra-hidro-2 H-piran-4il)fenil)amino)-3-metil-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]piridin-1il)ciclopentil)carbamato de metila; ((1 R ,3 R )-3-(6-((3-((ciclobutoxycarbonil)amino)-5-(1-metil-1 H-pirazol-4il)fenil)amino)-3-metil-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]piridin-1il)ciclopentil)carbamato de ciclobutila; ((1 R ,3 R )-3-(6-((3-((ciclobutoxycarbonil)amino)-5-(1-metil-1 H-pirazol-4il)fenil)amino)-3-metil-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]piridin-1il)ciclopentil)carbamato de etila; ((1 R ,3 R )-3-(6-((3-((ciclobutoxycarbonil)amino)-5-(1-metil-1 H-pirazol-4il)fenil)amino)-3-metil-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]piridin-1il)ciclopentil)carbamato de prop-2-in-1-ila; ((1 R ,3 R )-3-(6-((3-((ciclobutoxycarbonil)amino)-5-(1-metil-1 H-pirazol-4il)fenil)amino)-3-metil-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]piridin-1il)ciclopentil)carbamato de tetra-hidro-2H-piran-4-ila;((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de 4-fluorophenyl; ((1 R ,3 R )-3-(6-((6-cyclopropylpyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di Petição 870250102588, de 10 / 11 / 2025, pág. 554 / 574 57 / 71 hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(3-cyanophenyl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl;((1 R ,3 R )-3-(6-((3-cyclopropylimidazo[1,2-b]pyridazin-6-yl)amino)-3-(methyld3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-((cyclopropoxycarbonyl)amino)-5-methoxyphenyl)amino)-3metil-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-(cyclopropanecarboxamido)-5-(1-methyl-1 H-pyrazol-4yl)phenyl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-(methyl-d3)-6-((8-(1-methylcyclopropyl)quinolin-2-yl)amino)-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl)carbamate demethyl;((1 R ,3 R )-3-(6-((3-(3-fluoro-1-(methyl-d3)-1 H-pyrazol-4-yl)imidazo[1,2b]pyridazin-6-yl)amino)-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-(cyclobutoxymethyl)-6-(2,3-di-hidrobenzo[ b ][1,4]dioxin-6yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5 Request 870250102588, dated 10 / 11 / 2025, pág. 555 / 574 58 / 71 c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(3-aminopyrrolidin-1-yl)pyridin-2-yl)amino)-3-methyl-2oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-((cyclopentylamino)metil)-6-(2,3-dihydrobenzo[ b ][1,4]dioxin-6-yl)pyridin-2-yl)amino)-3-methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((2-(piperidin-1-yl)pyrimidin-4-yl)amino)-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate demethyl;((1 R ,3 R )-3-(6-((2'-methoxy-4-methyl-[2,4'-bipyridin]-6-yl)amino)-3-methyl-2oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((4-(pyridin-4-yl)thiazol-2-yl)amino)-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-fluoro-6'-(trifluoromethyl)-[2,3'-bipyridin]-6-yl)amino)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[b][1,4]dioxin-6-yl)-4-((( S )-3fluoropirrolidin-1-yl)methyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihidro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1R,3R)-3-(6-((6-(4-(cyanomethyl)phenyl)-5-fluoropyridin-2-yl)amino)-3-methyl2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate demethyl;((1 R ,3 R )-3-(6-((6-(4-cyclopropylphenyl)-5-fluoropyridin-2-yl)amino)-3-methyl2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((5-fluoro-6-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)amino)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxin-6-yl)-4Petição 870250102588, dated 10 / 11 / 2025, pág. 556 / 574 59 / 71 (morpholinomethyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((2-(2-methoxypyridin-4-yl)pyrimidin-4-yl)amino)-3-(methyl-d3)2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxin-6-yl)-4-(octa-hidro-2 Hpirido[1,2-a ]pyrazine-2-carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl;((1 R ,3 R )-3-(6-((2-(5-azaspiro[2.4]heptan-5-yl)pyrimidin-4-yl)amino)-3methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((2-(3,3-difluoropirrolidin-1-yl)pyrimidin-4-yl)amino)-3-methyl2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin4-yl)amino)-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxin-6-yl)-4-(( R )-3fluoropyrrolidina-1-carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((1-(pyridin-4-yl)-1 H-pyrazol-3-yl)amino)-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate demethyl;((1 R ,3 R )-3-(6-((6-(2,3-di-hidrobenzo[ b ][1,4]dioxin-6-yl)-4-(morphonline-4carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((2-((3,3-difluorocyclopentyl)amino)pyrimidin-4-yl)amino)-3metil-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((2-(3,3-difluoropyrrolidin-1-yl)-6-methylpyrimidin-4-yl)amino) Petição 870250102588, de 10 / 11 / 2025, pág. 557 / 574 60 / 71 3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((2-((tetra-hydro-2 H-pyran-4yl)amino)pyrimidin-4-yl)amino)-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(3-methyl-2-oxo-6-((6-(piperidine-1-carbonyl)pyridin-2yl)amino)-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl;and ((1 R ,3 R )-3-(6-((6-(cyclo-hexylcarbamoyl)pyridin-2-yl)amino)-3-methyl-2-oxo2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ou um sal pharmaceutically aceitável do mesmo.; 72. Compound, characterized by the fact that is selected between: (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6yl)amino)-5-(1-methyl-1H-pyrazol-4-yl)phenyl)carbamate of cyclobutylate; (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-6yl)amino)-5-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)carbamate of cyclobutylate; e (3-(1-ciclopropil-1 H-pirazol-4-il)-5-((3-metil-2-oxo-1-(tetra-hidrofuran-3il)-2,3-di-hidro-1 H-imidazo[4,5-c ]piridin-6-il)amino)fenil)carbamato de ciclobutila; ou um sal farmaceuticamente aceitável do mesmo.

73. Compound, according to indication 1, characterized by the fact that it is selected among: ((1 R,3 R)-3-(6-((1-(2-methoxyethyl)-3-(1-(trifluoromethyl)-1 H-pyrazol-4-yl)-1 Hpyrrole[3,2-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-1-methyl-2-oxo-7-(4(trifluoromethyl)pyridin-3-yl)-2,3-di-hidro-1 H-imidazo[4,5-b ]pyridin-5 Petição 870250102588, de 10 / 11 / 2025, pág. 558 / 574 61 / 71 il)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; N-(6-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinolin2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)spiro[3.3]heptan-2-yl)cyclopropanecarboxamide;N-((1 s, 4 s )-1-methyl-4-(3-(methyl-d3)-6-((2-methyl-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclo-hexyl)cyclopropanecarboxamide; N-((1 S ,3 R )-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hidroxypropan-2-yl)pyridin-2yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1metilcyclopentyl)cyclopropanecarboxamide; ((1 R ,3 R )-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hidroxypropan-2-yl)pyridin-2yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(1-methyl-1 H-pyrazol-4-yl)-8(trifluorometil)quinolin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamato de methyl; ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluorometil)thiazol-5yl)pyridin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamato de methyl;((1 R ,3 R )-3-(6-((8-(2-cyanopropan-2-yl)-4-(morpholine-4-carbonyl)quinolin2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-(1-(difluorometil)-1 H-pyrazol-4-yl)-2-methyl-8-(4(trifluorometil)piridin-3-yl)imidazo[1,2-b]piridazin-6-yl)amino)-3-(metil-d3)2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]piridin-1-yl)cyclopentyl-3d)carbamato de methyl; ((1 R ,3 R )-3-(6-((5-metóxi-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; Petition 870250102588, 10 / 11 / 2025, pág. 559 / 574 62 / 71 ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4-methylpyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c]pyridin-1yl)cyclopentyl)carbamate de methyl;((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((4-((3-(difluoromethyl)azetidin-1-yl)methyl)-6-(5(trifluoromethyl)thiazol-2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-cyclobutoxy-5-(1-methyl-1 H-pyrazol-4-yl)-4-(morpholine-4carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((2-(5-(difluorometil)thiophen-2-yl)-6-(hidroximetil)pirimidin-4yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(5-(difluoromethyl)thiophen-2-yl)-4-(morpholine-4carbonyl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl;((1 R ,3 R )-3-(6-((4-(1-acetylpiperidin-4-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro-1 H-imidazo[4,5c]pyridine-1-yl)cyclopentyl)methyl carbamate; 6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine3-yl)imidazo[1,2-b ]pyridazine-6-yl)amino)-1-((1 r,3 r)-3-(2-hydroxypropane-2yl)cyclobutyl)-3-(methyl-d3)-1,3-di-hydro-2 H-imidazo[4,5-c ]pyridine-2-one; ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropane-2-yl)thiazol-2-yl)-4-(1-methyl-1 Hpyrazol-4-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-zohydro[41,5-di-imi- ]pyridine-1-yl)cyclopentyl)methyl carbamate; and ((1 R ,3 R )-3-(3-(methyl-d3)-2-oxo-6-((6-(4-(trifluoromethyl)-1 H-pyrazol-1yl)pyridin-2-yl)amino)-2,3-di-hydro-1 H-imidazo[4,5-c ]cyclopenethyl methylcar); Petition 870250102588, dated 10 / 11 / 2025, p. 560 / 574 63 / 71 or a pharmaceutically acceptable salt of the same.; 74. Compound, according to indication 1, characterized by the fact that it is selected among: ((1 R ,3 R )-3-(3-(methyl-d3)-2-oxo-6-((1-(tetra-hydro-2 H-pyran-4-yl)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamato de methyl; ((1 R ,3 R )-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetra-hydro-2H-pyran-4-yl)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate; ((3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetra-hydro-2 H-pyran-4-yl-4-d)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-2,3-dihydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate demethyl;((3 R )-3-(6-((1-(1-cyanocyclopropyl)-3-(1-(trifluoromethyl)-1 H-pyrazol-4-yl)1H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate; ((1 R ,3 R )-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(difluoromethyl)-1 Hpyrazol-4-yl)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-b ]pyridin-5-yl)amino)-3(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((3-(1-(difluorometil)-1 H-pyrazol-4-yl)-7-(2-hidroxypropan2-yl)-2-metil-3 H-imidazo[4,5-b ]piridin-5-yl)amino)-3-(metil-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]piridin-1-yl)cyclopentyl)carbamato de methyl; N-((1 R ,3 R )-1-methyl-3-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8(trifluoromethyl)quinolin-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)cyclopropanecarboxamide;N-((1 S ,3 R )-3-(6-((7-(hidroximetil)-2-metil-3-(1-(trifluorometil)-1 Hpirazol-4-il)-2 H-pirazolo[4,3-b ]piridin-5-il)amino)-3-(metil-d3)-2-oxo-2,3 Petição 870250102588, de 10 / 11 / 2025, pág. 561 / 574 64 / 71 di-hidro-1 H-imidazo[4,5-c ]piridin-1-il)-1metilciclopentil)ciclopropanecarboxamida; ((1 R ,3 R )-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; N-((1 S ,3 R )-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1methylcyclopentyl)cyclopropanecarboxamide; N-((1 s ,4 s )-4-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1-methylcyclohexyl)cyclopropanecarboxamide;N-((1 S ,3 R )-3-(6-((2-((1 s ,3 s )-3-hidroxycyclobutyl)-3-(1-(trifluorometil)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(metil-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1metilcyclopentyl)cyclopropanecarboxamide; ((1 R ,3 R )-3-(6-((2-(2-hidróxi-2-metilpropil)-3-(1-(trifluorometil)-1 Hpirazol-4-yl)-2H-pyrazolo[4,3-b]piridin-5-yl)amino)-3-(metil-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]piridin-1-yl)cyclopentyl)carbamato de methyl; N-((1 S ,3 R )-3-(6-((2-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1methylcyclopentyl)cyclopropanecarboxamide; ((3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazol-4yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d )carbamato de methyl;((3R)-3-(6-((1-(2-hidróxi-2-metilpropil)-3-(1-(trifluorometil)-1H-pirazol-4il)-1 H-pirazolo[4,3-b ]piridin-5-il)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]piridin-1-il)ciclopentil-1- d )carbamato de methyla; Petição 870250102588, de 10 / 11 / 2025, pág. 562 / 574 65 / 71 N-((1 s ,4 s )-4-(6-((1-((1 r,4 r)-4-hidroxycyclo-hexyl)-3-(1-(trifluorometil)-1 Hpirazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(metil-d3)-2-oxo-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1-metilciclohexyl)cyclopropanecarboxamide; N-((1 s ,4 s )-1-methyl-4-(3-(methyl-d3)-6-((2-methyl-7-(morpholine-4-carbonyl)-3(1-(trifluoromethyl)-1 H-pyrazol-4-yl)-2 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-2oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclohexyl)cyclopropanecarboxamide; ((1 S ,3 R )-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1-methylcyclopentyl)carbamate de methyl;N-((1 S ,3 R )-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1 Hpyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3 )-2-oxo-2,3di-hydro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1-methylcyclopentyl)acetamida; ((3R)-3-(6-((7-(2-hydroxypropan-2-yl)-3-(1-(trifluoromethyl)-1H-pyrazol-4-yl)1H-pyrrolo[3,2-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate; ((3R)-3-(6-((4-(2-hydroxypropan-2-yl)-1-(1-(trifluoromethyl)-1H-pyrazol-4-yl)1H-pyrrolo[2,3-b ]pyridin-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate; ((3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetra-hidro-2H-pyran-4-yl)-3-(1(trifluoromethyl)-1 H-pyrazol-4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-2,3di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate;((3R)-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1H-pyrazol4-yl)-1 H-pyrazolo[4,3-b ]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d )carbamate demethyl; ((3R)-3-(6-((2-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1H-pirazol4-yl)-2 H-pirazolo[4,3-b ]piridin-5-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidroPetição 870250102588, de 10 / 11 / 2025, pág. 563 / 574 66 / 71 1H-imidazo[4,5-c ]piridin-1-yl)ciclopentyl-1- d )carbamato de methyla; ((1 R ,3 R )-3-(3-(methyl-d3)-6-((6-methyl-4-(morpholine-4-carbonyl)-8(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl)carbamate de methyl; N-((1 S ,3 R )-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hidroxipropan-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-1methylcyclopentyl)acetamida;4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)-N(methyl-d3)bicyclo[2.2.2]octano-1-carboxamida; N-cyclopropyl-4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c ]pyridin-1-yl)bicyclo[2.2.2]octano-1-carboxamida; 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)bicyclo[2.2.2]octan-1-yl)carboxamide; N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)bicyclo[2.2.2]octan-1-yl)acetamida; 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)bicyclo[2.2.1 ]heptane-1-carboxamide;N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2-yl)pyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c]pyridin-1yl)bicyclo[2.2.1]heptan-1-yl)acetamida; N-((1 S,3 R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazol-2yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)-1-methylcyclopentyl)propionamide; ((1 R ,3 R )-3-(6-((4-(2-hidroxipropan-2-yl)-6-(5-(2-hidroxipropan-2-yl)thiazol2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5 Petição 870250102588, dated 10 / 11 / 2025, pág. 564 / 574 67 / 71 c ]pyridin-1-yl)cyclopentyl)carbamate de methyl; ((1 R ,3 R )-3-(6-((6-(5-(1,1,1,3,3,3-hexafluoro-2-hidroxypropan-2-yl)thiazol2-yl)-4-(2-hidroxypropan-2-yl)pyridin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-dihidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamato de methyl;N-((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluoromethyl)thiazol-5yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)-1-methylcyclopentyl)acetamida; ((1 R ,3 R )-3-(6-((6-(5-(1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-yl)thiazol2-yl)-4-(2-hidroxypropan-2-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate; ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4-methylpyridin-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl-1-d)methylcarbamate; ((1 R ,3 R )-3-(6-((5-fluoro-6-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-4methylpyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-1-d)methylcarbamate; ((1 R ,3 R )-3-(6-((6-(5-(2-hidroxipropan-2-yl)thiazol-2-yl)-4-(methyl-d3)pyridin2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1yl)cyclopentyl-1-d)carbamate de methylate;N-((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-isopropoxythiazol-5yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro-1 H-imidazo[4,5c]pyridine-1-yl)-1-methylcyclopentyl)acetamide; N-((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-methoxythiazol-5-yl)pyridine2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-y ]pyridine-1-yl)1-methylcyclopentyl)acetamide; N-((1 S ,3 R )-3-(6-(((6-(2-ethoxythiazol-5-yl)-4-(2-hydroxypropan-2-yl)pyridine-2yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro-1 H-imidazo[4,5-c ]pyridine-1-yl)-1methylcyclopentyl)acetamide; ((1 R ,3 R )-3-(6-((6'-(5-(difluoromethyl)thiophene-2-yl)-4-(trifluoromethyl)-[3,4'bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydrothioãço[1 H-4 870250102588, dated 10 / 11 / 2025, pp. 565 / 574 68 / 71 c ]pyridine-1-yl)cyclopentyl)methyl carbamate;((1 S ,2 S ,4 S )-2-hidróxi-4-(6-((4-(2-hidroxypropan-2-yl)-6-(5(trifluorometil)thiazol-2-yl)piridin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-dihidro-1 H-imidazo[4,5-c ]piridin-1-yl)cyclopentyl)carbamato de methyl; ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluorometil)thiazol-2yl)pyridin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-3-d)carbamato de methyl; ((1 R ,3 R )-3-(3-(metil-d3)-6-((4-(1-metilpiperidin-4-yl)-6-(5(trifluorometil)thiazol-2-yl)pyridin-2-yl)amino)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamato de methyl; ((1 R ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluorometil)thiazol-2yl)pyridin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-1-d)carbamato de methyl; ((1 S ,3 R )-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluorometil)thiazol-2yl)pyridin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 H-imidazo[4,5c]pyridin-1-yl)cyclopentyl-1-d)carbamato de methyl;((1 S ,3 R )-3-(6-((3-(1-(difluoromethyl)-1 H-pyrazol-4-yl)-2-methyl-8-(4(trifluoromethyl)pyridin-3-yl)imidazo[1,2-b ]pyridazin-6-yl)amino)-3-(methyl-d3)2-oxo-2,3-di-hidro-1 H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1d) methyl carbamate; ((1 R ,3 R )-3-(6-((6-(5-(2-hidroxypropan-2-yl)thiazol-2-yl)-4-(tetra-hidro-2 Hpyran-4-yl)pyridin-2-yl)amino)-3-(metil-d3)-2-oxo-2,3-di-hidro-1 Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl)carbamato de methyl; ((1 R ,3 R )-3-(6-((6-(5-(2-hidroxipropan-2-yl)thiazol-2-yl)-4-(tetra-hidro-2 Hpiran-4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate; ((1 S ,3 R )-3-(6-((6-(5-(2-hidroxipropan-2-yl)thiazol-2-yl)-4-(tetra-hidro-2 Hpiran-4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hidro-1Himidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate;((1 R ,3 R )-3-(6-((6'-(5-(2-hydroxypropane-2-yl)thiazol-2-yl)-4-(trifluoromethyl)Petition 870250102588, dated 10 / 11 / 2025, p. 57 / 466 [3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro-1 Himidase[4,5-c ]pyridine-1-yl)cyclopentyl-1- d) methyl carbamate; ((1 S ,3 R )-3-(6-((6'-(5-(2-hydroxypropane-2-yl)thiazol-2-yl)-4-(trifluoromethyl)[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-da co-hydro-2,5,3-di-di ]pyridine-1-yl)cyclopentyl-1- d) methyl carbamate; ((1 R ,3 R )-3-(6-((6-(5-(2-hydroxypropane-2-yl)thiazol-2-yl)-4-(1-methylpiperidin4-yl)pyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-di-hydro-1 H-imidazo[4,5c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate; ((1 R ,3 R )-3-(6-((6'-(5-(2-hydroxypropane-2-yl)thiazol-2-yl)-2-(trifluoromethyl)[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-zo-hydro[Hymi-2,5-di-di- ]pyridine-1-yl)cyclopentyl-1- d) methyl carbamate;N-((1S,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2-methyl-8-(4(trifluoromethyl)pyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl)amino)-3-(methyl-d3)2-oxo-2,3-dihydro-1 H-imidazo[4,5-c]pyridin-1-yl)-1methylcyclopentyl)acetamide; and ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-(2-hydroxypropan2-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3dihydro-1H-imidazo[4,5-c ]pyridin-1-yl)cyclopentyl-1- d) methyl carbamate; or a pharmaceutically acceptable salt thereof; 75. A compound according to any one of claims 1 to 74, or a pharmaceutically acceptable salt thereof, characterized in that the compound is deuterated.

76. Pharmaceutical composition, characterized in that it comprises a compound, as defined in any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

77. Method of inhibiting the activity of the V617F variant of JAK2 kinase, characterized in that it comprises bringing the kinase into contact with a compound, as defined in any of claims 1 to 75, or a pharmaceutically acceptable salt thereof.

78. A method for treating cancer in a patient in need, characterized in that it comprises administering to the patient a therapeutically effective amount of a compound, as defined in any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof.

79. Method according to claim 78, characterized in that the cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, small bowel cancer, colon cancer, rectal cancer, anal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, testicular cancer, uterine cancer, vulvar cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, stomach cancer, thyroid cancer, parathyroid cancer, neuroendocrine cancer, skin cancer and brain cancer.

80. Method according to claim 78, characterized in that the cancer is a hematological cancer.

81. Method, according to claim 78, characterized in that the cancer is selected from leukemia, lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, acute myeloid leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myeloid leukemia, Hodgkin's or non-Hodgkin's lymphoma (a myeloproliferative neoplasm), myelodysplastic syndrome, chronic eosinophilic leukemia, Waldenstrom's macroglobulinemia, hairy cell lymphoma, chronic myelogenous lymphoma, acute lymphoblastic lymphoma, AIDS-related lymphoma, and Burkitt's lymphoma.

82. Method of treating a myeloproliferative disorder in a patient in need, characterized in that Petition 870250102588, dated 10 / 11 / 2025, pp. 568 / 574 71 / 71 involves administering to the patient a therapeutically effective amount of a compound, as defined in any of claims 1 to 75, or a pharmaceutically acceptable salt thereof.

83. Method, according to claim 82, characterized in that the myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, primary myelofibrosis, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, chronic myeloid leukemia, chronic myelomonocytic leukemia, hypereosinophilic syndrome and systemic mast cell disease.

84. A method for treating myelodysplastic syndrome in a patient in need, characterized in that it comprises administering to the patient a therapeutically effective amount of a compound, as defined in any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof.